

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant's name into English)

55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On August 20, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited ("Telix") filed the following announcements with the Australian Securities Exchange titled: (i) "Telix H1 2026 Results Presentation," (ii) "Telix H1 2026 Appendix 4D and Interim Report," and (iii) "Telix H1 2026 Results Announcement," copies of which are attached to this Form 6-K as Exhibit 99.1, Exhibit 99.2, and Exhibit 99.3, respectively.

Also attached as Exhibit 99.4 to this Form 6-K, are copies of Telix's unaudited interim consolidated financial statements for the half-year ended June 30, 2026, and the related Operating and Financial Review discussion for the half-year ended June 30, 2026, formatted in Extensible Business Reporting Language ("XBRL").

Exhibits 99.2 and 99.4 are incorporated by reference into Telix's Registration Statement on Form F-3ASR (File No. 333-293611) and Registration Statement on Form S-8 (File No. 333-283917).

99.1	Telix H1 2026 Results Presentation
99.2	Telix H1 2026 Appendix 4D and Interim Report
99.3	Telix H1 2026 Results Announcement
99.4	Telix Half-Year 2026 Operating and Financial Review and Unaudited Interim Consolidated Financial Statements
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Scheme Linkbase Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Telix Pharmaceuticals Limited

Date: August 20, 2026

By: /s/ Christian Krautkramer

Name: Christian Krautkramer

Title: Group General Counsel



H1 2026 Interim Results Presentation

August 20, 2026

ASX: TLX | NASDAQ: TLX



Radiopharmaceutical manufacturing suite at TMS North Melbourne.

Presenters



Dr. Christian Behrenbruch
Managing Director
and Group CEO



Darren Smith
Group Chief Financial
Officer



Kevin Richardson
CEO, Telix Precision
Medicine



Dr. David N. Cade
Chief Medical Officer



Agenda

- 1** CEO remarks
- 2** Financial update
- 3** Precision Medicine update
- 4** Therapeutics update
- 5** Q&A

Forward looking statement

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this presentation are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in this presentation.

This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Telix's actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of Telix's future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

Use of Non-IFRS Measures. Telix's results are reported under International Financial Reporting Standards (IFRS). This announcement includes various non-IFRS financial information to reflect its underlying performance, which have not been subject to audit or review. These non-IFRS measures include Adjusted EBITDA, which represents net earnings attributable to the Group excluding finance costs, income tax expense, depreciation and amortization, remeasurement of provisions, other income and expenses. As required by SEC rules, we have provided reconciliations of these non-IFRS financial measures to the most directly comparable IFRS measures, which for Adjusted EBITDA, is Profit/(loss) before income tax. The Group believes that these non-IFRS measures, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The non-IFRS measures are not defined by IFRS and therefore may not be directly comparable with other companies' alternative performance measures.

Telix's first generation PSMA-PET imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also known as ⁶⁸Ga PSMA-11 and marketed under the brand name Ilucix®), has been approved in multiple markets globally. Gozetix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA. Telix's osteomyelitis (bone infection) imaging agent, technetium-99m (^{99m}Tc) besilesomab (marketed under the brand name Scintimun®) is approved in 32 European countries and Mexico. Telix's miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the EEA. Registrations vary country to country. Refer to your local approved label or regulatory authority status for full information.

No other Telix drug or device has received marketing authorization in any jurisdiction. Any other Telix drug or device that is discussed in this presentation, including Zircaix and Pixclara, is investigational or under development and not approved by any regulatory authority. The efficacy or safety profile of any unapproved drug or device has not been determined by any regulatory authority. In addition, Zircaix and Pixclara brand names and launch are subject to final regulatory approval.

All trademarks and trade names referenced in this presentation are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.





CEO remarks

**Dr. Christian Behrenbruch
Managing Director
and Group CEO**



Delivering against our 2026 strategic priorities

Strong execution across commercial, regulatory and clinical milestones

1 Continue commercial growth

- ✓ Delivered **\$388M** in sales in H1 2026 for Illuccix® and Gozellix®, up **27% YoY**
- ✓ Illuccix® available in 22 countries, including 17 in Europe

2 Launch new products

- ✓ Secured Prescription Drug User Fee Act date for Pixclara®¹, **September 11, 2026**²
- ✓ Pixlumi®¹ **Marketing Authorization Application accepted** for review in Europe³

3 Advance five late-stage clinical programs

- ✓ **Advancing Phase 3 therapeutics programs:**
 - **TLX591-Tx** ProstACT Global: FDA alignment on safety and Part 2 Protocol in mCRPC⁴
 - **TLX101-Tx** IPAX BRIGHT⁵: dosing patients with recurrent glioblastoma
 - **TLX250-Tx** LUTEON: dosing patients with advanced ccRCC⁶
- ✓ **TLX090-Tx**⁷ SOLACE: dosing patients
- ✓ **BiPASS™**⁸ nearing completion of enrollment

On track to deliver in line with upper end of FY 2026 revenue guidance of \$950M - \$970M




1. Launch and brand names subject to final regulatory approval. Zircaix (TLX250-Px, ccRCC imaging), Pixclara and Pixlumi (TLX101-Px, glioma imaging).
2. Telix ASX disclosure April 10, 2026.
3. Telix media release May 1, 2026.
4. Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345, metastatic castration-resistant prostate cancer.
5. ClinicalTrials.gov ID: NCT07100730.
6. ClinicalTrials.gov ID: NCT07197580. Phase 3 study in Australia, phase 2a study in U.S./Europe. Clear cell renal cell carcinoma.
7. ClinicalTrials.gov ID: NCT07197645.
8. ClinicalTrials.gov ID: NCT07052214.

Continued commercial execution delivering growth

Delivered 22% YoY revenue growth

Market-leading position reinforced by differentiated products

- Group revenue increased by **22%** to **\$477M** driven by strong demand across our Precision Medicine portfolio
- Global revenue (ex-TMS) increased to **\$388M**, up **25%** YoY driven by Precision Medicine business market share gains
- Diversified revenue streams through TMS (**\$89M**¹) and international expansion



TMS = Telix Manufacturing Solutions.

1. TMS revenue from third parties. RLS is the largest component of TMS, contributing to third party revenue. Excludes revenues from Illucix and Gozellix sold through RLS.

2. Includes \$4M payment from China Grand Pharma collaboration.

3. Includes \$5M payment from China Grand Pharma collaboration.

Investments that expand our growth opportunities

Increased R&D investments to drive meaningful growth

EXPANDING INTO NEW INDICATIONS



Doubling the TAM by an incremental **~800,000+ scans per year**² and aiming to change the standard-of-care



New indication for diagnosis of brain metastasis, expanding the TAM by an incremental **100,000+ scans per year**⁴



TAM = Total addressable market, mHSPC = metastatic hormone sensitive prostate cancer.

1. Clinicaltrials.gov NCT07052214.
2. Based on positive scans for PS-RADS 2-4 (NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2025), includes negative scans at a ratio of 3.1 scan per positive case (Landa et al. PLOS ONE: 2024).
3. Launch and brand name subject to final regulatory approval.

EXPANDING THE PIPELINE

New, small molecule candidate, **TLX597-Tx** with potentially **best-in-class therapeutic profile**⁵

Two ongoing Phase 2 studies: OPTIMAL-PSMA⁶ in mCRPC and OPTIMAL-e⁷ to position the molecule for mHSPC




Entered into a co-development and co-commercialization agreement with **Regeneron** to develop next-generation candidates⁸

4. Based on internal estimates.
5. Presented at International Prostate Cancer Symposium, IPCS April 29, 2026.
6. Telix media release April 30, 2026; Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437.
7. Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336.
8. Telix ASX announcement April 12, 2026.

Expanding our manufacturing capabilities

Accelerating growth, de-risking execution and positioning for therapeutic launches





Financial update

Darren Smith
Chief Financial Officer



H1 2026 Key financial metrics

Strong financial performance across growth, profitability and cash generation



1. Refers to Group Income Statement. EBITDA refers to adjusted group earnings before interest, tax, depreciation and amortization. Net profit refers to Net profit after tax.

H1 2026 Income statement (Group)

Strong execution driving 22% revenue growth and 148% EBITDA expansion YoY

- **Gross margin (GM)** of **55%**, increased 2% YoY driven by disciplined pricing, manufacturing & distribution efficiencies
- **R&D investments** up **51% YoY**, driven by progress on four late-stage programs¹. Increased investment enabled by strong commercial execution and initial payment by Regeneron²
- **Operating expenses**³ reduced by **1%** as % of revenue driven by expense control
- **Operating profit** of **\$46M**, reflecting robust revenue growth, initial payment from Regeneron and disciplined cost management

	H1 2026 US\$M	% of revenue	H1 2025 US\$M	% of revenue	YoY change
Revenue	477		390		22%
Cost of sales	(217)		(181)		20%
Gross profit	260	55%	209	53%	24%
Other income	40	8%	—	—	*
Research and development (R&D)	(124)	(26)%	(82)	(21)%	51%
Operating expenses	(136)	(29)%	(116)	(30)%	17%
Other gains/(losses)	6	1%	(1)	—	*
Operating profit	46	10%	10	3%	360%
Finance income	2	—	4	1%	(50)%
Finance costs	(19)	(4)%	(19)	(5)%	—
Profit/(loss) before tax	29	6%	(5)	(1)%	*
Adjusted EBITDA	52	11%	21	5%	148%


* Percentage not meaningful



1. ProSTATE Global, Phase 3 study NCT 06520345, LUTEON, Phase 2/3 study, NCT 07197580, IPAX BrIGHT, Phase 3 study NCT 07100730, BiPASS, Phase 3 study NCT 07052214.
2. Other income refers to an upfront payment of \$40M from Regeneron.
3. Operating expenses comprises S&M, G&A, M&D.

Strong revenue generation provides flexibility to reinvest

Discretionary R&D investment driving new growth opportunities



1: TMS revenue from third parties. RLS is the largest component of Telix Manufacturing Solutions, TMS, contributing to third party revenue. Excludes revenues from Illucix and Gozellix sold through RLS.

Precision Medicine delivering growth and high margins

A highly profitable business delivering 26% YoY EBITDA growth

- **Revenue** increased by **27%** to **\$388M**, driven by continued adoption of Illuccix and Gozellix across all markets
 - Strong demand supported by differentiated products, reimbursement strategy and global expansion
- **Gross margin expanded 1% YoY to 65%**¹, reflecting a favorable product mix and disciplined pricing strategy
- **R&D investments up 42% YoY** driven by Pixclara², Zircaix² and BiPASS™ to deliver near-term growth
- **Delivered EBITDA³ growth of 26% YoY to \$132M**, while continuing to reinvest in key, near-term pipeline initiatives



Precision Medicine

1. Cost of sales includes intersegment distribution fees of \$12M (H1 2025: \$6M).
2. Launch and brand names subject to final regulatory approval.
3. Refers to Adjusted EBITDA.

	H1 2026	% of	H1 2025	% of	YoY
	US\$M	revenue	US\$M	revenue	change
Revenue	388		306		27%
Cost of sales	(134)		(109)		23%
Gross profit	254	65%	197	64%	29%
Research and development (R&D)	(54)	(14)%	(38)	(12)%	42%
Operating expenses	(69)	(18)%	(56)	(18)%	23%
Other gains/(losses) (net)	1	—	(2)	(1)%	*
Operating profit	132	34%	101	33%	29%
Adjusted EBITDA	132	34%	105	34%	26%

* Percentage not meaningful

Telix Manufacturing Solutions (TMS)

Investment in manufacturing and supply chain to scale up operations

- TMS generated **\$89M** of third-party revenue, up **10% YoY¹**, primarily driven by RLS
- RLS drove manufacturing and supply chain efficiencies, with internal revenue up **73% YoY to \$57M²**
- **\$23M EBITDA impact** driven by targeted investments in future therapeutic growth
 - Seneffe GMP capacity build-out for therapeutic candidates
 - Yokohama, ARTMS QIS® installation to support isotope production
 - RLS expansion to add therapy manufacturing lines

	H1 2026	% of revenue	H1 2025	% of revenue	YoY Change
	US\$M		US\$M		
External revenue	89		81		10%
Internal revenue	57		33		73%
Cost of sales	(138)		(103)		34%
Gross profit	8	5%	11	10%	(27)%
Research and development (R&D)	(3)	(2)%	(3)	(3)%	—%
Operating expenses	(38)	28%	(28)	27%	36%
Operating loss	(33)	(23)%	(20)	(18)%	65%
Adjusted EBITDA (loss)	(23)	(16)%	(13)	(11)%	77%



Manufacturing Solutions

1. Prior period comparisons reflect RLS results since acquisition close as of January 28, 2025.
2. Internal revenue is eliminated on consolidation.

FY 2026 guidance


Continued growth trajectory

Revenue guidance range: \$950M to \$970M¹

- Based on approved products and geographies
- ~25% growth in Precision Medicine revenue
- Potential upside pending regulatory approvals
- Revenue is expected to come in at the upper end of guidance

R&D guidance range: \$230M to \$270M

- Pipeline expansion: TLX597-Tx
- Research collaboration with Regeneron
- Pixclara² indication expansion
- BiPASS study expansion



We will continue reinvesting our earnings to position the Company for long-term growth



Guidance is based on expected global and domestic economic conditions and subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. See Disclaimer for more information.

1. Excludes \$40 million non-refundable other income received from Regeneron.

2. Launch and brand names subject to final regulatory approval.




Precision Medicine

Precision Medicine update

Kevin Richardson
Precision Medicine, CEO




Precision Medicine portfolio delivered 31% YoY growth and 9% QoQ growth



Global infrastructure buildout to enable therapeutic launches

Building a global footprint with regulators, customers and payers



(kit for the preparation of gallium
Ga 68 gozetotide Injection)

Global approvals and launches on track

- Illuccix has marketing authorizations in **24 countries**¹
- Commercially available in **22 countries**²
- Completed Phase 3 study in China - **NDA under review**³
- **Completed patient enrollment** in Phase 3 study in Japan⁴



Precision Medicine

1. Australia, Brazil, U.S., Canada, UK, Ireland, France, Spain, Germany, Italy, Portugal, Belgium, Netherlands, Luxembourg, Norway, Sweden, Denmark, Finland, Austria, Czech Republic, Slovakia, Cyprus, Greece, Malta.
2. Australia, Brazil, U.S., Canada, UK, Ireland, France, Spain, Germany, Italy, Portugal, Belgium, Netherlands, Luxembourg, Norway, Sweden, Denmark, Finland, Austria, Czech Republic, Slovakia, Switzerland. Temporary supply in Switzerland due to local shortages.
3. Telix media release January 19, 2026. ClinicalTrials.gov ID: NCT05847348.
4. Telix media release July 17, 2026. Japan Registry of Clinical Trials identifier: JRCT2031250473.

Two first-in-class imaging agents for glioma and renal masses potentially first to market^{1,2}



PDUFA date: **September 11, 2026**,
Pixlumi^{®3} **MAA accepted** in Europe

Included in National Comprehensive
Cancer Network (**NCCN[®]**) **guidelines**

Inclusion in **International guidelines**:
EANM/EANO/RANO/SNMMI

Expanding into new indication: **brain metastases⁴**

**Potentially first to market (U.S.)¹
for imaging of gliomas**



Precision Medicine

PDUFA = Prescription Drug User Fee Act. MAA = Marketing authorization application. EANM = European Association of Nuclear Medicine. EANO = European Association of Neuro-Oncology. RANO = Response Assessment in Neuro-Oncology. SNMMI = Society of Nuclear Medicine and Molecular Imaging. BLA = Biologics License Application. ACNM = American College of Nuclear Medicine.

1. Subject to FDA approval.

2. First to market for Pixclara refers to the U.S.

3. Launch and brand names subject to final regulatory approval.

4. ASX release July 20, 2025.



BLA resubmission in progress


Breakthrough Therapy Designation and
Fast Track Designation

Inclusion in the **International guidelines**:
SNMMI, EANM and ACNM for molecular imaging
of renal masses

**Potentially first radiolabeled biologic to
market¹ for imaging of renal masses**

Current state: PSMA-PET transformed staging and BCR detection


Initial biopsy protocol has remained unchanged since the addition of MRI



TAM = Total addressable market, BCR = Biochemical recurrence, nmCRPC = non-metastatic castration-resistant prostate cancer, RLT = Radioligand therapy.
ClinicalTrials.gov: NCT07052214. Annual PSMA-PET scan volume in the U.S. based on internal estimates.

Future state: BiPASS revolutionizes biopsy decision-making

Potential to double the size of the existing PSMA market





Therapeutics update and outlook

Dr. David N. Cade
Chief Medical Officer



Pipeline: Late-stage and “next-generation” assets



PSMA: Prostate-specific membrane antigen.
CAIX: Carbonic anhydrase IX.
LAT1: L-Type amino acid transporter 1.
CD66: Cluster of differentiation 66.

PDGFRα: Platelet-derived growth factor receptor alpha.
mAb: Monoclonal antibody.
SM: Small molecule.
FAP: Fibroblast activation protein.

Progressing across early and late-stage therapeutics pipeline

Select pipeline highlights

Delivering on our late-stage pipeline



Phase 3 study for TLX591-Tx for mCRPC reached alignment with FDA on safety data to progress to Part 2¹



TLX101-Tx², Phase 3 study for glioblastoma completed enrollment of first cohort



TLX250-Tx, Phase 2/3 study for ccRCC³ started dosing patients



Therapeutics

Advancing our earlier stage candidates

TLX597-Tx, Phase 2 study for mCRPC completed enrollment in OPTIMAL-PSMA⁵, 120 patients, and started dosing patients in OPTIMAL-e for mHSPC⁶



TLX090-Tx⁴, Phase 1 study for bone pain in patients with osteoblastic lesions continues enrolling patients




Collaboration with Regeneron focused on alpha therapies, including targets for lung cancer⁷

1. Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345.
2. ClinicalTrials.gov ID: NCT07100730.
3. ClinicalTrials.gov ID: NCT07197580.
4. ClinicalTrials.gov ID: NCT07197645.

5. Telix LinkedIn June 25, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437.
6. Telix media release July 16, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336.
7. Telix ASX disclosure April 13, 2026.

Our multi-product prostate cancer therapy portfolio

Aligned to disease state, patient needs and clinical opportunity



A catalyst rich 2026

Select milestones for Therapeutics candidates

- ✓ **Regeneron collaboration**
- **TLX591-Tx** for mCRPC, ProstACT Global
 - ✓ **Part 1 data readout**
 - Part 2 international site expansion, interim analysis¹
- **TLX592-Tx** for mCRPC, AlphaPRO, patient dosing
- ✓ **TLX597-Tx** for mCRPC, OPTIMAL-PSMA, enrollment completion. OPTIMAL-e, patient dosing
- **TLX090-Tx** for metastatic bone pain, SOLACE, enrollment completion
- ✓ **TLX250-Tx** for ccRCC, LUTEON, patient dosing
- **TLX252-Tx** for ccRCC and other CAIX-expressing tumors, trial commencement
- **TLX101-Tx** for recurrent GBM
 - ✓ IPAX BrIGHT, first patient cohort dosed
 - IPAX 2- data readout MTD (Max tolerated dose)
- **TLX102-Tx** for recurrent GBM and leptomeningeal disease, trial commencement
- **TLX400-Tx** recommencement of clinical activity



QIS = QUANTM irradiation system, a cyclotron-based isotope production system. NDA = New drug application, MAA = Marketing authorization application, IND = Investigational new drug.
 1. Protocol ¹⁷⁷Lu-TLX591-203.
 2. Brand name subject to final regulatory approval.

Select milestones for Precision Medicine candidates

- ✓ **Pixclara² NDA resubmission (U.S.)**
- ✓ **Pixlumi² MAA submission (Europe)**
- ✓ **Pixclara² IND submission for new indication**
- **Zircaix² BLA resubmission (U.S.)**
- **BiPASS** enrollment completion
- ✓ **Illuccix** Japan, enrollment completion
- **Illuccix** China, regulatory approval/launch
- **TLX593-Px (AlFluorTM)** trial commencement

Select milestones for Telix Manufacturing Solutions

- ✓ Commence **cyclotron** installations at key RLS sites
- ✓ **TMS North Melbourne site opening**
- **50 ARTMS QIS® installations globally**



Q&A



Appendix 4D

Half-year ended

June 30, 2026

Results announcement to the market

Current Reporting Period:	June 30, 2026
Previous Reporting Period:	June 30, 2025

This page and the following pages comprise the half-year information given to the ASX under Listing Rule 4.2A.

The results are prepared in accordance with International Financial Reporting Standards (IFRS), and also comply with Australian Accounting Standards. Amounts are presented in US dollars (US\$).

Revenue and net profit/(loss)

	6 months to June 30, 2026	Change	Change	Change	6 months to June 30, 2025
	US\$'000		US\$'000	%	US\$'000
Revenue from contracts with customers	477,350	Up	86,991	22	390,359
Profit/(loss) after income tax for the year attributable to	38,330	Up	40,622	1,772	(2,292)
Total comprehensive income for the period attributable to members	9,458	Up	6,203	191	3,255

No dividend was proposed or paid. Should any dividends be paid in the future, no assurances can be given as to the level of franking credits attaching to such dividends.

	June 30, 2026	June 30, 2025
	Cents	Cents
Profit/(loss) per share	11.30	(0.68)
Net tangible assets per share	(83.00)	(68.37)
Dividend per share	-	-

Explanation of results

Telix continues to deliver strong revenue growth, with the Company generating total revenue of \$477,350,000 for the half-year (2025: \$390,359,000) with associated cost of sales of \$217,001,000 (2025: \$181,736,000). Gross profit increased to \$260,349,000 for the half-year (2025: \$208,623,000).

As Telix continues to grow and scale, operating expenditure in the half-year totalled \$259,562,000 (2025: \$197,128,000). Included within operating expenditure was \$123,828,000 (2025: \$81,583,000) related to R&D activities for the Company's assets and development programs. Telix also recorded other income generated from our collaboration with Regeneron Pharmaceuticals, Inc. of \$40,000,000 (2025: \$nil) and other gains of \$5,575,000 (2025: losses of \$1,105,000).

Telix recorded an operating profit for the half-year of \$46,362,000 (2025: \$10,390,000), primarily driven by continued strong growth in U.S. sales of Illuccix and Gozellix and other income associated with the collaboration with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Finance income totaled \$2,274,000 (2025: \$3,616,000) and finance costs were \$19,388,000 for the half-year (2025: \$18,842,000).

Income tax benefit for the half-year was \$9,082,000 (2025: \$2,544,000), leading to a net profit for the period of \$38,330,000 (2025: loss of \$2,292,000).

For further commentary on the Company's results and other information required by Listing Rule 4.2A, please refer to the Company's investor releases and Interim Report, including the Financial review and Financial report lodged with the ASX today.

Auditor's review

This report is based on the Interim financial report for the half-year ended June 30, 2026 of Telix Pharmaceuticals Limited and its controlled entities, which has been reviewed by PricewaterhouseCoopers (PwC). The Independent auditor's review report provided by PwC is included in the Interim financial report.

The Appendix 4D and Interim financial report for the half-year ended June 30, 2026 have been approved for release by the Board of Directors.



Shomalin Naidoo
Company Secretary (Interim)

August 20, 2026



Telix Pharmaceuticals Limited

ACN 616 620 369

Interim Report June 30, 2026

Lodged with the ASX under Listing Rule 4.2A

Directors' report	3
Auditor's independence declaration	21
Interim financial report	22
Directors' declaration	42
Independent auditor's review report	43
Glossary of terms and abbreviations	45
Company directory	46

Legal notice. This report is intended for global use.

This report covers Telix's global operations, including subsidiaries, unless otherwise noted. A reference to Telix, Telix Group, we, us and our and similar expressions refer collectively to Telix Pharmaceuticals Limited and its related bodies corporate. The information contained in this report is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix in any jurisdiction, including the United States (U.S.). The information and opinions contained in this report are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this report, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this report.

Telix products are currently investigational use only unless indicated and are subject to future regulatory developments and product approvals. Ilucix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozetlix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA. Telix's osteomyelitis (bone infection) imaging agent, technetium-99m (^{99m}Tc) besilecomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix's miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction. Any other Telix drug or device that is discussed in this report, including Zircaix and Pixlara, is investigational or under development and not approved by any regulatory authority. The efficacy or safety profile of any unapproved drug or device has not been determined by any regulatory authority. In addition, Zircaix and Pixlara brand names and launch are subject to final regulatory approval. Registrations vary from country to country. Some statements about products, registered product indications or procedures may differ in certain countries. Therefore, always consult the country specific product information, package leaflets or instructions for use. Any content relating to third party products is based on publicly available data and is accurate at the date of publication.

Forward-looking statements

This report contains forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

This report also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of Telix's future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

Readers should read this report together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX) and U.S. Securities and Exchange Commission (SEC) or on our website. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance.

Non-IFRS financial measures

Telix's results are reported under International Financial Reporting Standards (IFRS). This report includes various non-IFRS financial information to reflect its underlying performance, which has not been subject to audit or review. These non-IFRS measures include Adjusted EBITDA, which represents net earnings attributable to the Group excluding finance costs, income tax expense, depreciation and amortization, remeasurement of provisions, other income and expenses. As required by SEC rules, we have provided reconciliations of these non-IFRS financial measures to the most directly comparable IFRS measures, which for Adjusted EBITDA, is Profit/(loss) before income tax. The Group believes that these non-IFRS measures, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The non-IFRS measures are not defined by IFRS and therefore may not be directly comparable with other companies' alternative performance measures.

Trademarks and Trade Names

All trademarks and trade names referenced in this report are the property of Telix or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.
Telix Pharmaceuticals Limited ABN 85 616 620 369 / ACN 616 620 339

The background of the slide is a solid blue color. In the upper right corner, there are several concentric, curved white lines that sweep across the frame, creating a dynamic, abstract design.

Directors' report

Directors

The Board of Directors of Telix Pharmaceuticals Limited is pleased to present its report on the consolidated entity (Group) for the half-year ended June 30, 2026 (H1 2026). The Group consists of Telix Pharmaceuticals Limited (Telix) and its wholly owned or controlled subsidiaries. The following persons were Directors of Telix Pharmaceuticals Limited during the half-year ended June 30, 2026 and up to the date of this report:

Name	Title
Christian Behrenbruch	Managing Director and Group Chief Executive Officer
David Gill	Non-Executive Director (appointed May 11, 2026)
William Jellison	Non-Executive Director (appointed May 11, 2026)
Marie McDonald	Non-Executive Director
Mark Nelson ¹	Non-Executive Director and Interim Chair (Interim Chair appointed February 3, 2026)
Tiffany Olson	Non-Executive Director and Chair (resigned February 3, 2026)
Maria Rivas	Non-Executive Director (appointed May 11, 2026)
Jann Skinner	Non-Executive Director

Operating and financial review

The following discussion and analysis are based upon and should be read together with our consolidated interim financial statements and the accompanying notes and other financial information included elsewhere in this Interim Report. This discussion includes both historical information and forward-looking information based upon current expectations that involve risk, uncertainties and assumptions. Our actual results may differ materially from management's expectations as a result of various factors, including, but not limited to, those discussed in "Item 3. Key Information — D. Risk Factors" and elsewhere in our previously filed 2025 Annual Report.

Our interim consolidated financial statements as of June 30, 2026 and December 31, 2025 and for the periods ended June 30, 2026 and June 30, 2025 have been prepared in accordance with IFRS Accounting Standards as issued by the IASB.

Operating review

Telix is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix continued to execute against its integrated growth strategy during H1 2026, underpinned by five core areas of focus: advancing its late-stage therapeutic pipeline, growing its industry-leading Precision Medicine business, strengthening its commercial execution, investing in its next generation R&D portfolio, and expanding its vertically integrated manufacturing and distribution capabilities. This model is designed to support sustainable growth by using commercial revenues to fund the development of additional late-stage therapeutic and diagnostic product candidates, while building the infrastructure required to bring radiopharmaceutical products to patients at scale.

The Group's commercial performance continued to provide a strong platform for investment in future growth. Revenue from contracts with customers increased to \$477.3 million for the period, up 22% compared with the period ended June 30, 2025, driven primarily by continued demand for Illuccix® and Gozellix® in the U.S. and supported by a full six months of contribution from RLS Radiopharmacies. Precision Medicine revenue increased 27%, reflecting higher sales volumes, pricing and market share gains for Telix's commercial PSMA-PET² imaging franchise. The costs associated with such sales and our operating and other expenses resulted in a profit after tax of \$38.3 million for the period ended June 30, 2026, compared with a loss after tax of \$2.3 million for the period ended June 30, 2025.

Telix increased R&D investment in H1 2026 to support both near-term and long-term growth opportunities. R&D costs increased to \$123.8 million for H1 2026, up 52% compared with H1 2025, primarily reflecting investment in late-stage therapeutic assets and regulatory filings across the Precision Medicine portfolio:

- **TLX591-Tx** (lutetium-177 (¹⁷⁷Lu) rosopitamab tetraxetan), a therapeutic radio antibody-drug conjugate (rADC), being evaluated in the Phase 3 ProstACT Global clinical trial for the treatment of patients with prostate cancer³.

¹ Dr. Nelson was appointed Interim Chair of the Board following Tiffany Olson's resignation as Chair and Non-Executive Director, effective February 3, 2026.

² Imaging of prostate-specific membrane antigen with positron emission tomography.

³ ClinicalTrials.gov ID: [NCT06520345](https://clinicaltrials.gov/ct2/show/study/NCT06520345).

- **TLX250-Tx** (lutetium (¹⁷⁷Lu) girentuximab tetraxetan), a therapeutic rADC being evaluated in the Phase 2/3 LUTEON trial for the treatment of patients with kidney cancer¹.
- **TLX101-Tx** (¹³¹I-iodofalan), a therapeutic small molecule being evaluated in the Phase 2/3 IPAX BrIGHT trial for the treatment of patients with glioblastoma (brain cancer)².
- **TLX591-Px/TLX007-Px** (⁶⁸Ga-PSMA-11) for prostate cancer imaging in the pre-biopsy setting (BiPASS™)³.
- **TLX101-Px** (Pixclara®⁴, floretyrosine F 18) for glioma (brain cancer) imaging.
- **TLX250-Px** (Zircaix®⁴, zirconium-89 (⁸⁹Zr) girentuximab senvedoxam) for kidney cancer imaging.

In April 2026, Telix refinanced its existing Convertible Bonds due in 2029 on improved terms, lowering the cost of funding and extending its financial flexibility. This transaction was undertaken ahead of maturity and the new Convertible Bonds due in 2031 provide greater flexibility as the Company continues to invest in growth.

Also in April 2026, the Group entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to jointly develop and commercialize next-generation radiopharmaceutical therapies. The collaboration combines Telix's radiopharmaceutical development and manufacturing capabilities with Regeneron's antibody discovery and oncology expertise. Under the collaboration, the parties will co-develop and co-commercialize multiple therapeutic programs on a 50/50 cost- and profit-sharing basis. Telix received a payment of \$40.0 million on entering the collaboration agreement in respect of four initial therapeutic programs, with Regeneron holding options to expand the collaboration to additional programs.

Telix continued to expand its vertically integrated manufacturing and distribution infrastructure during H1 2026, supporting both current commercial supply and future therapeutic product delivery. Telix Manufacturing Solutions (TMS) reported \$146.2 million total segment revenue, which includes \$88.7 million from third-party product sales and service fees, and \$57.5 million internal revenue⁵, reflecting growth in sales of Illuccix® and Gozellix® through the RLS network and contributing to Group gross margin improvement.

During the reporting period, the Company announced that it had appointed three additional Non-Executive Directors (NEDs), effective May 11, 2026, as part of Board expansion and succession planning⁶. David Gill, María Rivas, MD, and William (Bill) Jellison further strengthen the Board's clinical, commercial, financial and governance expertise, enhancing the Company's capabilities as a dual-listed, commercial-stage biopharmaceutical company. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as NED.

Progress for the half-year ended June 30, 2026 is outlined in the following table:

**Deliver our
late-stage
therapeutic
pipeline**

TLX591-Tx (lutetium (¹⁷⁷Lu) rosopatomab tetraxetan):

- **Part 1 of ProstACT Global:** Phase 3 trial of lead prostate cancer therapy candidate, met safety and dosimetry objectives with no new safety signals observed⁷. Data presented in late-breaking oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois (U.S.)⁸.
- **Part 2 of ProstACT Global:** United States Food and Drug Administration (FDA) alignment on protocol, statistical analysis plan, and ongoing safety monitoring plan⁹. Continues to enroll well in regions where recruitment is open including Australia, Canada, New Zealand, Singapore, South Korea, Türkiye and the United Kingdom.

TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan):

- First patient dosed in LUTEON¹⁰, a pivotal trial of TLX250-Tx as a monotherapy in advanced clear cell renal cell carcinoma (ccRCC).

TLX101-Tx (¹³¹I-iodofalan):

- First patient cohort fully enrolled in Part 1 of IPAX BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma¹¹.
- Completed patient enrollment in IPAX-2, a Phase 1 study evaluating TLX101-Tx in patients with newly diagnosed glioblastoma, with no dose-limiting toxicities observed to date¹².

¹ ClinicalTrials.gov ID: [NCT07197580](#).

² ClinicalTrials.gov ID: [NCT07100730](#).

³ ClinicalTrials.gov ID: [NCT07052214](#).

⁴ Brand name subject to final regulatory review.

⁵ Inter-segment revenue is eliminated on consolidation, refer to note 3 of the Interim financial report lodged today with the ASX.

⁶ Telix ASX disclosures April 2, 2026 and April 9, 2026.

⁷ Telix media release March 9, 2026. ClinicalTrials.gov ID: [NCT06520345](#).

⁸ Telix media release June 2, 2026. Barata et al. *J Clin Oncol* 44, LB45009. 2026.

⁹ Telix ASX disclosure July 2, 2026. Initiation of Part 2 in the U.S. remains subject to the FDA's review of an Investigational New Drug (IND) amendment.

¹⁰ Telix media release July 21, 2026. ClinicalTrials.gov ID: [NCT07197580](#).

¹¹ Telix ASX disclosure July 21, 2026. ClinicalTrials.gov ID: [NCT07100730](#).

¹² Telix media release May 19, 2026. ClinicalTrials.gov ID: [NCT05450744](#).

Build the next generation of radio-pharmaceuticals

Regeneron collaboration

- Entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies¹.
- The collaboration combines Telix's radiopharmaceutical development, manufacturing and supply chain capabilities with Regeneron's leading antibody discovery and development platforms, creating a framework to advance multiple novel oncology programs and further strengthen Telix's position in precision medicine.

TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA):

- OPTIMAL-PSMA Phase 2 trial evaluating TLX597-Tx for mCRPC completed patient enrollment². Trial design and rationale published in *European Urology Focus*³ and the *Journal of Nuclear Medicine*⁴.
- First patients dosed in the OPTIMAL-e Phase 2 trial, evaluating TLX597-Tx for metastatic hormone sensitive prostate cancer⁵.

TLX400-Tx (¹⁷⁷Lu-DOTAGA.Glu.(FAPi)2)

- Results demonstrating encouraging clinical anti-tumor activity and safety profile in medullary thyroid cancer published in the *European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Research*⁶.

TLX300-Px (⁸⁹Zr-olaratumab):

- Telix continues to dose patients in ZOLAR, a Phase 1, first-in-human (FIH) imaging study for patients with advanced, metastatic soft tissue sarcoma (STS) and other platelet derived growth factor receptor alpha (PDGFRα) positive tumors, aiming to demonstrate proof of concept for therapy⁷.

TLX090-Tx (¹⁵³Sm-DOTMP):

- Telix continues to dose patients in SOLACE, a Phase 1 study for pain palliation in patients with osteoblastic bone metastases from prostate and breast cancers⁸.

Grow our industry-leading Precision Medicine business

Ilucix® (TLX591-Px, ⁶⁸Ga PSMA-11):

- Approved in 24 countries worldwide⁹.
- China:** New Drug Application (NDA) under review by the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE)¹⁰.
- Japan:** Dosed first patient¹¹ and completed enrollment¹² in Phase 3 Japan registrational study¹³. Preparing NDA with clinical data from the Phase 3 local study intended to support the application. Conditional Approval application under Pharmaceuticals and Medical Devices Agency (PMDA) review¹⁴.

BiPASS™:

- Phase 3 study of Ilucix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting, enrollment nearing completion.

¹ Telix ASX disclosure April 13, 2026.

² Telix LinkedIn June 25, 2026. Australian New Zealand Clinical Trials Registry ID: [ACTRN12625000971437](#).

³ Sheehan-Dare et al. *Eur Urol Focus*. 2026.

⁴ Khan et al. *J Nucl Med*. 2026.

⁵ Telix media release July 16, 2026. Australian New Zealand Clinical Trials Registry ID: [ACTRN12626000034336](#).

⁶ Ballal et al. *EJNMMI Res*. 2026.

⁷ ClinicalTrials.gov ID: [NCT06537596](#).

⁸ ClinicalTrials.gov ID: [NCT07197645](#).

⁹ Australia, Austria, Belgium, Brazil, Canada, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovakia, Spain, Sweden, UK, U.S.

¹⁰ Telix media release January 20, 2026.

¹¹ Telix media release January 29, 2026.

¹² Telix media release July 17, 2026.

¹³ Japan Registry of Clinical Trials Identifier: JRCT2031250473.

¹⁴ Telix media release January 20, 2026.

Grow our industry-leading Precision Medicine business (contd.)

TLX101-Px, (floretyrosine F 18) for glioma (brain cancer) imaging:

- Resubmitted NDA accepted by U.S. FDA for Pixclara¹ with a PDUFA² goal date of September 11, 2026³.
- Marketing Authorization Application (MAA) for Pixlumi^{®1} in Europe validated and accepted for review⁴.
- Investigational New Drug (IND) application successfully cleared, with Study May Proceed notification received from FDA for Phase 3 registrational study for indication expansion for the diagnosis of brain metastases.

Zircaix¹ (TLX250-Px, zirconium-89 (⁸⁹Zr) girentuximab senvedoxam) for kidney cancer imaging:

- Continued to progress U.S. Biologics License Application (BLA) resubmission with final Chemistry, Manufacturing and Controls (CMC) documentation nearing completion. Telix has been granted an extension of the BLA resubmission, following receipt of a corrected Complete Response Letter (CRL)⁵. Telix continues to work closely with the FDA to ensure the resubmission package comprehensively addresses all outstanding CRL items.

Expand our global infrastructure for product delivery

TMS North Melbourne

- Opened in partnership with the Melbourne Theranostic Innovation Centre (MTIC)⁶. The purpose-built facility combines radiochemistry laboratories, clinical product manufacturing, patient dosing and imaging that aims to provide advanced clinical infrastructure and R&D capabilities to accelerate the development of targeted radiopharmaceuticals.

TMS Seneffe (Brussels South)

- Successfully completed its first Good Manufacturing Practice (GMP) production run of a lutetium-based therapeutic candidate, representing a significant operational milestone and further validating the facility's capabilities to support the manufacture of Telix's next-generation therapeutics.

TMS Yokohama

- Installed ARTMS' QUANTM[®] Irradiation System (QIS[®]) at TMS Yokohama (Japan), expanding isotope production capabilities and enabling local Zirconium-89 (⁸⁹Zr) manufacturing to support Telix's portfolio. The installation represents further progress in scaling the ARTMS network and advancing toward the Company's target of 50 QIS[®] installations globally by the end of 2026.

Prospects and likely developments

The future prospects of Telix's growth and operational targets will be assisted by:

- continued revenue growth of Illuccix[®] and Gozellix[®].
- marketing authorization and successful commercial launches of follow-on imaging agents: Pixclara¹ (TLX101-Px) and Zircaix¹ (TLX250-Px).
- advancement of the therapeutic pipeline.
- integration and expansion of the RLS business.
- operationalization of the TMS network.

More information relating to the factors that could affect our growth and operational targets is provided in the Risk Factors section of Telix's 2025 Annual Report.

¹ Brand name subject to final regulatory approval.

² Prescription Drug User Fee Act.


³ Telix ASX disclosure April 10, 2026.

⁴ Telix media release May 1, 2026.

⁵ Corrected CRL issued April 10, 2026.

⁶ Telix media release July 16, 2026.

Financial review



In 2026, Telix continues on a significant growth trajectory, driven by the global commercial success of Illuccix® and Gozellix®. As the Company advances toward near-term regulatory milestones and progresses a promising pipeline of therapeutic candidates, these strategic investments in our late-stage candidates are positioning Telix to deliver its next phase of growth and make a meaningful difference to patients' lives, underpinned by a resilient and diversified business model with multiple revenue streams.

Our operations have been financed primarily through cash generated by our commercial operations and the issuance of Ordinary Shares and Convertible Bonds.

Reported profit after tax attributable to Telix Shareholders was \$38.3 million for the period ended June 30, 2026, compared to a loss of \$2.3 million for the period ended June 30, 2025. The net profit reflects the impact of income on entering our strategic collaboration with Regeneron, and continued success in our commercial businesses, allowing us to increase investment in our Therapeutic pipeline.

Our total comprehensive income was \$9.5 million for the period ended June 30, 2026, compared to \$3.3 million for the period ended June 30, 2025. We expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. In addition, if and when we seek and obtain regulatory approval to commercialize additional product candidates, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our total comprehensive income or loss may fluctuate significantly from period-to-period, depending on the timing of our clinical trials and our expenditures on other research and development activities.

The following table sets forth a summary of the Group's Consolidated statement of comprehensive income for the periods ended June 30, 2026 and June 30, 2025.

	Half-year ended		HY 2026 vs. 2025	
	June 30 2026	June 30 2025	Change	Change
	US\$'000	US\$'000	US\$'000	%
(in thousands, except percentage and per share data)				
Continuing operations				
Revenue from contracts with customers	477,350	390,359	86,991	22
Cost of sales	(217,001)	(181,736)	(35,265)	19
Gross profit	260,349	208,623	51,726	25
Other income	40,000	-	40,000	*
Research and development costs	(123,828)	(81,583)	(42,245)	52
Selling and marketing expenses	(58,358)	(48,973)	(9,385)	19
Manufacturing and distribution costs	(28,713)	(18,849)	(9,864)	52
General and administration costs	(48,663)	(47,723)	(940)	2
Other gains/(losses)(net)	5,575	(1,105)	6,680	*
Operating profit	46,362	10,390	35,972	346
Finance income	2,274	3,616	(1,342)	(37)
Finance costs	(19,388)	(18,842)	(546)	3
Profit/(loss) before income tax	29,248	(4,836)	34,084	*
Income tax benefit	9,082	2,544	6,538	257
Profit/(loss) for the period	38,330	(2,292)	40,622	*
Profit/(loss) for the period attributable to:				
Owners of Telex Pharmaceuticals Limited	38,330	(2,292)	40,622	*
Other comprehensive income:				
<i>Items that will not be reclassified to profit or loss in subsequent periods:</i>				
Changes in the fair value of investments at fair value through other comprehensive income	1,207	(1,381)	2,588	*
<i>Items to be reclassified to profit or loss in subsequent periods:</i>				
Exchange differences on translation of foreign operations	(30,079)	6,928	(37,007)	*
Total comprehensive income for the period	9,458	3,255	6,203	191

* Percentage not meaningful

Revenue from contracts with customers

The Group delivered sustained growth in revenue. Revenue from contracts with customers was \$477.3 million for the period ended June 30, 2026, an increase of \$87.0 million, or 22%, compared to \$390.4 million for the period ended June 30, 2025. The Precision Medicine business was the standout driver, generating \$388.6 million, while the Manufacturing Solutions business (TMS) continued to build momentum, generating \$88.7 million in sales of third-party products and services. This increase is also attributable to six months of revenue from RLS in 2026, compared to five months of revenue in 2025 (acquired on January 28, 2025).

Cost of sales

Cost of sales increased by \$35.3 million, or 19%, to \$217.0 million for the period ended June 30, 2026, from \$181.7 million for the period ended June 30, 2025. The increase was primarily driven by increased sales volumes from our Precision Medicine business.

Gross margin improved in 2026 relative to 2025, increasing to 55% for the period ended June 30, 2026 (compared to 53% for the period ended June 30, 2025), reflecting the product mix of high value, Precision Medicine products in Telix's portfolio and the sales of higher volume and lower margin SPECT¹ imaging products at RLS. The Group's gross margin also reflects the effect of a full half-year of the RLS business. Precision Medicine gross margin improved during the period ended June 30, 2026 to 65% (64% for the period ended June 30, 2025), supported by increased sales of Gozellix® in the U.S., disciplined pricing and effective control of cost of sales across the portfolio.

Research and development costs

Revenue growth enabled an increased investment into R&D. R&D costs were \$123.8 million for the period ended June 30, 2026, an increase of \$42.2 million, or 52%, compared to \$81.6 million for the period ended June 30, 2025. In line with our communicated strategy, the Company is investing a proportion of its revenue into R&D with the goal of creating further revenue streams. Accordingly, expenditure predominantly focused on advancing clinical trials for late-stage therapeutic assets and progressing regulatory resubmissions for Precision Medicine assets.

R&D investment reflects:

- the inclusion of a new Tx candidate, TLX597-Tx, a next generation PSMA-targeting prostate cancer radioligand therapy.
- expansion of the BiPASS™ study, the first study designed to gain marketing authorization for ⁶⁸Ga-PSMA-PET imaging in the pre-biopsy setting.
- continued enrollment in Part 2 of the ProstACT Global Phase 3 trial of TLX591-Tx.
- preparing the Zircaix² (TLX250-Px) BLA and the Pixclara² (TLX101-Px) NDA resubmissions.

Selling and marketing expenses

Selling and marketing expenses were \$58.4 million for the period ended June 30, 2026, an increase of \$9.4 million, or 19%, compared to \$49.0 million for the period ended June 30, 2025. This increase was primarily driven by increased investment in promotional activities and sales force operations, deployed to drive higher global sales volumes of Illuccix® and Gozellix®.

Manufacturing and distribution costs

Manufacturing and distribution costs were \$28.7 million for the period ended June 30, 2026, an increase of \$9.9 million, or 52%, compared to \$18.8 million for the period ended June 30, 2025. This increase was primarily driven by the impact of six months of RLS operations on the Group results when compared to approximately five months post-acquisition in 2025, and higher costs associated with increased activity across our TMS sites.

General and administration costs

General and administration costs were \$48.7 million for the period ended June 30, 2026, an increase of \$1.0 million, or 2%, compared to \$47.7 million for the period ended June 30, 2025. This increase was driven by:

- the impact of six months of RLS operations on the Group results.
- increased legal, IT infrastructure and software costs.

Other income

Other income for the period resulted from the \$40.0 million initial, non-refundable payment received as part of the collaboration with Regeneron entered into in April 2026. The Group received the payment in respect of four initial therapeutic programs, with Regeneron holding options to expand the collaboration to additional programs. Refer to note 4.4 of the Interim financial report for further details.

Other gains/(losses) (net)

Other gains (net) were \$5.6 million for the period ended June 30, 2026, a change of \$6.7 million, compared to other losses (net) of \$1.1 million for the period ended June 30, 2025. The gain in the current period primarily resulted from realized and unrealized currency gains and gains on contingent consideration related to the RLS acquisition.

¹ Single-photon emission computed tomography.

² Brand name subject to final regulatory approval.

Finance income

Finance income was \$2.3 million for the period ended June 30, 2026, a decrease of \$1.3 million, or 37%, compared to \$3.6 million for the period ended June 30, 2025. Following the acquisition of RLS in January 2025 and associated cash settlement of the transaction, there was a decrease in cash and cash equivalents placed into short term deposits in the period ended June 30, 2026 compared to the prior period.

Finance costs

Finance costs were \$19.4 million for the period ended June 30, 2026, an increase of \$0.6 million, or 3%, compared to \$18.8 million for the period ended June 30, 2025. This increase reflects the impact of the repayment of substantially all of the Convertible Bonds issued in July 2024 and the issue of new Convertible Bonds in April 2026 at a lower coupon rate. A gain of \$2.9 million on the repurchase of Convertible Bonds is included within finance costs.

Income tax benefit

Income tax benefit was \$9.1 million for the period ended June 30, 2026, an increase of \$6.6 million compared to \$2.5 million for the period ended June 30, 2025. This resulted from the recognition of \$21.4 million in deferred tax benefits attributable to deductible temporary differences. Current tax expense for the period ended June 30, 2026 was \$12.3 million, decreased from \$21.5 million for the period ended June 30, 2025 as a result of the decrease in taxable profits generated in the U.S. and Belgium.

Segment results

Our three reportable segments are Precision Medicine, Therapeutics and Manufacturing Solutions.

We evaluate the performance of our segments based on Adjusted EBITDA, calculated as earnings before interest, tax, depreciation and amortization, adjusted for other gains and losses which may have an impact on the degree to which earnings reflect the results of core operations, such as remeasurement of contingent consideration, non-recurring income and expenditure, foreign exchange gains and losses on monetary items, and impairment or impairment reversal where the impairment is the result of an isolated, non-recurring event.

Our management uses Adjusted EBITDA to assess the core operating performance of segments and to make decisions about the allocation of resources. We also believe this measure provides useful information to users of our financial statements by allowing for the assessment of underlying trends in our current operational performance by excluding the impacts of non-recurring costs.

Precision Medicine

The Precision Medicine segment focuses on the commercial sales of Illuccix®, Gozellix® and other diagnostic products that may obtain regulatory approvals. This segment includes royalties and sales of goods (which account for the majority of our revenue from operations), as well as the sales and marketing expenses and costs of sales necessary to support those revenues and R&D costs associated with development activities of our diagnostic pipeline.

The following table sets forth the results of operations for our Precision Medicine segment for the periods ended June 30, 2026 and June 30, 2025.

	Half-year ended		HY2026 vs. HY2025	
	June 30 2026	June 30 2025	Change	Change
	US\$'000	US\$'000	US\$'000	%
	(in thousands, except percentage data)			
Revenue from contracts with customers	388,633	305,835	82,798	27
Cost of sales	(134,600)	(108,839)	(25,761)	24
Gross profit	254,033	196,996	57,037	29
Research and development costs	(54,482)	(38,116)	(16,366)	43
Selling and marketing expenses	(49,236)	(40,886)	(8,350)	20
Manufacturing and distribution costs	(6,625)	(4,105)	(2,520)	61
General and administration costs	(12,508)	(11,317)	(1,191)	11
Other gains/(losses) (net)	1,195	(1,593)	2,788	(175)
Operating profit/(loss)	132,377	100,979	31,398	31
Other (gains)/losses (net)	(1,195)	1,593	(2,788)	(175)
Depreciation and amortization	707	2,074	(1,367)	(66)
Adjusted EBITDA	131,889	104,646	27,243	26

For the period ended June 30, 2026, revenue from contracts with customers for our Precision Medicine segment consisted of \$388.2 million (H1 2025: \$305.8 million) in sales of goods and \$0.4 million (H1 2025: \$0.1 million) in royalty revenue. U.S. sales from Gozellix® and Illuccix® was the primary driver of a 27% increase in revenue, reflecting continued growth in sales volume, pricing and market share gains. Average daily demand for doses continued to grow throughout the first half of the year.

Cost of sales increased 24%, driven by higher manufacturing volumes, distribution costs, and radiopharmacy-related expenses. Gross margin improved to 65% compared to 64% in the prior period, primarily reflecting higher gross margins achieved on Gozellix® and stable manufacturing and distribution costs.

R&D expenses were \$54.5 million in the period ended June 30, 2026, compared to \$38.1 million in the period ended June 30, 2025. The investment was primarily driven by the resubmission of the Pixclara¹ NDA, which contained an expanded clinical evidence package of two major retrospective studies, expanded recruitment for the BiPASS™ study, which is nearing target enrollment, and preparing the Zircaix¹ BLA resubmission. The Illuccix Japan registrational study has also completed enrollment, and a NDA for TLX591-Px is currently under regulatory review with the Chinese NMPA. We incurred \$4.0 million in the period ended June 30, 2026, compared to \$5.2 million in the period ended June 30, 2025 on Zircaix¹ commercial inventory to prepare the business for commercial launch.

Selling and marketing expenses were \$49.2 million in the period ended June 30, 2026, compared to \$40.9 million in the period ended June 30, 2025. This increase was primarily driven by focused incremental investment in sales force operations, to drive higher sales volumes of Illuccix® and Gozellix® in the U.S. and accelerate the commercial launch in Europe, where we saw modest growth throughout the first half of the year.

Manufacturing and distribution costs were \$6.6 million in the period ended June 30, 2026, compared to \$4.1 million in the period ended June 30, 2025, reflecting an increase in facility and staff costs to support supply chain and quality activities to deliver clinical and commercial products.

General and administration costs were \$12.5 million in the period ended June 30, 2026, compared to \$11.3 million in the period ended June 30, 2025, reflecting operating leverage and stabilization in corporate activities and related overheads.

Adjusted EBITDA increased by \$27.2 million, or 26% to \$131.9 million for the period ended June 30, 2026, up from \$104.6 million in the period ended June 30, 2025, reflecting the growth in commercial revenues and stabilization in gross margins, partially offset by higher operating expenditure.

¹ Brand name subject to final regulatory approval.

Therapeutics

The Therapeutics segment focuses on the development of our core therapeutic pipeline for commercialization. This segment includes revenue received from license agreements prior to commercialization and research and development services.

The following table sets forth the results of operations for our Therapeutics segment for the periods ended June 30, 2026 and June 30, 2025.

	Half-year ended		HY2026 vs. HY2025	
	June 30 2026	June 30 2025	Change	Change
	US\$'000	US\$'000	US\$'000	%
	(in thousands, except percentage data)			
Revenue from contracts with customers	-	3,994	(3,994)	(100)
Cost of sales	-	(108)	108	(100)
Gross profit	-	3,886	(3,886)	(100)
Other income	40,000	-	40,000	*
Research and development costs	(67,968)	(43,868)	(24,100)	55
Selling and marketing expenses	-	(464)	464	(100)
Manufacturing and distribution costs	(2,348)	(1,710)	(638)	37
General and administration costs	(2,215)	(2,002)	(213)	11
Other gains (net)	1,240	19	1,221	*
Operating loss	(31,291)	(44,139)	12,848	(29)
Other (gains) (net)	(1,240)	(19)	(1,221)	*
Depreciation and amortization	149	117	32	27
Adjusted EBITDA	(32,382)	(44,041)	11,659	(26)

* Percentage not meaningful

For the period ended June 30, 2026, there was no revenue from contracts with customers for our Therapeutics segment (H1 2025: \$4.0 million related to R&D services revenue). The period-over-period change in revenue from contracts with customers for our Therapeutics segment reflected completion of the revenue recognition associated with the first upfront payment received from the Grand Pharmaceutical Group Limited (Grand Pharma) contract.

Research and development costs were \$68.0 million in the period ended June 30, 2026, compared to \$43.9 million in the period ended June 30, 2025. This increase primarily reflects continued progress in Part 2 of the Phase 3 ProstACT Global trial, as well as ongoing development of IPAX-2, LUTEON and IPAX BRIGHT. Additional efforts were directed toward advancing TLX597-Tx and TLX090-Tx. Expenditure during the period included costs associated with manufacturing activities, site activations, and patient recruitment and dosing activities. Approximately 55% of the Group's R&D investment was directed toward progressing the Group's therapeutic programs, consistent with expectations and reflecting the continued prioritization of late-stage and high-value pipeline assets.

Selling and marketing expenses were \$nil in the period ended June 30, 2026, compared to \$0.5 million in the period ended June 30, 2025. The decrease was predominantly due to a decrease in employment contractor costs.

Manufacturing and distribution costs were \$2.3 million in the period ended June 30, 2026, compared to \$1.7 million in the period ended June 30, 2025, predominantly due to the increase in CMC activities undertaken by our Manufacturing Solutions business to advance our therapeutics pipeline and logistics costs in delivering clinical doses to patients.

General and administration costs were \$2.2 million in the period ended June 30, 2026, compared to \$2.0 million in the period ended June 30, 2025, reflecting a higher allocation of corporate services provided to support the growth in development activities, including an increase in finance, intellectual property and legal costs.

Other income of \$40.0 million was received on entering the Research and Development Collaboration Agreement with Regeneron in April 2026. Under the collaboration, the parties will co-develop and co-commercialize multiple therapeutic programs on a 50/50 cost- and profit-sharing basis, combining the Group's radiopharmaceutical development and manufacturing capabilities with Regeneron's antibody discovery and oncology expertise.

Other gains (net) were \$1.2 million in the period ended June 30, 2026, compared to \$nil in the period ended June 30, 2025.

Adjusted EBITDA for the Therapeutics segment was a loss of \$32.4 million in the period ended June 30, 2026, compared to a loss of \$44.0 million in the period ended June 30, 2025, reflecting the \$40.0 million received on entering the Research and Development Collaboration Agreement with Regeneron, offset by the increase in activities as our late-stage therapeutics products progress through the clinical stages of development.

Manufacturing Solutions

The Manufacturing Solutions segment focuses on the operations of our vertically integrated supply chain and manufacturing business and includes our production TMS facilities at Seneffe (Brussels South), North Melbourne, Sacramento and Yokohama, ARTMS, IsoTherapeutics, and RLS Radiopharmacies. This segment comprises distribution service fee revenue, as well as revenue generated from the sale of PET and SPECT products at RLS. Outside of RLS, revenue is generated by the provision of contract manufacturing services to our Therapeutics and Precision Medicine segments, and to companies in the radiopharmaceutical industry. Operating expenses are associated with RLS and our production facilities in various locations.

The following table sets forth the results of operations for our Manufacturing Solutions segment for the periods ended June 30, 2026 and June 30, 2025.

	Half-year ended		HY2026 vs. HY2025	
	June 30 2026	June 30 2025	Change	Change
	US\$'000	US\$'000	US\$'000	%
(in thousands, except percentage data)				
Revenue from contracts with customers	88,717	80,530	8,187	10
Inter-segment revenue	57,543	33,761	23,782	70
Cost of sales	(138,435)	(103,485)	(34,950)	34
Gross profit	7,825	10,806	(2,981)	(28)
Research and development costs	(2,828)	(2,664)	(164)	6
Selling and marketing expenses	(9,122)	(7,623)	(1,499)	20
Manufacturing and distribution costs	(19,740)	(13,034)	(6,706)	51
General and administration costs	(8,902)	(7,116)	(1,786)	25
Other (losses)/gains (net)	(176)	27	(203)	(765)
Operating loss	(32,943)	(19,604)	(13,339)	68
Other losses/(gains) (net)	176	(27)	203	(765)
Depreciation and amortization	9,811	6,969	2,842	41
Adjusted EBITDA	(22,956)	(12,662)	(10,294)	81

For the period ended June 30, 2026, revenue from contracts with customers for our Manufacturing Solutions segment consisted of \$88.7 million (2025: \$80.5 million) in services revenue, with the period-over-period increase related to a full six months of operations of the RLS business acquired in late January 2025. Inter-segment revenue was \$57.5 million for the period ended June 30, 2026 versus \$33.8 million in 2025. This increase of \$23.8 million is attributable to higher dose volumes of Telix PSMA products at RLS as well as increased activity from our TMS units supporting other parts of the Telix business.

R&D costs within the Manufacturing Solutions segment remained consistent at \$2.8 million in the period ended June 30, 2026, compared to \$2.7 million in the period ended June 30, 2025.

Selling and marketing expenses were \$9.1 million in the period ended June 30, 2026, compared to \$7.6 million in the period ended June 30, 2025 reflecting the six months of operations from the newly acquired RLS. These costs comprise predominantly amortization of acquired intangible assets of \$2.5 million, employment costs, sales commissions and travel costs related to sales and marketing personnel.

Manufacturing and distribution costs were \$19.7 million and general and administration costs were \$8.9 million for our Manufacturing Solutions segment for the period ended June 30, 2026 (compared to \$13.0 million and \$7.1 million for the period ended June 30, 2025, respectively). These increases were predominantly driven by six months of personnel and occupancy costs from the RLS business, combined with increased activity to prepare the Seneffe (Brussels South) facility for GMP commercial production.

Other losses were \$0.2 million in the period ended June 30, 2026, compared to \$nil in the period ended June 30, 2025, comprising the remeasurement of provisions related to contingent consideration liabilities for ARTMS and RLS. The remeasurements were based on revised probabilities applied to the achievement of certain commercial milestones.

For the period ended June 30, 2026, Adjusted EBITDA for the Manufacturing Solutions business was a loss of \$23.0 million, compared to a loss of \$12.7 million in the period ended June 30, 2025. The period-over-period change in Adjusted EBITDA was driven by increased investment in our manufacturing, supply chain and logistics functions and the continued buildout of our Seneffe, Yokohama and North Melbourne facilities.

RLS contributed \$5.5 million toward the operating loss in the period ended June 30, 2026, compared to \$4.6 million in the period ended June 30, 2025. In addition, RLS contributed \$2.3 million toward the TMS segment's Adjusted EBITDA loss in the period ended June 30, 2026, compared to \$3.9 million in the period ended June 30, 2025. RLS's operating loss was relatively stable versus the comparative period, with Adjusted EBITDA reflecting the improvement in the performance of the business and the strategic investment in our vertically integrated infrastructure.

Cash flows

The following table summarizes our cash flows for the periods presented:

	Half-year ended	
	June 30 2026	June 30 2025
	US\$'000	US\$'000
	(in thousands)	
Net cash from operating activities	23,036	17,749
Net cash used in investing activities	(33,717)	(258,854)
Net cash provided by/(used in) financing activities	118,427	(2,923)
Net increase/(decrease) in cash held	107,746	(244,028)

Operating activities

Net cash from operating activities was \$23.0 million during the period ended June 30, 2026. The primary source of cash from operating activities was \$442.9 million in receipts from customers, which predominantly consisted of collections from sales from the Precision Medicine and Manufacturing Solutions businesses. Receipts of \$40.0 million on entering into the collaboration agreement with Regeneron are also included in operating activities. The improved customer receipts reflect sales growth from the Precision Medicine business and a full six months of RLS third-party product sales. The primary uses of cash in operating activities were payments to suppliers and employees of \$439.0 million. Other operating cash outflows included \$1.3 million in contingent consideration payments and \$14.8 million in income tax payments.

Net cash from operating activities was \$17.7 million during the period ended June 30, 2025. The primary source of cash from operating activities was \$372.0 million in receipts from customers, which predominantly consisted of collections from sales of Illuccix® from Precision Medicine and five months of receipts from Manufacturing Solutions businesses. The primary uses of cash in operating activities were payments to suppliers and employees of \$348.6 million. Other operating cash outflows included \$3.4 million in income tax payments.

Investing activities

Net cash used in investing activities was \$33.7 million during the period ended June 30, 2026, reflecting targeted capital investment in our pipeline and global manufacturing network. The primary uses of cash in investing activities related to:

- \$13.4 million to settle the contingent consideration related to the acquisitions of RLS and deferred consideration associated with the suite of FAP targeting candidates.
- \$14.5 million for the expanded investment at TMS sites across RLS Radiopharmacies, the IsoTherapeutics site in Angleton, Texas (U.S.), the site in Yokohama (Japan), and our facilities in Seneffe (Brussels South, Belgium) and North Melbourne (Australia).

Net cash used in investing activities was \$258.9 million during the period ended June 30, 2025. The primary uses of cash in investing activities were the acquisition of businesses. We invested \$224.7 million in payments toward our acquisitions of RLS and assets of ImaginAb and \$17.1 million in payments related to the acquisition of intellectual property associated with FAP targeting candidates, and \$6.7 million in property, plant and equipment purchases for the buildout of our manufacturing facilities.

Financing activities

For the period ended June 30, 2026, net cash provided by financing activities totaled \$118.4 million. Financing activity cash flows mainly comprised:

- \$587.5 million proceeds from the issuance of New Bonds.
- \$466.5 million outflow from the repayment of borrowings, reflecting the settlement of the Existing Bonds issued in 2024.
- \$3.9 million paid toward the principal element of lease liabilities.
- \$1.4 million from the issuance of new ordinary shares on the exercise of options previously granted to employees.

For the period ended June 30, 2025, net cash used in financing activities totaled \$2.9 million. Financing activity cash flows included \$0.7 million received from the issuance of new ordinary shares on the exercise of options previously granted to employees, repayments of principal of \$0.5 million toward existing bank loans and \$3.1 million paid toward lease liabilities.

Off-balance sheet arrangements

During the periods presented, we did not, and we do not currently, engage in off-balance sheet financing arrangements as defined under SEC rules, such as relationships with other entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our consolidated statement of financial position. In addition, we do not engage in trading activities involving non-exchange traded contracts.

Liquidity and capital resources

Prior to the fiscal year ended December 31, 2023, we incurred operating losses in each year since our founding. We anticipate that as we expand through strategic acquisitions, increase our sales and marketing efforts and expand our investment in R&D, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, strategic collaborations and other third-party funding arrangements. Our future liquidity and capital resources will depend on product revenue from the successful continued commercialization of Illuccix® and Gozellix®, revenue from any future products for which we obtain regulatory approval and the R&D costs and other expenditure necessary to support these initiatives and future products. Our total comprehensive income was \$9.5 million for the period ended June 30, 2026. Our total comprehensive income was \$3.3 million for the period ended June 30, 2025. As of June 30, 2026, we had cash and cash equivalents of \$251.9 million and accumulated losses of \$110.9 million. As of June 30, 2026, we held 93.1% of our cash in U.S. dollars, 4.8% in Australian dollars, 1.1% in Euros, 0.4% in Canadian dollars, 0.2% in British pounds, and 0.2% in Swiss Francs.

Sources and uses of liquidity

Our operations have been financed primarily through cash generated by our commercial operations and the issuance and sale of new ordinary shares and Convertible Bonds.

We intend to leverage our commercial revenues and the proceeds raised from the issuance of and sale of new ordinary shares and convertible bonds as a source of funding for the development of additional therapeutic and diagnostic product candidates in our pipeline, including conducting label-expanding trials across our portfolio of diagnostic imaging agents and advancing clinical trials for our therapeutic product candidates. In the periods ended June 30, 2026 and 2025, we received \$442.9 million and \$372.0 million respectively, in receipts from customers, which predominantly consisted of collections from sales from our Precision Medicine and Manufacturing Solutions businesses.

In the first quarter of 2022, we entered into two loan agreements whereby BNP Paribas agreed to lend us \$6.8 million and IMBC Group agreed to lend us \$4.5 million. Each loan is denominated in Euros, in the amounts of €6.1 million and €4.0 million, respectively, and has been translated to US\$ based on the applicable exchange rate as of June 30, 2026. Each loan has a 10-year term and an interest rate of 1.85% per annum, payable monthly, and each is repayable in 96 monthly installments beginning at the end of a two-year grace period. As of June 30, 2026, the outstanding balance of these facilities was \$9.4 million (translated based on the applicable exchange rate as of June 30, 2026). In connection with the loan agreement with BNP Paribas, we also entered a roll-over loan agreement whereby BNP Paribas agreed to lend us an additional \$2.3 million (€2.0 million, translated based on the applicable exchange rate as of June 30, 2026). The loan has a two-year extendable term and a per annum interest rate calculated by adding the eurozone interbank interest rate as of the determination date to a 1.5% margin, payable based on our choice of interest period ranging from 1 month to 12 months for each advance (with a default interest period of three months if no alternative is chosen), and it is repayable in full upon its expiration date. We have used the borrowings from these loans in order to fund the renovation and redevelopment of our Seneffe (Brussels South) production facility.

On July 30, 2024 the Group completed the issue of \$426,140,000 (A\$650,000,000) in convertible bonds maturing in 2029. The bonds were convertible into fully paid ordinary shares in Telix Pharmaceuticals Limited. The initial conversion price of the convertible bonds was A\$24.78 per share, subject to anti-dilution adjustments set out in the final terms and conditions of the convertible bonds. The net proceeds were \$416,324,000, after transaction costs.

The convertible bonds bore interest at a rate of 2.375 per cent per annum. Interest was payable quarterly in arrears on October 30, January 30, April 30 and July 30 in each year, beginning on October 30, 2024. The convertible bonds would have matured on or about July 30, 2029.

On December 17, 2024, the Group entered into an agreement with HSBC Bank Australia Limited ("HSBC") to obtain a working capital facility of up to \$34,435,000 (A\$50,000,000). To date, the Group has not utilized this facility and has incurred establishment fee costs of \$98,000 (A\$150,000) associated with the facility. The working capital facility is secured by a cash security deposit on an interest-bearing term deposit of \$34,435,000 (A\$50,000,000) held by HSBC with a maturity date equivalent to the term of the facility. There are no financial covenants associated with the facility.

On April 15, 2026, the Group announced the successful settlement of the issue of US\$600,000,000 1.50 per cent Convertible Notes due 2031 (New Bonds). The Group concurrently completed the on-market repurchase of approximately A\$637,000,000 in principal of the A\$650,000,000 2.375% Convertible Bonds due 2029 issued by Telix in July 2024 (Existing Bonds). The Existing Bonds repurchased represent approximately 98% of the outstanding Existing Bonds. In May 2026, we repurchased a further A\$5 million of the Existing Bonds. The New Bonds are listed on the Singapore Exchange Securities Trading Limited (SGX-ST).

The New Bonds bear interest at a rate of 1.50 per cent per annum. Interest is payable quarterly in arrears on January 22, April 22, July 22 and October 22 in each year, beginning on July 22, 2026. The New Bonds will mature on or about April 22, 2031, unless redeemed, repurchased, or converted in accordance with their terms.

Funding requirements

We believe that our existing cash resources and cash that we expect to generate from sales from the Precision Medicine and Manufacturing Solutions businesses will be sufficient to meet our projected operating expenses and capital expenditure requirements for at least the next 12 months. Our expectations regarding our short-term and long-term funding requirements are based on assumptions that may prove to be wrong, and we may need additional capital resources to fund our operating plans and capital expenditure requirements.

We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the commercialization of products for which we receive regulatory approval and continue clinical development of our therapeutic product candidates. We expect to finance our operating activities through cash generated from commercial sales, existing cash and cash equivalents and financing activities, which may include equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise capital through the sale of equity or convertible debt securities, the ownership interest of our investors will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates. If we are unable to raise funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Our present and future funding requirements will depend on many factors, including, among other things:

- the amount of revenue received from commercial sales of products for which we receive marketing approval.
- the initiation, progress, timing, costs and results of our clinical trials for our product candidates.
- the costs associated with in-licensing or acquiring assets to expand our pipeline, acquiring businesses or assets to vertically integrate our supply chain and manufacturing and acquiring complementary business.
- the amount of milestones and royalties that we may be required to pay under existing acquisition and licensing agreements.
- costs associated with expanding our organization.
- the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringement raised by third parties.
- the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of these product candidates.

- the costs of operating as a public listed company in both Australia and the U.S.

For more information as to the risks associated with our future funding needs, see "Item 3. Key Information — D. Risk Factors" in our previously filed 2025 Annual Report.

Alternative performance measures

In reporting financial information, the Group presents alternative performance measures (APMs) which are not defined or specified under the requirements of IFRS. The Group believes that these APMs, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The alternative performance measures are not defined by IFRS and therefore may not be directly comparable with other companies' alternative performance measures. The key APMs that the Group uses are outlined below.

APM	Closest equivalent IFRS measure	Reconciling items to IFRS measure	Definition and purpose
Income statement measures			
Adjusted earnings before interest, tax, depreciation and amortization (Adjusted EBITDA)	Profit/(loss) before income tax	Finance costs, income tax expense, depreciation and amortization, remeasurement of provisions, other gains/(losses).	Used to help assess current operational performance excluding the impacts of non-operating expenditure, finance costs and finance income, depreciation and amortization and taxation expense. It is a measure that management uses internally to assess the performance of the Group's segments and make decisions on the allocation of resources.
Balance sheet measures			
Net tangible asset per share	None	Net assets excluding intangible assets, deferred tax assets and right-of-use assets divided by the Group's weighted average number of ordinary shares on issue.	Disclosed in the Group's Appendix 4E as required by Rule 4.3A of the ASX listing rules.

Metric	Half-year ended	
	June 30 2026	June 30 2025
	\$'000	\$'000
Profit/(loss) before income tax	29,248	(4,836)
Adjusting items:		
Finance income	(2,274)	(3,616)
Finance costs	19,388	18,842
Depreciation and amortization	11,155	9,585
Other (gains)/losses net	(5,575)	1,105
Adjusted EBITDA	51,942	21,080

Foreign private issuer status

We report under the Exchange Act as a "foreign private issuer" under U.S. securities laws. In our capacity as a foreign private issuer, we are exempt from certain SEC and Nasdaq requirements.

Consequently, we are not subject to all of the disclosure requirements applicable to U.S. domestic public companies. For example, we are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, at present, our executive officers, the members of our board of directors and our principal shareholders are exempt from the reporting and "short-swing" profit recovery provisions of Section 16 of the Exchange Act and the reporting rules under the Exchange Act with respect to their purchases and sales of our securities. However, absent an exemption from the SEC, following recent legislative changes that became effective on March 18, 2026, our officers and directors will be subject to the insider reporting obligations under Section 16(a) of the Exchange Act, including the requirements to file Forms 3, 4

and 5, pursuant to the Holding Foreign Insiders Accountable Act enacted on December 18, 2025. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies the securities of which are registered under the Exchange Act. In addition, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information.

We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We will remain a foreign private issuer until such time that 50% or more of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i) the majority of the members of either our board of directors or our global management team are U.S. citizens or residents; (ii) more than 50% of our assets are located in the U.S.; or (iii) our business is administered principally in the U.S.

We have taken advantage of certain reduced reporting and other requirements in this Interim Report. Accordingly, the information contained herein may be different from the information you receive from other public companies.

Changes to share capital

Total number of shares and options on issue

The Company had the below equity instruments on issue:

	At the date of this report	June 30, 2026	December 31, 2025
	Number	Number	Number
Shares on issue	339,784,294	339,784,294	338,777,049
Options, PSARs and share rights on issue	36,387,067	36,387,067	31,744,502
Convertible bonds	6,250	6,250	3,250

Issue of fully paid ordinary shares for acquisitions during the period

ImaginAb Inc.

On May 8, 2026 the Company issued 264,943 fully paid ordinary Telix shares to settle the deferred consideration associated with the acquisition of ImaginAb Inc. assets in 2025, on conclusion of a 15-month indemnity period.

Exercise of unlisted share rights, options and performance share appreciation rights (PSARs) for the issue of fully paid ordinary shares

Ordinary shares of Telix issued during the half-year ended June 30, 2026 on the exercise of options granted over unissued shares were as follows:

- a total of 742,000 fully paid ordinary shares were issued upon exercise of 1,525,000 unlisted share options or PSARs.

Since June 30, 2026 to the date of this Interim Report, no shares were issued from the exercise of options under Telix's Equity Incentive Plan.

Lapse of unlisted share options

A total of 1,858,000 share options lapsed unexercised, during the period. These options lapsed in accordance with the terms of their grant.

Issue of unlisted PSARs and share rights

During the period a total of 8,029,000 unlisted share appreciation rights (SARs), PSARs and deferred share rights (SRs) were issued to employees and Directors of the Group. This included the following:

- 339,835 PSARs and 27,121 SRs to the Managing Director and Group Chief Executive Officer, Christian Behrenbruch following shareholder approval at the Company's AGM held on May 21, 2026. These PSARs have a notional exercise price of A\$10.86 per PSAR. PSARs have a three-year performance measurement period. The SRs have a \$nil exercise price and a one-year measurement period, with a service condition. The vesting is subject to achievement of published performance measures, following the completion of the performance measurement period.
- 96,381 SARs to Non-Executive Directors following shareholder approval at the Company's AGM held on May 21, 2026, as outlined below:

	Number of SARs	Notional Exercise Price	Type of share backing
Marie McDonald	23,139	A\$13.43	ASX
David Gill	30,048	US\$9.47	ADS
William Jellison	21,597	US\$9.47	ADS
Maria Rivas	21,597	US\$9.47	ADS

SARs have a three-year measurement period, with a service condition. The SARs have a term that ends on the fifth anniversary of the date of grant.

As at June 30, 2026, the number of equity incentives on issue under the Equity Incentive Plan and issued under exception 13 of Listing Rule 7.2 was 7.8% (December 31, 2025: 6.4%).

Issue and concurrent repurchase of convertible bonds

On April 15, 2026, the Group announced the successful settlement of the issue of US\$600 million 1.50 per cent Convertible Notes due 2031 (New Bonds). The Group concurrently completed the on-market repurchase of approximately A\$637 million in principal of the A\$650 million 2.375% Convertible Bonds due 2029 issued by Telix in July 2024 (Existing Bonds). The Existing Bonds repurchased represent approximately 98% of the outstanding Existing Bonds. In May 2026, we repurchased a further A\$5 million of the Existing Bonds. The New Bonds are listed on the Singapore Exchange Securities Trading Limited (SGX-ST).

Rounding

The Company is of a kind referred to in ASIC Legislative Instrument 2026/183, relating to the "rounding off" of amounts in the Australian Directors' report and Interim financial report. Amounts in this report are rounded off in accordance with the instrument to the nearest thousand dollars or, in certain cases, to the nearest dollar.

Events subsequent to the end of the financial year

There were no matters or circumstances from the end of the reporting period to the date of this report, which have significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 21 in this report.

This report is made in accordance with a resolution of Directors.



Mark Nelson
Interim Chair
August 20, 2026



Christian Behrenbruch
Managing Director and Group CEO
August 20, 2026



Auditor's independence declaration

As lead auditor of Telix Pharmaceuticals Limited's financial report for the half-year ended June 30, 2026, I declare that, to the best of my knowledge and belief, there have been:

- a) no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review of the financial report; and
- b) no contraventions of any applicable code of professional conduct in relation to the review of the financial report.

A handwritten signature in black ink, appearing to read 'J. Roberts' with a stylized flourish at the end.

Jon Roberts
Partner
PricewaterhouseCoopers

Melbourne
August 20, 2026

PricewaterhouseCoopers, ABN 52 780 433 757
2 Riverside Quay, SOUTHBANK VIC 3006,
GPO Box 1331 MELBOURNE VIC 3001
T: +61 3 8603 1000, F: +61 3 8603 1999, www.pwc.com.au

pwc.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

Interim financial report

Contents

Consolidated financial statements for the half-year ended June 30, 2026

	<i>Page</i>
Interim consolidated statement of comprehensive income	23
Interim consolidated statement of financial position	24
Interim consolidated statement of changes in equity	26
Interim consolidated statement of cash flows	27
Notes to the interim consolidated financial statements	28

Interim consolidated statement of comprehensive income
for the half-year ended June 30, 2026

		June 30 2026	June 30 2025
	Note	US\$'000	US\$'000
Continuing operations			
Revenue from contracts with customers	4.1	477,350	390,359
Cost of sales		(217,001)	(181,736)
Gross profit		260,349	208,623
Other income	4.4	40,000	-
Research and development costs		(123,828)	(81,583)
Selling and marketing expenses		(58,358)	(48,973)
Manufacturing and distribution costs		(28,713)	(18,849)
General and administration costs		(48,663)	(47,723)
Other gains/(losses)(net)		5,575	(1,105)
Operating profit		46,362	10,390
Finance income		2,274	3,616
Finance costs	4.5	(19,388)	(18,842)
Profit/(loss) before income tax		29,248	(4,836)
Income tax benefit		9,082	2,544
Profit/(loss) for the period		38,330	(2,292)
Profit/(loss) for the period attributable to:			
Owners of Telix Pharmaceuticals Limited		38,330	(2,292)
Other comprehensive income:			
<i>Items that will not be reclassified to profit or loss in subsequent periods:</i>			
Changes in the fair value of investments at fair value through other comprehensive income		1,207	(1,381)
<i>Items to be reclassified to profit or loss in subsequent periods:</i>			
Exchange differences on translation of foreign operations		(30,079)	6,928
Total comprehensive income for the period		9,458	3,255
Total comprehensive income for the period attributable to:			
Owners of Telix Pharmaceuticals Limited		9,458	3,255

	June 30 2026	June 30 2025
	Cents	Cents
Basic earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company	11.30	(0.68)
Diluted earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company	10.74	(0.68)

The above interim consolidated statement of comprehensive income should be read in conjunction with the notes to the Interim consolidated financial statements.

Interim consolidated statement of financial position

as at June 30, 2026

		June 30 2026	December 31 2025
	Note	US\$'000	US\$'000
Current assets			
Cash and cash equivalents		251,910	141,866
Trade and other receivables		163,556	129,202
Inventories		39,029	37,080
Current tax asset		6,832	6,043
Other current assets		26,694	16,089
Total current assets		488,021	330,280
Non-current assets			
Financial assets		40,412	37,094
Deferred tax assets		85,295	59,353
Property, plant and equipment		72,238	58,661
Right-of-use assets		57,390	56,950
Intangible assets	5	584,610	592,823
Other non-current assets		33,885	28,825
Total non-current assets		873,830	833,706
Total assets		1,361,851	1,163,986
Current liabilities			
Trade and other payables		168,972	150,349
Borrowings	6	11,508	13,110
Current tax payable		33,852	30,742
Contract liabilities		390	402
Lease liabilities		3,916	5,548
Provisions		520	562
Contingent consideration		2,900	11,540
Employee benefit obligations		20,286	19,371
Total current liabilities		242,344	231,624
Non-current liabilities			
Borrowings	6	504,877	391,914
Lease liabilities		59,560	56,534
Deferred tax liabilities		43,301	44,706
Other non-current liabilities		3,224	3,517
Provisions		8,562	9,177
Contingent consideration		11,701	10,694
Employee benefit obligations		607	444
Total non-current liabilities		631,832	516,986
Total liabilities		874,176	748,610
Net assets		487,675	415,376

		June 30 2026	December 31 2025
	Note	US\$'000	US\$'000
Equity			
Share capital	8.1	490,920	479,962
Share capital reserve		28,142	(11,612)
Other reserves	8.2	79,509	101,564
Accumulated losses		(110,896)	(154,538)
Total equity		487,675	415,376

The above interim consolidated statement of financial position should be read in conjunction with the notes to the interim consolidated financial statements.

Interim consolidated statement of changes in equity
for the half-year ended June 30, 2026

		Share capital	Share capital reserve	Other reserves	Accumulated losses	Total equity
	Note	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Balance as at January 1, 2026		479,962	(11,612)	101,564	(154,538)	415,376
Profit for the period		-	-	-	38,330	38,330
Other comprehensive loss		-	-	(28,872)	-	(28,872)
Total comprehensive income		-	-	(28,872)	38,330	9,458
Issue of shares on acquisitions	8.1	2,790	-	-	-	2,790
Issue of shares on exercise of options	8.1	8,168	(6,796)	-	-	1,372
Repurchase of convertible bonds	6.1	-	(43,254)	-	-	(43,254)
Issue of convertible bonds	6.1	-	91,709	-	-	91,709
Transaction costs arising on convertible bonds issue		-	(1,905)	-	-	(1,905)
Share-based payments to employees	8.2	-	-	12,129	-	12,129
Transfer on exercise of options	8.2	-	-	(5,312)	5,312	-
		10,958	39,754	6,817	5,312	62,841
Balance as at June 30, 2026		490,920	28,142	79,509	(110,896)	487,675
Balance as at January 1, 2025		414,012	15,945	75,894	(152,914)	352,937
Loss for the period		-	-	-	(2,292)	(2,292)
Other comprehensive income		-	-	5,547	-	5,547
Total comprehensive income		-	-	5,547	(2,292)	3,255
Issue of shares on acquisitions		30,127	-	-	-	30,127
Issue of shares on exercise of options		24,513	(23,837)	-	-	676
Share-based payments to employees		-	-	11,786	-	11,786
Share-based payments associated with acquisitions		-	-	23,160	-	23,160
Transfer on satisfaction of acquisition performance rights		4,458	-	(4,458)	-	-
Transfer on exercise of options		-	-	(4,224)	4,224	-
		59,098	(23,837)	26,264	4,224	65,749
Balance as at June 30, 2025		473,110	(7,892)	107,705	(150,982)	421,941

The above interim consolidated statement of changes of equity should be read in conjunction with the notes to the interim consolidated financial statements.

Interim consolidated statement of cash flows
for the half-year ended June 30, 2026

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Cash flows from operating activities		
Receipts from customers	442,884	372,005
Receipts from collaboration agreements	40,000	-
Payments to suppliers and employees	(439,037)	(348,629)
Payments for contingent consideration	(1,250)	-
Income taxes paid	(14,806)	(3,357)
Interest received	2,222	3,617
Interest paid	(6,977)	(5,887)
Net cash from operating activities	23,036	17,749
Cash flows from investing activities		
Payments for investments in financial assets	(1,000)	(826)
Payments for acquisition of subsidiaries, net of cash acquired	-	(224,659)
Purchases of intangible assets	(332)	(17,109)
Purchases of other non-current assets	(4,509)	(4,577)
Purchases of property, plant and equipment	(14,456)	(6,668)
Payments for contingent consideration	(8,808)	(5,015)
Payments for deferred consideration	(4,612)	-
Net cash used in investing activities	(33,717)	(258,854)
Cash flows from financing activities		
Proceeds from borrowings	587,453	-
Repayment of borrowings	(466,453)	(451)
Principal element of lease payments	(3,939)	(3,148)
Proceeds from issue of shares and other equity	1,366	676
Net cash provided by/(used in) financing activities	118,427	(2,923)
Net increase/(decrease) in cash held	107,746	(244,028)
Net foreign exchange differences	2,298	11,185
Cash and cash equivalents at the beginning of the half-year	141,866	439,999
Cash and cash equivalents at the end of the half-year	251,910	207,156

The above interim consolidated statement of cash flows should be read in conjunction with the notes to the interim consolidated financial statements.

Notes to the interim consolidated financial statements

1. Corporate information

Telix Pharmaceuticals Limited ("Telix" or "the Company") is a for-profit company incorporated and domiciled in Australia. It is limited by shares that are publicly traded on the Australian Securities Exchange (ASX: TLX) and on the Nasdaq Global Select Market (NASDAQ: TLX). Telix develops and distributes commercial radiopharmaceutical products and continues to develop a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases.

Telix is the ultimate parent company of the Telix Pharmaceuticals Group (the Group).

This consolidated financial report of Telix Pharmaceuticals Limited for the half-year ended June 30, 2026 was authorized for issue in accordance with a resolution of the Directors on August 20, 2026.

2. Material accounting policy information

This Interim financial report for the half-year reporting period ended June 30, 2026 has been prepared in accordance with IAS 34 / AASB 134 Interim Financial Reporting and the Corporations Act 2001 (Cth). This Interim financial report does not include all the notes of the type normally included in an Annual financial report. Accordingly, this report is to be read in conjunction with the Annual Report for the year ended December 31, 2025.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

A number of new or amended standards became applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting these standards. The Group has identified that there is no impact of new standards issued but not yet applied.

2.1. Going concern

These financial statements have been prepared on the basis that the Company is a going concern.

For the half-year ended June 30, 2026, the Group generated a profit after income tax of \$38,330,000 (June 30, 2025: loss after income tax of \$2,292,000) and cash generated from operating activities of \$23,036,000 (June 30, 2025: \$17,749,000). As at June 30, 2026, the net assets of the Group stood at \$487,675,000 (December 31, 2025: \$415,376,000) with cash on hand of \$251,910,000 (December 31, 2025: \$141,866,000).

Cash on hand and anticipated future cash inflows in relation to commercial activities are considered sufficient to meet the Group's forecasted cash outflows in relation to research and development activities currently underway and other committed business activities for at least 12 months from the date of this report.

On this basis, the Directors are satisfied that the Group continues to be a going concern as at the date of issuance of these financial statements. Further, the Directors are of the opinion that no asset is likely to be realized for an amount less than the amount at which it is recorded in the consolidated statement of financial position as at June 30, 2026.

As such, no adjustment has been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or the classification of liabilities that might be necessary should the Group not continue as a going concern.

2.2. Other income

Other income includes income recognized in profit or loss that arises from operating activities that does not stem from relationships with customers. This income arises from certain types of arrangements, as outlined below.

Collaboration agreements

The Group may enter into collaboration agreements to research, develop, manufacture, and commercialize products and/or product candidates. Each agreement is unique in nature and such arrangements may involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. At contract inception, the Group assesses whether these agreements would be within the scope of IFRS 15 / AASB 15 Revenue from Contracts with Customers or IFRS 11 / AASB 11 Joint Arrangements.

A counterparty to the contract would not be a customer if, for example, the counterparty has contracted with the Group to participate in an activity or process in which the parties to the contract share in the risks and benefits that result from the activity or process (such as developing assets in a collaboration agreement) rather than to obtain the output of the entity's ordinary activities.

In such collaboration agreements where research costs are shared, any reimbursement of costs from the collaboration partner are recognized on a net basis in research expense.

3. Segment reporting

The Group has operations in the Americas, Asia-Pacific, and Europe, Middle East and Africa (EMEA) regions, with a significant presence in the U.S., Australia and Belgium.

Reportable segments

The Group's operating segments are based on the reports reviewed by the Group Chief Executive Officer who is considered to be the chief operating decision maker.

Segment performance is evaluated based on Adjusted earnings before interest, tax, depreciation and amortization ("Adjusted EBITDA"). Adjusted EBITDA excludes the effects of the remeasurement of contingent consideration and government grant liabilities and other gains/(losses) which may have an impact on the quality of earnings such as impairments where the impairment is the result of an isolated, non-recurring event. Interest income and finance costs are not allocated to segments as this activity is managed by a central treasury function, which manages the cash position of the Group.

Segment assets and liabilities are measured in the same way as in the financial statements. The assets and liabilities are allocated based on the operations of the segment.

Reportable segment	Principal activities
Precision Medicine	Commercial sales of Illuccix, Gozellix and other diagnostic products subsequent to obtaining regulatory approvals. This segment includes the development activities of the Group's diagnostic pipeline. The Group's International and Medical Technologies businesses are operating segments that are included within the Precision Medicine reportable segment due to the similar nature of the diagnostic products being sold or developed for commercialization.
Therapeutics	Developing the Group's core therapeutic pipeline for commercialization. This segment includes revenue received from license agreements prior to commercialization, income from collaboration agreements and research and development services. This segment includes the development activities of the Group's therapeutic pipeline.
Manufacturing Solutions	This segment comprises revenues and costs associated with the Group's radiopharmacy network, other manufacturing facilities and assets associated with the Group's vertically integrated manufacturing and supply chain. This business includes facilities at Brussels South, IsoTherapeutics, TMS Sacramento, North Melbourne, ARTMS and RLS Radiopharmacies.

Reconciling items include head office and centrally managed costs.

3.1. Segment performance

	Precision Medicine	Therapeutics	Manufacturing Solutions	Inter- segment eliminations	Total segment
For the half-year ended June 30, 2026	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Revenue from contracts with customers	388,633	-	88,717	-	477,350
Inter-segment revenue	-	-	57,543	(57,543)	-
Cost of sales	(134,600)	-	(138,435)	56,034	(217,001)
Gross profit	254,033	-	7,825	(1,509)	260,349
Other income	-	40,000	-	-	40,000
Research and development costs	(54,482)	(67,968)	(2,828)	1,450	(123,828)
Selling and marketing expenses	(49,236)	-	(9,122)	-	(58,358)
Manufacturing and distribution costs	(6,625)	(2,348)	(19,740)	-	(28,713)
General and administration costs	(12,508)	(2,215)	(8,902)	-	(23,625)
Other gains/(losses) (net)	1,195	1,240	(176)	-	2,259
Operating profit/ (loss)	132,377	(31,291)	(32,943)	(59)	68,084
Other (gains)/losses (net)	(1,195)	(1,240)	176	-	(2,259)
Depreciation and amortization	707	149	9,811	-	10,667
Adjusted earnings/ (loss) before interest, tax, depreciation and amortization	131,889	(32,382)	(22,956)	(59)	76,492

For the half-year ended	Precision Medicine	Therapeutics	Manufacturing Solutions	Inter-segment eliminations	Total segment
June 30, 2025	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Revenue from contracts with customers	305,835	3,994	80,530	-	390,359
Inter-segment revenue	-	-	33,761	(33,761)	-
Cost of sales	(108,839)	(108)	(103,485)	30,696	(181,736)
Gross profit	196,996	3,886	10,806	(3,065)	208,623
Research and development costs	(38,116)	(43,868)	(2,664)	3,065	(81,583)
Selling and marketing expenses	(40,886)	(464)	(7,623)	-	(48,973)
Manufacturing and distribution costs	(4,105)	(1,710)	(13,034)	-	(18,849)
General and administration costs	(11,317)	(2,002)	(7,116)	-	(20,435)
Other (losses)/gains (net)	(1,593)	19	27	-	(1,547)
Operating profit/(loss)	100,979	(44,139)	(19,604)	-	37,236
Other losses/(gains) (net)	1,593	(19)	(27)	-	1,547
Depreciation and amortization	2,074	117	6,969	-	9,160
Adjusted earnings/(loss) before interest, tax, depreciation and amortization	104,646	(44,041)	(12,662)	-	47,943

Activities between segments are carried out at arm's length and are eliminated on consolidation. The amounts presented are measured consistently with the Group's external reporting. Segment assets are allocated based on the operations of the segment and the physical location of the asset.

3.2. Reconciliation of total segment adjusted EBITDA to profit/(loss) before income tax

		June 30 2026	June 30 2025
	Note	US\$'000	US\$'000
Total segment adjusted EBITDA		76,492	47,943
Unallocated income, expenses and eliminations:			
General and administration costs		(25,038)	(27,288)
Other gains/(losses) (net)		5,575	(1,105)
Finance income		2,274	3,616
Finance costs	4.5	(19,388)	(18,842)
Depreciation and amortization	4.3	(10,667)	(9,160)
Profit/(loss) before income tax		29,248	(4,836)

General and administration costs include employment costs of \$9,800,000 (2025: \$17,189,000) and other centrally managed IT, legal and other corporate costs. The reduction in employment costs within General and administration costs was due to the allocation of employee share based payments to segments from January 1, 2026.

3.3. Operating segment assets and liabilities

	Precision Medicine	Therapeutics	Manufacturing Solutions	Total segment	Reconciling items	Group
June 30, 2026	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Total assets	323,308	232,997	523,819	1,080,124	281,727	1,361,851
Total liabilities	157,343	25,828	141,994	325,165	549,011	874,176
Additions to non-current assets	668	172	23,658	24,498	—	24,498

	Precision Medicine	Therapeutics	Manufacturing Solutions	Total segment	Reconciling items	Group
December 31, 2025	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Total assets	233,252	228,110	515,429	976,791	187,195	1,163,986
Total liabilities	159,523	17,099	156,599	333,221	415,389	748,610
Additions to non-current assets	19,503	67,715	324,472	411,690	7,840	419,530

Reconciling items primarily comprise cash and cash equivalents held centrally \$143,494,000 (2025: \$82,833,000), investments in financial assets \$39,412,000 (2025: \$37,094,000), property, plant and equipment \$8,638,000 (2025: \$6,915,000) and borrowings (convertible bonds) \$496,237,000 (2025: \$383,023,000) which are managed centrally.

3.4. Geographical information

	June 30, 2026	June 30, 2025
	Revenue by location of customer	Revenue by location of customer
	US\$'000	US\$'000
United States	468,074	381,051
Other countries	9,276	9,308
Total	477,350	390,359

	June 30, 2026	December 31, 2025
	Non-current assets by location of asset	Non-current assets by location of asset
	US\$'000	US\$'000
Australia	110,383	101,753
Belgium	58,441	59,460
Canada	83,156	86,643
United Kingdom	39,146	37,071
United States	492,532	481,181
Other countries	4,877	8,245
Total	788,535	774,353

The total non-current assets figure above excludes deferred tax assets.

4. Profit and loss information

4.1. Revenue from contracts with customers

Disaggregation of revenue from contracts with customers.

The Group derives revenue from the sale and transfer of goods and services over time and at a point in time under the following major business activities:

			June 30 2026	June 30 2025
	Recognition	Operating segment	US\$'000	US\$'000
Sale of goods	At a point in time	Precision Medicine	388,210	305,765
Sale of goods	At a point in time	Manufacturing Solutions	83,606	76,807
Royalty income	At a point in time	Precision Medicine	423	55
Provision of services	At a point in time	Manufacturing Solutions	-	15
Provision of services	Over time	Manufacturing Solutions	5,111	3,708
Research and development services	Over time	Precision Medicine	-	15
Research and development services	Over time	Therapeutics	-	3,994
Total revenue from continuing operations			477,350	390,359

4.2. Employment costs

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Salaries and wages	117,683	94,813
Sales commissions	4,914	3,235
Share-based payment charge	12,129	11,585
Non-Executive Directors' fees	416	386
	135,142	110,019

Salaries and wages of \$1,098,000 (2025: \$916,000) are included within cost of sales in the interim consolidated statement of comprehensive income.

4.3. Depreciation and amortization

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Amortization of intangible assets	4,204	4,620
Depreciation	6,951	4,965
	11,155	9,585

4.4. Other income

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Other income from collaboration agreements	(40,000)	-
	(40,000)	-

*Regeneron Pharmaceuticals, Inc.*Overview

In April 2026, Telix entered into a research and development collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") to jointly develop and commercialize next generation radiopharmaceutical therapeutic candidates and radio-diagnostics to support patient selection and treatment response assessment. The collaboration leverages Regeneron's capabilities in antibody discovery and development and Telix's radiopharmaceutical platform, development expertise and manufacturing capabilities.

The parties will conduct research and development activities pursuant to jointly agreed research and development plans and budgets, overseen through joint governance committees. The collaboration is structured for four initial therapeutic programs, with Regeneron having the option to expand to include four additional programs. Each party is responsible for activities aligned to its respective technical expertise.

The parties will share agreed research and development costs equally, with each party responsible for funding the activities it performs and reimbursing the other party for its share of agreed costs. Telix and Regeneron will also share equally in the global commercialization costs and potential profits, with Telix retaining the option to co-promote certain potential products. If Telix elects to opt out of the co-funding model for a particular program, it would be entitled to receive development and commercial milestones, plus low double-digit royalties on future net sales, for that program.

Treatment of initial consideration

The Group has determined that the arrangement is that of a collaboration whereby Regeneron and Telix are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. As such, Regeneron is not determined to be a customer to which Telix transferred control of goods or services. The \$40,000,000 initial consideration received from Regeneron has been recognized as other income to reflect the contribution of Telix's background intellectual property into the collaboration at inception of the arrangement.

Treatment of subsequent expenditure through the collaboration

All future spending under the collaboration will be shared equally between Regeneron and Telix. Any reimbursements of research costs from Regeneron to Telix will be recognized on a net basis in research expense. Further Telix's obligation to fund its portion of the collaboration's expenditure will be recognized within research expense.

4.5. Finance costs

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Unwind of discount	14,533	12,410
Interest expense on lease liabilities	1,783	1,054
Convertible bond interest expense	5,334	4,911
(Gain) on repurchase of convertible bond	(2,935)	-
Interest expense	303	231
Bank fees	370	236
Finance costs	19,388	18,842

The Group recognized a gain of \$2,935,000 on repurchase of the Existing Bonds being the difference between the carrying amount of the financial liability that has been extinguished and the consideration paid. Refer to note 6.1 for further details.

5. Intangible assets

	Goodwill	Intellectual property	Customer relationships and brands	Software	Patents	Licenses	Total
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Balance at January 1, 2026	198,988	231,399	85,197	4,324	372	72,543	592,823
Additions	-	172	167	-	-	-	339
Reclassifications	-	-	-	-	-	-	-
Amortization charge	-	-	(3,000)	(196)	(3)	(1,005)	(4,204)
Changes in provisions	-	(539)	-	-	-	-	(539)
Exchange differences	(1,475)	(2,000)	-	(96)	1	(239)	(3,809)
Balance at June 30, 2026	197,513	229,032	82,364	4,032	370	71,299	584,610
Cost	197,513	249,036	91,389	4,756	710	74,816	618,220
Accumulated amortization	-	(20,004)	(9,025)	(724)	(340)	(3,517)	(33,610)
Net book amount	197,513	229,032	82,364	4,032	370	71,299	584,610
Balance as at January 1, 2025	66,586	176,426	741	2,284	318	11,503	257,858
Acquisition of businesses	143,660	-	90,200	806	-	15,400	250,066
Additions	-	32,410	127	1,291	46	46,030	79,904
Measurement period adjustments	4,731	-	-	-	-	-	4,731
Reclassifications	(18,759)	18,759	-	-	-	-	-
Amortization charge	-	(2,026)	(5,871)	(460)	(17)	(1,508)	(9,882)
Impairments	-	-	-	-	-	(566)	(566)
Changes in provisions	6	(565)	-	-	-	-	(559)
Exchange differences	2,764	6,395	-	403	25	1,684	11,271
Balance at December 31, 2025	198,988	231,399	85,197	4,324	372	72,543	592,823
Cost	198,988	250,952	91,230	4,805	715	75,095	621,785
Accumulated amortization	-	(19,553)	(6,033)	(481)	(343)	(2,552)	(28,962)
Net book amount	198,988	231,399	85,197	4,324	372	72,543	592,823

The Group has considered reasonably possible changes in the key assumptions and has not identified any instances that could cause the carrying amounts of the intangible assets at June 30, 2026 to exceed their recoverable amounts.

6. Borrowings

	June 30, 2026		December 31, 2025	
	Current	Non-current	Current	Non-current
	US\$'000	US\$'000	US\$'000	US\$'000
<i>Secured</i>				
Bank loans	690	8,716	1,418	8,989
Working capital facility	-	(76)	-	(98)
Total secured borrowings	690	8,640	1,418	8,891
<i>Unsecured</i>				
Convertible bonds	10,818	496,237	11,692	383,023
Total unsecured borrowings	10,818	496,237	11,692	383,023
Total borrowings	11,508	504,877	13,110	391,914

6.1. Convertible bonds

On April 15, 2026, the Group announced the successful settlement of the issue of \$600,000,000 1.50 per cent Convertible Notes due 2031 (New Bonds). The Group concurrently completed the on-market repurchase of approximately A\$637,000,000 in principal of the A\$650,000,000 2.375% Convertible Bonds due 2029 issued by Telix in July 2024 (Existing Bonds). The Existing Bonds repurchased represent approximately 98% of the outstanding Existing Bonds. In May 2026, the Group repurchased a further A\$5,000,000 of the Existing Bonds. The New Bonds are listed on the Singapore Exchange Securities Trading Limited (SGX-ST).

The New Bonds will bear interest at a rate of 1.50 per cent per annum. Interest is payable quarterly in arrears on January 22, April 22, July 22 and October 22 in each year, beginning on July 22, 2026. The New Bonds will mature on or about April 22, 2031, unless redeemed, repurchased, or converted in accordance with their terms.

The convertible bonds are presented in the Group's consolidated statement of financial position as follows:

	June 30 2026	December 31 2025
	US\$'000	US\$'000
Opening balance	394,715	344,218
Unwind of discount	13,741	22,502
Interest expense	5,334	9,945
Interest paid	(5,101)	(9,871)
Repurchase of Existing Bonds	(422,499)	-
Face value of New Bonds issued	600,000	-
Transaction costs	(10,747)	-
Other equity securities - value of conversion rights	(91,709)	-
Exchange differences	23,321	27,921
Closing balance	507,055	394,715
Current	10,818	11,692
Non-current	496,237	383,023
Total convertible bond liability	507,055	394,715

Repurchase of existing convertible bonds

The total repurchase consideration is allocated between the liability and equity components using a methodology consistent with the initial recognition at issuance. The liability component is measured as the fair value of the remaining contractual cash flows at the repurchase date, discounted using prevailing market rates for comparable debt.

The equity component associated with the repurchase was \$43,254,000, calculated as the residual after allocating the fair value to the liability component. A resultant gain of \$2,935,000 was recognized in profit or loss only in respect of the liability component, being the difference between the carrying amount of the liability component immediately prior to repurchase and the portion of the repurchase consideration allocated to that liability component.

Issue of New Bonds

The initial fair value of the liability portion of the New Bonds was determined using a market interest rate for an equivalent non-convertible bond at the issue date. This fair value has been reduced by directly attributable transaction costs associated with the issue of the convertible bonds. The liability is subsequently recognized on an amortized cost basis until extinguished on conversion or maturity of the bonds, which has been assessed as April 22, 2029. The remainder of the proceeds is allocated to the conversion option and recognized as part of the share capital reserve, net of income tax and a proportion of transaction costs, and is not subsequently remeasured.

6.2 Fair value

For bank loans, the fair values are not materially different to their carrying amounts, since the interest payable on those borrowings is either close to current market rates or the borrowings are of a short-term nature.

For the convertible bonds, the fair value of the liability component is outlined below. The fair value is based on discounted cash flows using a current borrowing rate. They are classified as level 3 fair values in the fair value hierarchy due to the use of unobservable inputs, including own credit risk.

	June 30, 2026		December 31, 2025	
	Carrying amount	Fair value	Carrying amount	Fair value
	US\$'000	US\$'000	US\$'000	US\$'000
Bank loans	9,330	9,330	10,309	10,309
Convertible bonds	507,055	506,039	394,715	399,348

7. Contractual maturities of financial liabilities

	1-6 months	6-12 months	1-5 years	Over 5 years	Total contractual cash flows	Carrying amount of liabilities
As at June 30, 2026	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Non-derivatives						
Trade and other payables	169,954	691	256	-	170,901	168,972
Other non-current liabilities	-	-	4,534	-	4,534	3,224
Borrowings	5,114	5,228	644,763	2,117	657,222	516,385
Lease liabilities	7,373	7,279	36,108	40,948	91,708	63,476
Government grant liability	552	319	633	-	1,504	1,448
Contingent consideration	401	7,759	6,219	1,793	16,172	14,601
Total financial liabilities	183,394	21,276	692,513	44,858	942,041	768,106

	1-6 months	6-12 months	1-5 years	Over 5 years	Total contractual cash flows	Carrying amount of liabilities
As at December 31, 2025	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Non-derivatives						
Trade and other payables	114,261	36,088	-	-	150,349	150,349
Other non-current liabilities	-	-	3,673	-	3,673	3,517
Borrowings	5,860	5,958	469,257	3,024	484,099	405,024
Lease liabilities	3,051	3,969	44,409	34,994	86,423	62,082
Government grant liability	837	564	1,236	169	2,806	2,046
Contingent consideration	8,755	3,545	11,737	665	24,702	22,234
Total financial liabilities	132,764	50,124	530,312	38,852	752,052	645,252

8. Equity

8.1. Share capital

	June 30 2026	December 31 2025	June 30 2026	December 31 2025
	Number '000	Number '000	US\$'000	US\$'000
Opening balance	338,778	334,725	479,962	414,012
Shares issued through the exercise of share options and warrants ¹	742	1,693	8,168	29,722
Shares issued for Dedicaid ²	-	38	-	467
Shares issued for Lightpoint ³	-	269	-	4,467
Shares issued for Imaginab ⁴	265	2,053	2,790	31,294
Closing balance	339,785	338,778	490,920	479,962

1. Options exercised during the year through the employee Equity Incentive Plan resulted in 742,000 (2025: 1,693,000) shares being issued for a total value of \$8,168,000 (2025: \$29,722,000).

2. On April 27, 2023, the Group completed the acquisition of Dedicaid GmbH. The consideration for the acquisition comprised 207,000 in Telix shares at a 10-day volume weighted average price of shares on the execution date of A\$8.73 per share. During the prior year, the Group issued 37,575 fully paid ordinary shares upon satisfaction of certain milestones.

3. On November 1, 2023, the Group completed the acquisition of Lightpoint through the issue of 3,298,000 fully paid ordinary Telix shares at A\$9.37 per share. During the prior year, the Group issued 269,075 fully paid ordinary shares in satisfaction of Lightpoint milestone rights.

4. On January 30, 2025, the Group completed the acquisition of ImaginAb. The consideration included the issue of 2,053,311 fully paid ordinary Telix shares at A\$24.37 per share. On May 8, 2026 the Group issued 264,943 fully paid ordinary shares at A\$14.75 to settle the deferred consideration on conclusion of a 15-month indemnity period.

The weighted average ordinary shares for the period January 1, 2026 to June 30, 2026 is 339,220,212 (2025: 331,226,491). The Company does not have a limited amount of authorized capital under Australian law.

8.2. Other reserves

	Foreign currency translation reserve	Share-based payments reserve	Financial assets at FVOCI reserve	Total
	US\$'000	US\$'000	US\$'000	US\$'000
Balance as at January 1, 2026	(7,368)	114,073	(5,141)	101,564
Other comprehensive (loss)/income	(30,079)	-	1,207	(28,872)
Total comprehensive (loss)/income	(30,079)	-	1,207	(28,872)
Share-based payments to employees	-	12,129	-	12,129
Transfer on exercise of options	-	(5,312)	-	(5,312)
	-	6,817	-	6,817
Balance as at June 30, 2026	(37,447)	120,890	(3,934)	79,509

	Foreign currency translation reserve	Share-based payments reserve	Financial assets at FVOCI reserve	Total
	US\$'000	US\$'000	US\$'000	US\$'000
Balance as at January 1, 2025	(1,611)	81,404	(3,899)	75,894
Other comprehensive	(5,757)	-	(1,242)	(6,999)
Total comprehensive (loss)/income	(5,757)	-	(1,242)	(6,999)
Share-based payments to employees	-	19,350	-	19,350
Share-based payments associated with acquisitions	-	23,287	-	23,287
Transfer on satisfaction of acquisition performance rights	-	(4,467)	-	(4,467)
Transfer on exercise of options	-	(5,501)	-	(5,501)
	-	32,669	-	32,669
Balance as at December 31, 2025	(7,368)	114,073	(5,141)	101,564

9. Fair value

This section explains the judgments and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value in the financial statements.

9.1. Financial assets

Financial assets are categorized as either level 1 or level 3 financial assets and remeasured at each reporting date with movements recognized in other comprehensive income. The inputs used in the level 1 fair value calculations are with reference to published price quotations for the associated equity instruments in an active market. The sensitivity analysis below reflects exposure to financial assets measured by reference to published price quotations, which excludes the Group's restricted cash balance.

Level 3 financial assets are subject to key assumptions and unobservable inputs which include risk adjusted post-tax discount rates and forecasted discounted cashflows. These inputs significantly impact the underlying value of these assets.

Sensitivity of level 1 financial assets

An increase/(decrease) of 10% in the share price of each financial asset while holding all other variables constant will increase/(decrease) other comprehensive income by \$224,000 (December 31, 2025: \$102,000).

Sensitivity of level 3 financial assets

An increase/(decrease) of 10% in the discounted cashflows of each financial asset while holding all other variables constant will increase/(decrease) other comprehensive income by \$274,000 (December 31, 2025: \$266,000).

9.2. Financial liabilities

Contingent consideration liabilities are categorized as level 3 financial liabilities and remeasured at each reporting date with movements recognized in profit or loss, except in instances where changes are permitted to be added to/reduce an associated asset. The inputs used in fair value calculations are determined by Management.

The carrying amount of financial liabilities measured at fair value is principally calculated based on inputs other than quoted prices that are observable for these financial liabilities, either directly (i.e. as unquoted prices) or indirectly (i.e. derived from prices). Where no price information is available from a quoted market source, alternative market mechanisms or recent comparable transactions, fair value is estimated based on Management's views on relevant future prices, net of valuation allowances to accommodate liquidity, modelling and other risks implicit in such estimates.

Sensitivity of level 3 financial liabilities

The potential effect of using reasonably possible alternative assumptions in valuation models, based on a change in the most significant input, such as sales volumes, by an increase/(decrease) of 10% while holding all other variables constant will increase/(decrease) profit before tax by \$239,000 (December 31, 2025: \$275,000).

Valuation processes

The finance team of the Group performs the valuation of contingent consideration liabilities required for financial reporting purposes, including level 3 fair values. This team reports directly to the Chief Financial Officer (CFO). Discussions of valuation processes and results are held between the CFO and Board at least once every six months, in line with the Group's half-yearly reporting periods.

The main level 3 inputs used by the Group in measuring the fair value of contingent consideration liabilities are derived and evaluated as follows:

- discount rates are determined by an independent third-party using a weighted average cost of capital model to calculate a post-tax rate that reflects current market assessments of the time value of money and the risk specific to the asset.
- regulatory/marketing authorization approval dates and approval for marketing authorization probability risk factors are derived in consultation with the Group's regulatory team.
- expected sales volumes and net sales price per unit are estimated based on market information on annual incidence rates and information for similar products and expected market penetration.
- contingent consideration cash flows are estimated based on the terms of the sale contract. Changes in fair values are analyzed at the end of each reporting period during the half-yearly valuation discussion between the CFO and Board. As part of this discussion the CFO presents a report that explains the reason for the fair value movement.

10. Contingent liabilities

The Group has received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Group's disclosures regarding the development of the Group's prostate cancer therapeutic candidates. This matter remains a fact-finding request. Telix is cooperating with the subpoena including responding to the SEC's requests. The SEC has not asserted any charges against the Group or any of its personnel, and no conclusions have been reached. At this stage, the Group cannot predict the duration, scope or outcome of this matter. The Group will continue to monitor the inquiry and update its disclosures as appropriate.

On November 10, 2025, a putative securities class action complaint was filed in the United States District Court for the Southern District of Indiana seeking, among other relief, class certification, designation of a lead plaintiff, damages and a jury trial. On January 20, 2026, the Group was formally served the complaint on behalf of a purported U.S. shareholder. The Group has filed a motion to dismiss this matter. This case is still in its earliest stages, and the Group plans to rigorously defend itself in this matter. No class has been certified and the court has not ruled on any dispositive motions. At this stage, the Group cannot predict the duration, scope or outcome of this matter.

Legal fees and other costs associated with contingent matters, including litigation, regulatory inquiries and investigations, are expensed as incurred.

10.1. Commitments

The Group has commitments against existing development activities and capital commitments relating to property plant and equipment and the purchase of isotope raw materials. R&D commitments are estimated based on the contractual obligations included within agreements entered into by the Group, to the extent that a work order has been executed with the vendor.

The Group's supply agreements contain minimum purchase commitments in certain situations, the amount and timing of which are not known. Additionally, the Group enters into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for preclinical studies and clinical trials, research supplies and other services and drugs for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancellable contracts.

The Group has entered into in-licensing arrangements with various companies. Such agreements may require the Group to make payments on achievement of stages of development, launch or revenue milestones and may include variable payments that are based on unit sales or profit (e.g., royalty and profit share payments). The amount of variable payments under these agreements are inherently uncertain and difficult to predict, given the direct link to future sales, profit levels and the range of outcomes. These payments are not included in this table of contractual obligations.

To the extent a commitment is determined to be onerous, these are provided for within provisions in the Consolidated statement of financial position.

At June 30, 2026 and at the date of these financial statements, the Group had capital commitments relating to the construction of the Seneffe (Brussels South) manufacturing facility and the purchase of isotope raw materials from a vendor over a three-year period.

	Due < 1 year	Due > 1 year
	US\$'000	US\$'000
As at June 30, 2026		
Capital commitments	42,665	6,410
R&D commitments	53,234	13,309
	95,899	19,719
As at December 31, 2025		
Capital commitments	35,822	11,367
R&D commitments	30,402	7,601
	66,224	18,968

11. Events occurring after the reporting period

There were no subsequent events that required adjustment to or disclosure in the financial statements of the Group for the half-year ended June 30, 2026.

Directors' declaration

In the opinion of the Directors:

- a. the financial statements and notes of the Group are in accordance with the Australian *Corporations Act 2001* (*Cth*), including:
 - i. giving a true and fair view of the Group's financial position as at June 30, 2026 and of its performance for the half-year ended on that date.
 - ii. complying with applicable Accounting Standards, the Corporations Regulation 2001 and other mandatory professional reporting requirements.
- b. there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Directors and has been made after receiving the declarations by the Chief Executive Officer and Chief Financial Officer for the half-year ended June 30, 2026.



Mark Nelson
Interim Chair
August 20, 2026



Christian Behrenbruch
Managing Director and Group CEO
August 20, 2026



Independent auditor's review report to the members of Telix Pharmaceuticals Limited

Report on the half-year financial report

Conclusion

We have reviewed the half-year financial report of Telix Pharmaceuticals Limited (the Company) and the entities it controlled during the half-year (together the Group), which comprises the interim consolidated statement of financial position as at June 30, 2026, the interim consolidated statement of comprehensive income, interim consolidated statement of changes in equity and interim consolidated statement of cash flows for the half-year ended on that date, material accounting policy information and selected explanatory notes and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Telix Pharmaceuticals Limited does not comply with the *Corporations Act 2001* including:

1. giving a true and fair view of the Group's financial position as at June 30, 2026 and of its performance for the half-year ended on that date; and
2. complying with Accounting Standard AASB 134 Interim Financial Reporting and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity* (ASRE 2410). Our responsibilities are further described in the Auditor's responsibilities for the review of the half-year financial report section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

PricewaterhouseCoopers, ABN 52 780 433 757
2 Riverside Quay, SOUTHBANK VIC 3006,
GPO Box 1331 MELBOURNE VIC 3001
T: +61 3 8603 1000, F: +61 3 8603 1999, www.pwc.com.au

pwc.com.au

Liability limited by a scheme approved under Professional Standards Legislation.




Responsibilities of the directors for the half-year financial report


The directors of the Company are responsible for the preparation of the half-year financial report, in accordance with Australian Accounting Standards and the *Corporations Act 2001*, including giving a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement whether due to fraud or error.

Auditor's responsibilities for the review of the half-year financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at June 30, 2026 and of its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


PricewaterhouseCoopers



Jon Roberts
Partner

Melbourne
August 20, 2026

Glossary of terms and abbreviations

Abbreviation	Term	Abbreviation	Term
AASB	Australian Accounting Standards Board	MAA	Marketing Authorization Application
ADS	American Depositary Shares	mCRPC	Metastatic castration-resistant prostate cancer
AGM	Annual General Meeting	MDR	Medical Devices Regulation
ARC	Audit and Risk Committee	MHRA	Medicines and Healthcare Products Regulatory Agency
ASIC	Australian Securities and Investments Commission	MRI	Magnetic resonance imaging
ASX	Australian Securities Exchange	NDA	New Drug Application
AUASB	Auditing and Assurance Standards Board	NED	Non-Executive Director
BLA	Biologics License Application	NPP	Named patient program
CAIX	Carbonic anhydrase IX	NRC	Nuclear Regulatory Commission
ccRCC	Clear cell renal cell carcinoma	ODD	Orphan drug designation
CMC	Chemistry, Manufacturing and Controls	PDUFA	Prescription Drug User Fee Act
CRL	Complete Response Letter	PDGFR α	Platelet-derived growth factor receptor alpha
CT	Computed tomography	PET	Positron emission tomography
EAP	Early or expanded access program	PSA	Prostate-specific antigen
EBIT	Earnings before interest and taxes	PSARs	Performance Share Appreciation Rights
EBITDA	Earnings before interest, taxes, depreciation and amortization	PSMA	Prostate-specific membrane antigen
EBRT	External beam radiation therapy	PSMA-PET	Prostate-specific membrane antigen imaging with positron emission tomography
EEA	European Economic Area	R&D	Research and Development
EIP	Equity Incentive Plan	R&I	Research and Innovation
EMA	European Medicines Agency	rADC	Radio antibody-drug conjugate
ERMF	Enterprise Risk Management Framework	REACH	Registration, Evaluation and Authorization of Chemicals
ESG	Environment, Social and Governance	REMS	Risk Evaluation and Mitigation Strategy
ESPP	Employee Stock Purchase Plan	rPFS	Radiographic progression-free survival
FAP	Fibroblast activation protein	RTF	Refuse to File
FCPA	Foreign Corrupt Practices Act	SDP	Securities Dealing Policy
FDA	United States Food and Drug Administration	SEC	Securities and Exchange Commission
FIH	First-in-human	SGX	Securities Trading Limited
GAAP	Generally Accepted Accounting Principles	SoC	Standard of care
GET	Group Executive Team	SOP	Standard operating procedure
GMP	Good Manufacturing Practice	SOX	Sarbanes-Oxley Act
IFRS	International Financial Reporting Standards	SPECT	Single photon emission computed tomography
IIT	Investigator-initiated trial	STS	Soft tissue sarcoma
IND	Investigational new drug	STVR	Short Term Variable Remuneration
IRB	Institutional Review Board	TAT	Targeted alpha therapy
IRM	Indeterminate renal mass	TFR	Total Fixed Remuneration
ISMS	Information Security Management System	TGA	Therapeutic Goods Administration (Australia)
ISSB	International Sustainability Standards Board	TMS	Telix Manufacturing Solutions
KMP	Key management personnel		
LTVR	Long Term Variable Remuneration		

Company directory

Directors

Mark Nelson (Interim Chair)
Christian Behrenbruch (MD & CEO)
David Gill
William (Bill) Jellison
Marie McDonald
Maria Rivas
Jann Skinner

Company Secretary

Shomalin Naidoo (Interim)

Investor Relations and Corporate Communications

Kyahn Williamson

Registered Office

Telix Pharmaceuticals Limited
55 Flemington Road
North Melbourne VIC 3051
info@telixpharma.com
www.telixpharma.com

Australian Business Number

85 616 620 369

Securities Exchange Listing

Australian Securities Exchange
ASX: TLX

Nasdaq Global Select Market
NASDAQ: TLX

Auditor

PricewaterhouseCoopers
2 Riverside Quay
Southbank VIC 3006

Share Registry

MUFG Corporate Markets (AU) Limited
A division of MUFG Pension & Market Services
(Formerly Link Market Services)
Locked Bag A14 Sydney South NSW 1235
Australia

P: 1300 554 474
F: (02) 9287 0303
www.mpms.mufg.com

Depository Registry

JP Morgan Chase Bank N.A.Shareowner Services
P.O. Box 64504
St. Paul, MN 55164-0854

General (within U.S.) +1 800 990 1135
From outside the U.S. +1 651 453 2128
www.shareowneronline.com



Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX ANNOUNCEMENT

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

Melbourne (Australia) and Indianapolis, IN (U.S.) – August 20, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026.

H1 2026 key results

Group performance¹: Double-digit revenue growth and gross margin improvement

- Group revenue of US\$477 million, up 22%² year-over-year, tracking in line with the upper end of full year guidance of US\$950 million to US\$970 million.
- Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial performance, a favorable product mix and operational efficiencies.
- Adjusted EBITDA³ of US\$52 million, up 146% year-over-year reflecting strong demand across our product portfolio and initial non-refundable payment of US\$40 million from Regeneron collaboration⁴.
- Research & Development (R&D) investment of US\$124 million, primarily directed toward advancing late-stage therapeutic and precision medicine programs, supporting the Company's strategy to build diversified revenue streams.
- Entered into strategic collaboration with Regeneron to jointly develop and commercialize next generation radiopharmaceutical therapies⁴.
- Completed refinancing of existing convertible bond structure, issuing US\$600 million of new convertible bonds due 2031⁵.
- Profit after tax of US\$38 million includes US\$40 million of other income received from Regeneron and finance costs of US\$19 million, predominately related to refinancing of the convertible bonds.
- Generated positive operating cash flow of US\$23 million and maintained a cash balance of US\$252 million as of June 30, 2026.

Executive commentary

Managing Director and Group CEO, Dr. Christian Behrenbruch, stated: "Telix delivered an outstanding first half, with strong revenue growth, market share gains and significant progress across clinical and regulatory milestones. Our strengthened balance sheet is enabling increased investment in late-stage programs, including ProstACT Global, market expansion opportunities within our precision medicine portfolio and manufacturing and supply chain capabilities that differentiate Telix. With multiple near-term catalysts, we enter the second half with strong momentum and confidence."

¹ Group performance includes Telix Precision Medicine, Telix Therapeutics and Telix Manufacturing Solutions (TMS).

² All comparisons to H1 2025 results.

³ Earnings before interest, tax, depreciation and amortization.

⁴ Telix ASX disclosure April 13, 2026.

⁵ Telix ASX disclosure April 14, 2026.

Segment results

Telix Precision Medicine: Strong volume growth of Illuccix® and Gozellix®

- Precision Medicine segment revenue up by 27% year-over-year reflecting continued success of Telix's two product strategy, with Illuccix® and Gozellix® delivering growth in sales volumes and market share gains.
- Gross margin of 65% up 1% year-over-year.
- Adjusted (segment) EBITDA up by 26% year-over-year to US\$132 million.
- Patient enrollment nearing completion for Phase 3 BiPASS™ study of Illuccix and Gozellix for prostate cancer imaging in the pre-biopsy setting.
- Illuccix Japan Phase 3 registrational study enrollment completion⁶.
- New drug application (NDA) for Illuccix accepted and under review by the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE)⁷.
- TLX101-Px, (floretyrosine F 18) for glioma (brain cancer) imaging:
 - Pixclara^{®8} has been granted a PDUFA⁹ goal date by the FDA of September 11, 2026¹⁰.
 - Pixlumi^{®8} Marketing Authorization Application (MAA) in Europe validated and accepted for review¹¹.
 - Pixclara^{®8} Phase 3 Investigational New Drug (IND) application successfully cleared by FDA to explore indication expansion to brain metastases diagnosis.
- TLX250-Px, Zircaix^{®8} (zirconium-89 (⁸⁹Zr) girentuximab servedoxam) for kidney cancer imaging: Telix continues to make good progress toward near-term resubmission of its U.S. Biologics License Application (BLA). The Company has been granted an extension of the BLA resubmission deadline, following receipt of a corrected Complete Response Letter (CRL)¹². Telix continues to work closely with the FDA to ensure the resubmission package comprehensively addresses all outstanding CRL items.

Telix Therapeutics: Investment delivering significant advances across a number of key late-stage development programs

Of the R&D investment, US\$68 million was invested in the therapeutics pipeline. Milestones include:

- **TLX591-Tx (lutetium (¹⁷⁷Lu) rosopatomab tetraxetan):**
 - ProstACT Global Part 1 lead-in for Telix's lead prostate cancer therapy candidate in metastatic castration-resistant prostate cancer (mCRPC) met safety and dosimetry objectives, with no new safety signals observed¹³.
 - FDA confirmed that the safety data from Part 1 is sufficient to enable progression of Part 2 in the U.S. The FDA and Telix also achieved alignment on the Part 2 clinical trial protocol¹⁴.
 - Part 2 continues to enroll well in regions where recruitment is open including Australia, Canada, New Zealand, Singapore, South Korea, Türkiye and the United Kingdom.

⁶ Telix media release July 17, 2026. Japan Registry of Clinical Trials identifier: JRCT2031250473.

⁷ Telix media release January 20, 2026.

⁸ Launch and brand names subject to final regulatory approval. Zircaix (TLX250-Px, ccRCC imaging), Pixclara and Pixlumi (TLX101-Px, glioma imaging).

⁹ Prescription Drug User Fee Act.

¹⁰ Telix ASX disclosure April 10, 2026.

¹¹ Telix media release May 1, 2026.

¹² Corrected CRL issued April 10, 2026.

¹³ Telix ASX disclosure March 10, 2026.

¹⁴ Telix ASX disclosure July 2, 2026.

- **TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA):**
 - OPTIMAL-PSMA Phase 2 investigator-initiated trial (IIT) evaluating TLX597-Tx for mCRPC completed patient enrollment of 120 patients¹⁵.
 - OPTIMAL-e Phase 2 study evaluating TLX597-Tx for metastatic hormone sensitive prostate cancer (mHSPC) dosed first patients¹⁶.
- **TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan):**
 - Dosed first patient in LUTEON, a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC¹⁷.
- **TLX101-Tx (iodofalan ¹³¹I):**
 - Enrolled first patient cohort in Part 1 (assessing safety and dose optimization) of IPAX BRIGHT, a pivotal trial of TLX101-Tx in patients with recurrent glioblastoma¹⁸.
 - Completed patient enrollment in IPAX-2, a Phase 1 study evaluating TLX101-Tx in patients with newly diagnosed glioblastoma¹⁹.

Telix Manufacturing Solutions (TMS): Expanding Telix's global footprint to enable next phase of growth

Telix continues to invest in its global infrastructure, expanding its TMS operations. The TMS segment includes RLS Radiopharmacies (RLS), IsoTherapeutics (U.S.), and production (and R&D) facilities in Sacramento (U.S.), Seneffe (Belgium), North Melbourne (Australia) and Yokohama (Japan), representing a significantly expanded global production and manufacturing footprint. TMS is central to Telix's long-term growth strategy and is expected to support increasing commercial demand and future pipeline expansion.

- TMS reported US\$146 million total segment revenue, which includes US\$89 million from third-party product sales and service fees, and US\$58 million internal revenue²⁰, reflecting growth in sales of Illuccix and Gozellix through the RLS network and contributing to Group gross margin improvement.
- TMS operating loss of US\$33 million, includes US\$10 million of depreciation and amortization on acquired intangibles.
- Adjusted EBITDA loss for the TMS segment of US\$23 million (H1 2025: Adjusted EBITDA loss of US\$13 million), driven by increased investment in supply chain and logistics functions to meet anticipated therapeutics infrastructure needs.
- Other TMS milestones in H1 2026 include:
 - Opened TMS North Melbourne, in partnership with the Melbourne Theranostic Innovation Centre (MTIC), aiming to accelerate the development of targeted radiopharmaceuticals.
 - TMS Seneffe completed first Good Manufacturing Practice (GMP) production run of a lutetium-based therapeutic candidate, validating the facility's capabilities to support the manufacture of Telix's next-generation therapeutics.

¹⁵ Telix LinkedIn June 25, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437.

¹⁶ Telix media release July 16, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336.

¹⁷ Telix media release July 21, 2026. ClinicalTrials.gov ID: NCT07197580. Clear cell renal cell carcinoma.

¹⁸ ClinicalTrials.gov ID: NCT07100730.

¹⁹ ClinicalTrials.gov ID: NCT05450744.

²⁰ Inter-segment revenue is eliminated on consolidation, refer to note 3 of the Interim financial report lodged today with the ASX.

Guidance

- FY 2026 revenue and other income expected to be in excess of US\$1 billion, with revenue progressing in line with upper end of FY 2026 guidance of US\$950 million to US\$970 million and US\$40 million of other income received from Regeneron.
- Telix reaffirms R&D expenditure guidance of US\$230 million to US\$270 million, enabled by the Company's strong commercial performance and initial payment of US\$40 million received from Regeneron.

Corporate update

The Company advises that on August 20, 2026, it entered into an equity distribution agreement (EDA) with Morgan Stanley & Co. LLC and William Blair & Company, L.L.C. (together, the "Sales Agents") to establish an "at-the-market" (ATM) facility. Under the ATM facility, the Company may, from time to time, determine to offer and issue new fully paid ordinary shares ("Shares") at prevailing market prices in the form of American Depositary Shares (ADSs). Each ADS represents one Share. The ATM facility will provide an opportunity to facilitate greater access to the Company's securities on the Nasdaq stock exchange. The Company will control the offer process and has sole discretion over whether and when the ATM facility is used, the number of ADSs sold, and the minimum sale price of the ADSs. No offers or sales of ADSs will be made under the ATM facility unless and until a prospectus supplement has been filed with the U.S. Securities and Exchange Commission (SEC). The ATM facility will be subject to compliance with the ASX Listing Rules, including the Company's available share placement capacity.

Summary: Group financial results

	H1 2026	H1 2025
	US\$M	US\$M
Revenue	477	390
Cost of sales	(217)	(181)
Gross profit	260	209
Other income	40	—
Research and development	(124)	(82)
Selling and marketing	(58)	(49)
Manufacturing and distribution	(29)	(19)
General and administration	(49)	(48)
Other gains/(losses) (net)	6	(1)
Operating profit	46	10
Finance income	2	4
Finance costs	(19)	(19)
Profit/(loss) before income tax	29	(5)
Income tax benefit	9	3
Profit/(loss) after income tax	38	(2)
Adjusted EBITDA²¹	52	21
Net cash from operating activities	23	18

Investor call

An investor webcast and conference call will be held at 9:00 a.m. AEST today, Thursday, August 20, 2026 (7:00 p.m. EDT Wednesday, August 19, 2026). Participants can register for the webcast via this link:

<https://s1.c-conf.com/diamondpass/10056417-pz2402.html>

²¹ Earnings before interest, tax, depreciation and amortization and other gains/(losses) (net).

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix's commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA). The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatomab tetraxetan) in prostate cancer, TLX101-Tx (¹³¹I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on [LinkedIn](#), [X](#) and [Facebook](#).

Investor Relations

Annie Kasparian

annie.kasparian@telixpharma.com

Charlene Jaw

charlene.jaw@telixpharma.com

Guidance Disclaimer

The stated guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix's ability to protect its patents and other intellectual property.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors

No Offer or Solicitation

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities of the Company in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offers or sales of ADSs will be made under the EDA unless and until a prospectus supplement has been filed with the SEC.

Telix has filed an automatic shelf registration statement on Form F-3ASR (File No. 333-293611) with the SEC, which became immediately effective upon filing. Any offering of securities in connection with the at-the-market offering will be made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. A prospectus supplement describing the terms of the at-the-market offering will be filed with the SEC prior to any sales of ADSs under the EDA. When available, copies of the prospectus supplement and the accompanying base prospectus may be obtained from: Morgan Stanley & Co. LLC Attention: Prospectus Department 180 Varick Street, 2nd Floor New York, NY 10014 and William Blair & Company, L.L.C. Attention: Prospectus Department 150 North Riverside Plaza Chicago, IL 60606 or by accessing the SEC's website at www.sec.gov. The at-the-market facility will be subject to the ASX Listing Rules framework for share issuances, including applicable placement and participation limits.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its commercial products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Forward-looking statements may also include statements about the timing and use of the at-the-market facility established under the EDA, the potential sale of ADSs therefrom, Telix's intentions regarding activation of the at-the-market facility, and the anticipated benefits of the at-the-market facility. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Non-IFRS Financial Measures. Telix's results are reported under International Financial Reporting Standards (IFRS). This announcement includes various non-IFRS financial information to reflect its underlying performance, which have not been subject to audit or review. These non-IFRS measures include Adjusted EBITDA, which represents net earnings attributable to the Group excluding net finance costs, income tax expense, depreciation and amortization and other gains/(losses) (net). As required by SEC rules, we have provided reconciliations of these non-IFRS financial measures to the most directly comparable IFRS measures, which for Adjusted EBITDA, is Profit/(loss) before income tax. The Group believes that these non-IFRS measures, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The non-IFRS measures are not defined by IFRS and therefore may not be directly comparable with other companies' alternative performance measures.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Financial review

In 2026, Telix continues on a significant growth trajectory, driven by the global commercial success of Illuccix® and Gozellix®. As the Company advances toward near-term regulatory milestones and progresses a promising pipeline of therapeutic candidates, these strategic investments in our late-stage candidates are positioning Telix to deliver its next phase of growth and make a meaningful difference to patients' lives, underpinned by a resilient and diversified business model with multiple revenue streams.

Our operations have been financed primarily through cash generated by our commercial operations and the issuance of Ordinary Shares and Convertible Bonds.

Reported profit after tax attributable to Telix Shareholders was \$38.3 million for the period ended June 30, 2026, compared to a loss of \$2.3 million for the period ended June 30, 2025. The net profit reflects the impact of income on entering our strategic collaboration with Regeneron, and continued success in our commercial businesses, allowing us to increase investment in our Therapeutic pipeline.

Our total comprehensive income was \$9.5 million for the period ended June 30, 2026, compared to \$3.3 million for the period ended June 30, 2025. We expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. In addition, if and when we seek and obtain regulatory approval to commercialize additional product candidates, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our total comprehensive income or loss may fluctuate significantly from period-to-period, depending on the timing of our clinical trials and our expenditures on other research and development activities.

The following table sets forth a summary of the Group's Consolidated statement of comprehensive income for the periods ended June 30, 2026 and June 30, 2025.

	Half-year ended		HY 2026 vs. 2025	
	June 30 2026	June 30 2025	Change	Change
	US\$'000	US\$'000	US\$'000	%
(in thousands, except percentage and per share data)				
Continuing operations				
Revenue from contracts with customers	477,350	390,359	86,991	22
Cost of sales	(217,001)	(181,736)	(35,265)	19
Gross profit	260,349	208,623	51,726	25
Other income	40,000	-	40,000	*
Research and development costs	(123,828)	(81,583)	(42,245)	52
Selling and marketing expenses	(58,358)	(48,973)	(9,385)	19
Manufacturing and distribution costs	(28,713)	(18,849)	(9,864)	52
General and administration costs	(48,663)	(47,723)	(940)	2
Other gains/(losses)(net)	5,575	(1,105)	6,680	*
Operating profit	46,362	10,390	35,972	346
Finance income	2,274	3,616	(1,342)	(37)
Finance costs	(19,388)	(18,842)	(546)	3
Profit/(loss) before income tax	29,248	(4,836)	34,084	*
Income tax benefit	9,082	2,544	6,538	257
Profit/(loss) for the period	38,330	(2,292)	40,622	*
Profit/(loss) for the period attributable to:				
Owners of Telix Pharmaceuticals Limited	38,330	(2,292)	40,622	*
Other comprehensive income:				
<i>Items that will not be reclassified to profit or loss in subsequent periods:</i>				
Changes in the fair value of investments at fair value through other comprehensive income	1,207	(1,381)	2,588	*
<i>Items to be reclassified to profit or loss in subsequent periods:</i>				
Exchange differences on translation of foreign operations	(30,079)	6,928	(37,007)	*
Total comprehensive income for the period	9,458	3,255	6,203	191

* Percentage not meaningful

Revenue from contracts with customers

The Group delivered sustained growth in revenue. Revenue from contracts with customers was \$477.3 million for the period ended June 30, 2026, an increase of \$87.0 million, or 22%, compared to \$390.4 million for the period ended June 30, 2025. The Precision Medicine business was the standout driver, generating \$388.6 million, while the Manufacturing Solutions business (TMS) continued to build momentum, generating \$88.7 million in sales of third-party products and services. This increase is also attributable to six months of revenue from RLS in 2026, compared to five months of revenue in 2025 (acquired on January 28, 2025).

Cost of sales

Cost of sales increased by \$35.3 million, or 19%, to \$217.0 million for the period ended June 30, 2026, from \$181.7 million for the period ended June 30, 2025. The increase was primarily driven by increased sales volumes from our Precision Medicine business.

Gross margin improved in 2026 relative to 2025, increasing to 55% for the period ended June 30, 2026 (compared to 53% for the period ended June 30, 2025), reflecting the product mix of high value, Precision Medicine products in Telix's portfolio and the sales of higher volume and lower margin SPECT¹ imaging products at RLS. The Group's gross margin also reflects the effect of a full half-year of the RLS business. Precision Medicine gross margin improved during the period ended June 30, 2026 to 65% (64% for the period ended June 30, 2025), supported by increased sales of Gozellix® in the U.S., disciplined pricing and effective control of cost of sales across the portfolio.

Research and development costs

Revenue growth enabled an increased investment into R&D. R&D costs were \$123.8 million for the period ended June 30, 2026, an increase of \$42.2 million, or 52%, compared to \$81.6 million for the period ended June 30, 2025. In line with our communicated strategy, the Company is investing a proportion of its revenue into R&D with the goal of creating further revenue streams. Accordingly, expenditure predominantly focused on advancing clinical trials for late-stage therapeutic assets and progressing regulatory resubmissions for Precision Medicine assets.

R&D investment reflects:

- the inclusion of a new Tx candidate, TLX597-Tx, a next generation PSMA-targeting prostate cancer radioligand therapy.
- expansion of the BiPASS™ study, the first study designed to gain marketing authorization for ⁶⁸Ga-PSMA-PET imaging in the pre-biopsy setting.
- continued enrollment in Part 2 of the ProstACT Global Phase 3 trial of TLX591-Tx.
- preparing the Zircaix² (TLX250-Px) BLA and the Pixclara² (TLX101-Px) NDA resubmissions.

Selling and marketing expenses

Selling and marketing expenses were \$58.4 million for the period ended June 30, 2026, an increase of \$9.4 million, or 19%, compared to \$49.0 million for the period ended June 30, 2025. This increase was primarily driven by increased investment in promotional activities and sales force operations, deployed to drive higher global sales volumes of Illuucci® and Gozellix®.

Manufacturing and distribution costs

Manufacturing and distribution costs were \$28.7 million for the period ended June 30, 2026, an increase of \$9.9 million, or 52%, compared to \$18.8 million for the period ended June 30, 2025. This increase was primarily driven by the impact of six months of RLS operations on the Group results when compared to approximately five months post-acquisition in 2025, and higher costs associated with increased activity across our TMS sites.

General and administration costs

General and administration costs were \$48.7 million for the period ended June 30, 2026, an increase of \$1.0 million, or 2%, compared to \$47.7 million for the period ended June 30, 2025. This increase was driven by:

- the impact of six months of RLS operations on the Group results.
- increased legal, IT infrastructure and software costs.

Other income

Other income for the period resulted from the \$40.0 million initial, non-refundable payment received as part of the collaboration with Regeneron entered into in April 2026. The Group received the payment in respect of four initial therapeutic programs, with Regeneron holding options to expand the collaboration to additional programs. Refer to note 4.4 of the Interim financial report for further details.

Other gains/(losses) (net)

Other gains (net) were \$5.6 million for the period ended June 30, 2026, a change of \$6.7 million, compared to other losses (net) of \$1.1 million for the period ended June 30, 2025. The gain in the current period primarily resulted from realized and unrealized currency gains and gains on contingent consideration related to the RLS acquisition.

¹ Single-photon emission computed tomography.
² Brand name subject to final regulatory approval.

Finance income

Finance income was \$2.3 million for the period ended June 30, 2026, a decrease of \$1.3 million, or 37%, compared to \$3.6 million for the period ended June 30, 2025. Following the acquisition of RLS in January 2025 and associated cash settlement of the transaction, there was a decrease in cash and cash equivalents placed into short term deposits in the period ended June 30, 2026 compared to the prior period.

Finance costs

Finance costs were \$19.4 million for the period ended June 30, 2026, an increase of \$0.6 million, or 3%, compared to \$18.8 million for the period ended June 30, 2025. This increase reflects the impact of the repayment of substantially all of the Convertible Bonds issued in July 2024 and the issue of new Convertible Bonds in April 2026 at a lower coupon rate. A gain of \$2.9 million on the repurchase of Convertible Bonds is included within finance costs.

Income tax benefit

Income tax benefit was \$9.1 million for the period ended June 30, 2026, an increase of \$6.6 million compared to \$2.5 million for the period ended June 30, 2025. This resulted from the recognition of \$21.4 million in deferred tax benefits attributable to deductible temporary differences. Current tax expense for the period ended June 30, 2026 was \$12.3 million, decreased from \$21.5 million for the period ended June 30, 2025 as a result of the decrease in taxable profits generated in the U.S. and Belgium.

Segment results

Our three reportable segments are Precision Medicine, Therapeutics and Manufacturing Solutions.

We evaluate the performance of our segments based on Adjusted EBITDA, calculated as earnings before interest, tax, depreciation and amortization, adjusted for other gains and losses which may have an impact on the degree to which earnings reflect the results of core operations, such as remeasurement of contingent consideration, non-recurring income and expenditure, foreign exchange gains and losses on monetary items, and impairment or impairment reversal where the impairment is the result of an isolated, non-recurring event.

Our management uses Adjusted EBITDA to assess the core operating performance of segments and to make decisions about the allocation of resources. We also believe this measure provides useful information to users of our financial statements by allowing for the assessment of underlying trends in our current operational performance by excluding the impacts of non-recurring costs.

Precision Medicine

The Precision Medicine segment focuses on the commercial sales of Illuccix®, Gozellix® and other diagnostic products that may obtain regulatory approvals. This segment includes royalties and sales of goods (which account for the majority of our revenue from operations), as well as the sales and marketing expenses and costs of sales necessary to support those revenues and R&D costs associated with development activities of our diagnostic pipeline.

The following table sets forth the results of operations for our Precision Medicine segment for the period s ended June 30, 2026 and June 30, 2025 .

	Half-year ended		HY2026 vs. HY2025	
	June 30 2026	June 30 2025	Change	Change
	US\$'000	US\$'000	US\$'000	%
	(in thousands, except percentage data)			
Revenue from contracts with customers	388,633	305,835	82,798	27
Cost of sales	(134,600)	(108,839)	(25,761)	24
Gross profit	254,033	196,996	57,037	29
Research and development costs	(54,482)	(38,116)	(16,366)	43
Selling and marketing expenses	(49,236)	(40,886)	(8,350)	20
Manufacturing and distribution costs	(6,625)	(4,105)	(2,520)	61
General and administration costs	(12,508)	(11,317)	(1,191)	11
Other gains/(losses) (net)	1,195	(1,593)	2,788	(175)
Operating profit/(loss)	132,377	100,979	31,398	31
Other (gains)/losses (net)	(1,195)	1,593	(2,788)	(175)
Depreciation and amortization	707	2,074	(1,367)	(66)
Adjusted EBITDA	131,889	104,646	27,243	26

For the period ended June 30, 2026 , revenue from contracts with customers for our Precision Medicine segment consisted of \$388.2 million (H1 2025 : \$305.8 million) in sales of goods and \$0.4 million (H1 2025 : \$0.1 million) in royalty revenue. U.S. sales from Gozellix ® and Illuccix ® was the primary driver of a 27% increase in revenue, reflecting continued growth in sales volume, pricing and market share gains. Average daily demand for doses continued to grow throughout the first half of the year.

Cost of sales increased 24%, driven by higher manufacturing volumes, distribution costs, and radiopharmacy-related expenses. Gross margin improved to 65% compared to 64% in the prior period , primarily reflecting higher gross margins achieved on Gozellix ® and stable manufacturing and distribution costs.

R&D expenses were \$54.5 million in the period ended June 30, 2026 , compared to \$38.1 million in the period ended June 30, 2025 . The investment was primarily driven by the resubmission of the Pixclara ¹ NDA, which contained an expanded clinical evidence package of two major retrospective studies, expanded recruitment for the BiPASS™ study , which is nearing target enrollment, and preparing the Zircaix ¹ BLA resubmission. The Illuccix Japan registrational study has also completed enrollment, and a NDA for TLX591-Px is currently under regulatory review with the Chinese NMPA. We incurred \$4.0 million in the period ended June 30, 2026 , compared to \$5.2 million in the period ended June 30, 2025 on Zircaix ¹ commercial inventory to prepare the business for commercial launch.

Selling and marketing expenses were \$49.2 million in the period ended June 30, 2026 , compared to \$40.9 million in the period ended June 30, 2025 . This increase was primarily driven by focused incremental investment in sales force operations, to drive higher sales volumes of Illuccix ® and Gozellix ® in the U.S. and accelerate the commercial launch in Europe, where we saw modest growth throughout the first half of the year.

Manufacturing and distribution costs were \$6.6 million in the period ended June 30, 2026 , compared to \$4.1 million in the period ended June 30, 2025 , reflecting an increase in facility and staff costs to support supply chain and quality activities to deliver clinical and commercial products.

General and administration costs were \$12.5 million in the period ended June 30, 2026 , compared to \$11.3 million in the period ended June 30, 2025 , reflecting operating leverage and stabilization in corporate activities and related overheads.

Adjusted EBITDA increased by \$27.2 million , or 26% to \$131.9 million for the period ended June 30, 2026 , up from \$104.6 million in the period ended June 30, 2025 , reflecting the growth in commercial revenues and stabilization in gross margins, partially offset by higher operating expenditure.

¹ Brand name subject to final regulatory approval .

Therapeutics

The Therapeutics segment focuses on the development of our core therapeutic pipeline for commercialization. This segment includes revenue received from license agreements prior to commercialization and research and development services.

The following table sets forth the results of operations for our Therapeutics segment for the period s ended June 30, 2026 and June 30, 2025 .

	Half-year ended		HY2026 vs. HY2025	
	June 30 2026	June 30 2025	Change	Change
	US\$'000	US\$'000	US\$'000	%
(in thousands, except percentage data)				
Revenue from contracts with customers	-	3,994	(3,994)	(100)
Cost of sales	-	(108)	108	(100)
Gross profit	-	3,886	(3,886)	(100)
Other income	40,000	-	40,000	*
Research and development costs	(67,968)	(43,868)	(24,100)	55
Selling and marketing expenses	-	(464)	464	(100)
Manufacturing and distribution costs	(2,348)	(1,710)	(638)	37
General and administration costs	(2,215)	(2,002)	(213)	11
Other gains (net)	1,240	19	1,221	*
Operating loss	(31,291)	(44,139)	12,848	(29)
Other (gains) (net)	(1,240)	(19)	(1,221)	*
Depreciation and amortization	149	117	32	27
Adjusted EBITDA	(32,382)	(44,041)	11,659	(26)

* Percentage not meaningful

For the period ended June 30, 2026 , there was no revenue from contracts with customers for our Therapeutics segment (H1 2025 : \$4.0 million related to R&D services revenue). The period-over-period change in revenue from contracts with customers for our Therapeutics segment reflected completion of the revenue recognition associated with the first upfront payment received from the Grand Pharmaceutical Group Limited (Grand Pharma) contract.

Research and development costs were \$68.0 million in the period ended June 30, 2026 , compared to \$43.9 million in the period ended June 30, 2025 . This increase primarily reflects continued progress in Part 2 of the Phase 3 ProstACT Global trial, as well as ongoing development of IPAX-2, LUTEON and IPAX BrIGHT. Additional efforts were directed toward advancing TLX597-Tx and TLX090-Tx. Expenditure during the period included costs associated with manufacturing activities, site activations, and patient recruitment and dosing activities. Approximately 55% of the Group's R&D investment was directed toward progressing the Group's therapeutic programs, consistent with expectations and reflecting the continued prioritization of late-stage and high-value pipeline assets.

Selling and marketing expenses were \$ nil in the period ended June 30, 2026 , compared to \$0.5 million in the period ended June 30, 2025 . The decrease was predominantly due to a decrease in employment contractor costs.

Manufacturing and distribution costs were \$2.3 million in the period ended June 30, 2026 , compared to \$1.7 million in the period ended June 30, 2025 , predominantly due to the increase in CMC activities undertaken by our Manufacturing Solutions business to advance our therapeutics pipeline and logistics costs in delivering clinical doses to patients.

General and administration costs were \$2.2 million in the period ended June 30, 2026 , compared to \$2.0 million in the period ended June 30, 2025 , reflecting a higher allocation of corporate services provided to support the growth in development activities, including an increase in finance, intellectual property and legal costs.

Other income of \$40.0 million was received on entering the Research and Development Collaboration Agreement with Regeneron in April 2026 . Under the collaboration, the parties will co-develop and co-commercialize multiple therapeutic programs on a 50/50 cost- and profit-sharing basis, combining the Group's radiopharmaceutical development and manufacturing capabilities with Regeneron's antibody discovery and oncology expertise.

Other gains (net) were \$1.2 million in the period ended June 30, 2026, compared to \$ nil in the period ended June 30, 2025.

Adjusted EBITDA for the Therapeutics segment was a loss of \$32.4 million in the period ended June 30, 2026, compared to a loss of \$44.0 million in the period ended June 30, 2025, reflecting the \$40.0 million received on entering the Research and Development Collaboration Agreement with Regeneron, offset by the increase in activities as our late-stage therapeutics products progress through the clinical stages of development.

Manufacturing Solutions

The Manufacturing Solutions segment focuses on the operations of our vertically integrated supply chain and manufacturing business and includes our production TMS facilities at Seneffe (Brussels South), North Melbourne, Sacramento and Yokohama, ARTMS, IsoTherapeutics, and RLS Radiopharmacies. This segment comprises distribution service fee revenue, as well as revenue generated from the sale of PET and SPECT products at RLS. Outside of RLS, revenue is generated by the provision of contract manufacturing services to our Therapeutics and Precision Medicine segments, and to companies in the radiopharmaceutical industry. Operating expenses are associated with RLS and our production facilities in various locations.

The following table sets forth the results of operations for our Manufacturing Solutions segment for the periods ended June 30, 2026 and June 30, 2025.

	Half-year ended		HY2026 vs. HY2025	
	June 30 2026	June 30 2025	Change	Change
	US\$'000	US\$'000	US\$'000	%
(in thousands, except percentage data)				
Revenue from contracts with customers	88,717	80,530	8,187	10
Inter-segment revenue	57,543	33,761	23,782	70
Cost of sales	(138,435)	(103,485)	(34,950)	34
Gross profit	7,825	10,806	(2,981)	(28)
Research and development costs	(2,828)	(2,664)	(164)	6
Selling and marketing expenses	(9,122)	(7,623)	(1,499)	20
Manufacturing and distribution costs	(19,740)	(13,034)	(6,706)	51
General and administration costs	(8,902)	(7,116)	(1,786)	25
Other (losses)/gains (net)	(176)	27	(203)	(765)
Operating loss	(32,943)	(19,604)	(13,339)	68
Other losses/(gains) (net)	176	(27)	203	(765)
Depreciation and amortization	9,811	6,969	2,842	41
Adjusted EBITDA	(22,956)	(12,662)	(10,294)	81

For the period ended June 30, 2026, revenue from contracts with customers for our Manufacturing Solutions segment consisted of \$88.7 million (2025: \$80.5 million) in services revenue, with the period-over-period increase related to a full six months of operations of the RLS business acquired in late January 2025. Inter-segment revenue was \$57.5 million for the period ended June 30, 2026 versus \$33.8 million in 2025. This increase of \$23.8 million is attributable to higher dose volumes of Telix PSMA products at RLS as well as increased activity from our TMS units supporting other parts of the Telix business.

R&D costs within the Manufacturing Solutions segment remained consistent at \$2.8 million in the period ended June 30, 2026, compared to \$2.7 million in the period ended June 30, 2025.

Selling and marketing expenses were \$9.1 million in the period ended June 30, 2026, compared to \$7.6 million in the period ended June 30, 2025 reflecting the six months of operations from the newly acquired RLS. These costs comprise predominantly amortization of acquired intangible assets of \$2.5 million, employment costs, sales commissions and travel costs related to sales and marketing personnel.

Manufacturing and distribution costs were \$19.7 million and general and administration costs were \$8.9 million for our Manufacturing Solutions segment for the period ended June 30, 2026 (compared to \$13.0 million and \$7.1 million for the period ended June 30, 2025, respectively). These increases were predominantly driven by six months of personnel and occupancy costs from the RLS business, combined with increased activity to prepare the Seneffe (Brussels South) facility for GMP commercial production.

Other losses were \$0.2 million in the period ended June 30, 2026, compared to \$ nil in the period ended June 30, 2025, comprising the remeasurement of provisions related to contingent consideration liabilities for ARTMS and RLS. The remeasurements were based on revised probabilities applied to the achievement of certain commercial milestones.

For the period ended June 30, 2026, Adjusted EBITDA for the Manufacturing Solutions business was a loss of \$23.0 million, compared to a loss of \$12.7 million in the period ended June 30, 2025. The period-over-period change in Adjusted EBITDA was driven by increased investment in our manufacturing, supply chain and logistics functions and the continued buildout of our Seneffe, Yokohama and North Melbourne facilities.

RLS contributed \$5.5 million toward the operating loss in the period ended June 30, 2026, compared to \$4.6 million in the period ended June 30, 2025. In addition, RLS contributed \$2.3 million toward the TMS segment's Adjusted EBITDA loss in the period ended June 30, 2026, compared to \$3.9 million in the period ended June 30, 2025. RLS's operating loss was relatively stable versus the comparative period, with Adjusted EBITDA reflecting the improvement in the performance of the business and the strategic investment in our vertically integrated infrastructure.

Cash flows

The following table summarizes our cash flows for the periods presented:

	Half-year ended	
	June 30 2026	June 30 2025
	US\$'000	US\$'000
	(in thousands)	
Net cash from operating activities	23,036	17,749
Net cash used in investing activities	(33,717)	(258,854)
Net cash provided by/(used in) financing activities	118,427	(2,923)
Net increase/(decrease) in cash held	107,746	(244,028)

Operating activities

Net cash from operating activities was \$23.0 million during the period ended June 30, 2026. The primary source of cash from operating activities was \$442.9 million in receipts from customers, which predominantly consisted of collections from sales from the Precision Medicine and Manufacturing Solutions businesses. Receipts of \$40.0 million on entering into the collaboration agreement with Regeneron are also included in operating activities. The improved customer receipts reflect sales growth from the Precision Medicine business and a full six months of RLS third-party product sales. The primary uses of cash in operating activities were payments to suppliers and employees of \$439.0 million. Other operating cash outflows included \$1.3 million in contingent consideration payments and \$14.8 million in income tax payments.

Net cash from operating activities was \$17.7 million during the period ended June 30, 2025. The primary source of cash from operating activities was \$372.0 million in receipts from customers, which predominantly consisted of collections from sales of Illuccix® from Precision Medicine and five months of receipts from Manufacturing Solutions businesses. The primary uses of cash in operating activities were payments to suppliers and employees of \$348.6 million. Other operating cash outflows included \$3.4 million in income tax payments.

Investing activities

Net cash used in investing activities was \$33.7 million during the period ended June 30, 2026, reflecting targeted capital investment in our pipeline and global manufacturing network. The primary uses of cash in investing activities related to:

- \$13.4 million to settle the contingent consideration related to the acquisitions of RLS and deferred consideration associated with the suite of FAP targeting candidates.
- \$14.5 million for the expanded investment at TMS sites across RLS Radiopharmacies, the IsoTherapeutics site in Angleton, Texas (U.S.), the site in Yokohama (Japan), and our facilities in Seneffe (Brussels South, Belgium) and North Melbourne (Australia).

Net cash used in investing activities was \$258.9 million during the period ended June 30, 2025. The primary uses of cash in investing activities were the acquisition of businesses. We invested \$224.7 million in payments toward our acquisitions of RLS and assets of ImaginAb and \$17.1 million in payments related to the acquisition of intellectual property associated with FAP targeting candidates, and \$6.7 million in property, plant and equipment purchases for the buildout of our manufacturing facilities.

Financing activities

For the period ended June 30, 2026, net cash provided by financing activities totaled \$118.4 million. Financing activity cash flows mainly comprised:

- \$587.5 million proceeds from the issuance of New Bonds.
- \$466.5 million outflow from the repayment of borrowings, reflecting the settlement of the Existing Bonds issued in 2024.
- \$3.9 million paid toward the principal element of lease liabilities.
- \$1.4 million from the issuance of new ordinary shares on the exercise of options previously granted to employees.

For the period ended June 30, 2025, net cash used in financing activities totaled \$2.9 million. Financing activity cash flows included \$0.7 million received from the issuance of new ordinary shares on the exercise of options previously granted to employees, repayments of principal of \$0.5 million toward existing bank loans and \$3.1 million paid toward lease liabilities.

Off-balance sheet arrangements

During the periods presented, we did not, and we do not currently, engage in off-balance sheet financing arrangements as defined under SEC rules, such as relationships with other entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our consolidated statement of financial position. In addition, we do not engage in trading activities involving non-exchange traded contracts.

Liquidity and capital resources

Prior to the fiscal year ended December 31, 2023, we incurred operating losses in each year since our founding. We anticipate that as we expand through strategic acquisitions, increase our sales and marketing efforts and expand our investment in R&D, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, strategic collaborations and other third-party funding arrangements. Our future liquidity and capital resources will depend on product revenue from the successful continued commercialization of Illucix® and Gozellix®, revenue from any future products for which we obtain regulatory approval and the R&D costs and other expenditure necessary to support these initiatives and future products. Our total comprehensive income was \$9.5 million for the period ended June 30, 2026. Our total comprehensive income was \$3.3 million for the period ended June 30, 2025. As of June 30, 2026, we had cash and cash equivalents of \$251.9 million and accumulated losses of \$110.9 million. As of June 30, 2026, we held 93.1% of our cash in U.S. dollars, 4.8% in Australian dollars, 1.1% in Euros, 0.4% in Canadian dollars, 0.2% in British pounds, and 0.2% in Swiss Francs.

Sources and uses of liquidity

Our operations have been financed primarily through cash generated by our commercial operations and the issuance and sale of new ordinary shares and Convertible Bonds.

We intend to leverage our commercial revenues and the proceeds raised from the issuance of and sale of new ordinary shares and convertible bonds as a source of funding for the development of additional therapeutic and diagnostic product candidates in our pipeline, including conducting label-expanding trials across our portfolio of diagnostic imaging agents and advancing clinical trials for our therapeutic product candidates. In the periods ended June 30, 2026 and 2025, we received \$442.9 million and \$372.0 million respectively, in receipts from customers, which predominantly consisted of collections from sales from our Precision Medicine and Manufacturing Solutions businesses.

In the first quarter of 2022, we entered into two loan agreements whereby BNP Paribas agreed to lend us \$6.8 million and IMBC Group agreed to lend us \$4.5 million. Each loan is denominated in Euros, in the amounts of €6.1 million and €4.0 million, respectively, and has been translated to US\$ based on the applicable exchange rate as of June 30, 2026. Each loan has a 10-year term and an interest rate of 1.85% per annum, payable monthly, and each is repayable in 96 monthly installments beginning at the end of a two-year grace period. As of June 30, 2026, the outstanding balance of these facilities was \$9.4 million (translated based on the applicable exchange rate as of June 30, 2026). In connection with the loan agreement with BNP Paribas, we also entered a roll-over loan agreement whereby BNP Paribas agreed to lend us an additional \$2.3 million (€2.0 million, translated based on the applicable exchange rate as of June 30, 2026). The loan has a two-year extendable term and a per annum interest rate calculated by adding the eurozone interbank interest rate as of the determination date to a 1.5% margin, payable based on our choice of interest period ranging from 1 month to 12 months for each advance (with a default interest period of three months if no alternative is chosen), and it is repayable in full upon its expiration date. We have used the borrowings from these loans in order to fund the renovation and redevelopment of our Seneffe (Brussels South) production facility.

On July 30, 2024, the Group completed the issue of \$426,140,000 (A\$650,000,000) in convertible bonds maturing in 2029. The bonds were convertible into fully paid ordinary shares in Telix Pharmaceuticals Limited. The initial conversion price of the convertible bonds was A\$24.78 per share, subject to anti-dilution adjustments set out in the final terms and conditions of the convertible bonds. The net proceeds were \$416,324,000, after transaction costs.

The convertible bonds bore interest at a rate of 2.375 per cent per annum. Interest was payable quarterly in arrears on October 30, January 30, April 30 and July 30 in each year, beginning on October 30, 2024. The convertible bonds would have matured on or about July 30, 2029.

On December 17, 2024, the Group entered into an agreement with HSBC Bank Australia Limited ("HSBC") to obtain a working capital facility of up to \$34,435,000 (A\$50,000,000). To date, the Group has not utilized this facility and has incurred establishment fee costs of \$98,000 (A\$150,000) associated with the facility. The working capital facility is secured by a cash security deposit on an interest-bearing term deposit of \$34,435,000 (A\$50,000,000) held by HSBC with a maturity date equivalent to the term of the facility. There are no financial covenants associated with the facility.

On April 15, 2026, the Group announced the successful settlement of the issue of US\$600,000,000 1.50 per cent Convertible Notes due 2031 (New Bonds). The Group concurrently completed the on-market repurchase of approximately A\$637,000,000 in principal of the A\$650,000,000 2.375% C convertible Bonds due 2029 issued by Telix in July 2024 (Existing Bonds). The Existing Bonds repurchased represent approximately 98% of the outstanding Existing Bonds. In May 2026, we repurchased a further A\$5 million of the Existing Bonds. The New Bonds are listed on the Singapore Exchange Securities Trading Limited (SGX-ST).

The New Bonds bear interest at a rate of 1.50 per cent per annum. Interest is payable quarterly in arrears on January 22, April 22, July 22 and October 22 in each year, beginning on July 22, 2026. The New Bonds will mature on or about April 22, 2031, unless redeemed, repurchased, or converted in accordance with their terms.

Funding requirements

We believe that our existing cash resources and cash that we expect to generate from sales from the Precision Medicine and Manufacturing Solutions businesses will be sufficient to meet our projected operating expenses and capital expenditure requirements for at least the next 12 months. Our expectations regarding our short-term and long-term funding requirements are based on assumptions that may prove to be wrong, and we may need additional capital resources to fund our operating plans and capital expenditure requirements.

We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the commercialization of products for which we receive regulatory approval and continue clinical development of our therapeutic product candidates. We expect to finance our operating activities through cash generated from commercial sales, existing cash and cash equivalents and financing activities, which may include equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise capital through the sale of equity or convertible debt securities, the ownership interest of our investors will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates. If we are unable to raise funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Our present and future funding requirements will depend on many factors, including, among other things:

- the amount of revenue received from commercial sales of products for which we receive marketing approval.
- the initiation, progress, timing, costs and results of our clinical trials for our product candidates.
- the costs associated with in-licensing or acquiring assets to expand our pipeline, acquiring businesses or assets to vertically integrate our supply chain and manufacturing and acquiring complementary business.
- the amount of milestones and royalties that we may be required to pay under existing acquisition and licensing agreements.
- costs associated with expanding our organization.
- the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringement raised by third parties.
- the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of these product candidates.

- the costs of operating as a public listed company in both Australia and the U.S.

For more information as to the risks associated with our future funding needs, see "Item 3. Key Information Factors" in our previously filed 2025 Annual Report.

— D. Risk

Alternative performance measures

In reporting financial information, the Group presents alternative performance measures (APMs) which are not defined or specified under the requirements of IFRS. The Group believes that these APMs, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The alternative performance measures are not defined by IFRS and therefore may not be directly comparable with other companies' alternative performance measures. The key APMs that the Group uses are outlined below.

APM	Closest equivalent IFRS measure	Reconciling items to IFRS measure	Definition and purpose
Income statement measures			
Adjusted earnings before interest, tax, depreciation and amortization (Adjusted EBITDA)	Profit/(loss) before income tax	Finance costs, income tax expense, depreciation and amortization, remeasurement of provisions, other gains/(losses).	Used to help assess current operational performance excluding the impacts of non-operating expenditure, finance costs and finance income, depreciation and amortization and taxation expense. It is a measure that management uses internally to assess the performance of the Group's segments and make decisions on the allocation of resources.
Balance sheet measures			
Net tangible asset per share	None	Net assets excluding intangible assets, deferred tax assets and right-of-use assets divided by the Group's weighted average number of ordinary shares on issue.	Disclosed in the Group's Appendix 4E as required by Rule 4.3A of the ASX listing rules.

Metric	Half-year ended	
	June 30 2026	June 30 2025
	\$'000	\$'000
Profit/(loss) before income tax	29,248	(4,836)
Adjusting items:		
Finance income	(2,274)	(3,616)
Finance costs	19,388	18,842
Depreciation and amortization	11,155	9,585
Other (gains)/losses net	(5,575)	1,105
Adjusted EBITDA	51,942	21,080

Foreign private issuer status

We report under the Exchange Act as a "foreign private issuer" under U.S. securities laws. In our capacity as a foreign private issuer, we are exempt from certain SEC and Nasdaq requirements.

Consequently, we are not subject to all of the disclosure requirements applicable to U.S. domestic public companies. For example, we are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, at present, our executive officers, the members of our board of directors and our principal shareholders are exempt from the reporting and "short-swing" profit recovery provisions of Section 16 of the Exchange Act and the reporting rules under the Exchange Act with respect to their purchases and sales of our securities. However, absent an exemption from the SEC, following recent legislative changes that became effective on March 18, 2026, our officers and directors will be subject to the insider reporting obligations under Section 16(a) of the Exchange Act, including the requirements to file Forms 3, 4

and 5, pursuant to the Holding Foreign Insiders Accountable Act enacted on December 18, 2025. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies the securities of which are registered under the Exchange Act. In addition, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information.

We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We will remain a foreign private issuer until such time that 50% or more of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i) the majority of the members of either our board of directors or our global management team are U.S. citizens or residents; (ii) more than 50% of our assets are located in the U.S.; or (iii) our business is administered principally in the U.S.

We have taken advantage of certain reduced reporting and other requirements in this Interim Report. Accordingly, the information contained herein may be different from the information you receive from other public companies.

Changes to share capital

Total number of shares and options on issue

The Company had the below equity instruments on issue:

	At the date of this report	June 30, 2026	December 31, 2025
	Number	Number	Number
Shares on issue	339,784,294	339,784,294	338,777,049
Options, PSARs and share rights on issue	36,387,067	36,387,067	31,744,502
Convertible bonds	6,250	6,250	3,250

Issue of fully paid ordinary shares for acquisitions during the period

ImaginAb Inc.

On May 8, 2026 the Company issued 264,943 fully paid ordinary Telix shares to settle the deferred consideration associated with the acquisition of *ImaginAb Inc.* assets in 2025, on conclusion of a 15-month indemnity period.

Exercise of unlisted share rights, options and performance share appreciation rights (PSARs) for the issue of fully paid ordinary shares

Ordinary shares of Telix issued during the half-year ended June 30, 2026 on the exercise of options granted over unissued shares were as follows:

- a total of 742,000 fully paid ordinary shares were issued upon exercise of 1,525,000 unlisted share options or PSARs.

Since June 30, 2026 to the date of this Interim Report, no shares were issued from the exercise of options under Telix's Equity Incentive Plan.

Lapse of unlisted share options

A total of 1,858,000 share options lapsed unexercised, during the period. These options lapsed in accordance with the terms of their grant.

Issue of unlisted PSARs and share rights

During the period a total of 8,029,000 unlisted share appreciation rights (SARs), PSARs and deferred share rights (SRs) were issued to employees and Directors of the Group. This included the following:

- 339,835 PSARs and 27,121 SRs to the Managing Director and Group Chief Executive Officer, Christian Behrenbruch following shareholder approval at the Company's AGM held on May 21, 2026. These PSARs have a notional exercise price of A\$10.86 per PSAR. PSARs have a three-year performance measurement period. The SRs have a \$nil exercise price and a one-year measurement period, with a service condition. The vesting is subject to achievement of published performance measures, following the completion of the performance measurement period.
- 96,381 SARs to Non-Executive Directors following shareholder approval at the Company's AGM held on May 21, 2026, as outlined below:

	Number of SARs	Notional Exercise Price	Type of share backing
Marie McDonald	23,139	A\$13.43	ASX
David Gill	30,048	US\$9.47	ADS
William Jellison	21,597	US\$9.47	ADS
Maria Rivas	21,597	US\$9.47	ADS

SARs have a three-year measurement period, with a service condition. The SARs have a term that ends on the fifth anniversary of the date of grant.

As at June 30, 2026, the number of equity incentives on issue under the Equity Incentive Plan and issued under exception 13 of Listing Rule 7.2 was 7.8% (December 31, 2025 : 6.4%).

Issue and concurrent repurchase of convertible bonds

On April 15, 2026, the Group announced the successful settlement of the issue of US\$600 million 1.50 per cent Convertible Notes due 2031 (New Bonds). The Group concurrently completed the on-market repurchase of approximately A\$637 million in principal of the A\$650 million 2.375% Convertible Bonds due 2029 issued by Telix in July 2024 (Existing Bonds). The Existing Bonds repurchased represent approximately 98% of the outstanding Existing Bonds. In May 2026, we repurchased a further A\$5 million of the Existing Bonds. The New Bonds are listed on the Singapore Exchange Securities Trading Limited (SGX-ST).

Rounding

The Company is of a kind referred to in ASIC Legislative Instrument 2026/183, relating to the "rounding off" of amounts in the Australian Directors' report and Interim financial report. Amounts in this report are rounded off in accordance with the instrument to the nearest thousand dollars or, in certain cases, to the nearest dollar.

Events subsequent to the end of the financial year

There were no matters or circumstances from the end of the reporting period to the date of this report, which have significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group.



Mark Nelson
Interim Chair
August 20, 2026



Christian Behrenbruch
Managing Director and Group CEO
August 20, 2026

Interim consolidated statement of comprehensive income
for the half-year ended June 30, 2026

		June 30 2026	June 30 2025
	Note	US\$'000	US\$'000
Continuing operations			
Revenue from contracts with customers	4.1	477,350	390,359
Cost of sales		(217,001)	(181,736)
Gross profit		260,349	208,623
Other income	4.4	40,000	-
Research and development costs		(123,828)	(81,583)
Selling and marketing expenses		(58,358)	(48,973)
Manufacturing and distribution costs		(28,713)	(18,849)
General and administration costs		(48,663)	(47,723)
Other gains/(losses)(net)		5,575	(1,105)
Operating profit		46,362	10,390
Finance income		2,274	3,616
Finance costs	4.5	(19,388)	(18,842)
Profit/(loss) before income tax		29,248	(4,836)
Income tax benefit		9,082	2,544
Profit/(loss) for the period		38,330	(2,292)
Profit/(loss) for the period attributable to:			
Owners of Telix Pharmaceuticals Limited		38,330	(2,292)
Other comprehensive income:			
<i>Items that will not be reclassified to profit or loss in subsequent periods:</i>			
Changes in the fair value of investments at fair value through other comprehensive income		1,207	(1,381)
<i>Items to be reclassified to profit or loss in subsequent periods:</i>			
Exchange differences on translation of foreign operations		(30,079)	6,928
Total comprehensive income for the period		9,458	3,255
Total comprehensive income for the period attributable to:			
Owners of Telix Pharmaceuticals Limited		9,458	3,255
		June 30 2026	June 30 2025
		Cents	Cents
Basic earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company		11.30	(0.68)
Diluted earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company		10.74	(0.68)

The above interim consolidated statement of comprehensive income should be read in conjunction with the notes to the Interim consolidated financial statements.

Interim consolidated statement of financial position
as at June 30, 2026

		June 30 2026	December 31 2025
	Note	US\$'000	US\$'000
Current assets			
Cash and cash equivalents		251,910	141,866
Trade and other receivables		163,556	129,202
Inventories		39,029	37,080
Current tax asset		6,832	6,043
Other current assets		26,694	16,089
Total current assets		488,021	330,280
Non-current assets			
Financial assets		40,412	37,094
Deferred tax assets		85,295	59,353
Property, plant and equipment		72,238	58,661
Right-of-use assets		57,390	56,950
Intangible assets	5	584,610	592,823
Other non-current assets		33,885	28,825
Total non-current assets		873,830	833,706
Total assets		1,361,851	1,163,986
Current liabilities			
Trade and other payables		168,972	150,349
Borrowings	6	11,508	13,110
Current tax payable		33,852	30,742
Contract liabilities		390	402
Lease liabilities		3,916	5,548
Provisions		520	562
Contingent consideration		2,900	11,540
Employee benefit obligations		20,286	19,371
Total current liabilities		242,344	231,624
Non-current liabilities			
Borrowings	6	504,877	391,914
Lease liabilities		59,560	56,534
Deferred tax liabilities		43,301	44,706
Other non-current liabilities		3,224	3,517
Provisions		8,562	9,177
Contingent consideration		11,701	10,694
Employee benefit obligations		607	444
Total non-current liabilities		631,832	516,986
Total liabilities		874,176	748,610
Net assets		487,675	415,376

		June 30 2026	December 31 2025
	Note	US\$'000	US\$'000
Equity			
Share capital	8.1	490,920	479,962
Share capital reserve		28,142	(11,612)
Other reserves	8.2	79,509	101,564
Accumulated losses		(110,896)	(154,538)
Total equity		487,675	415,376

The above interim consolidated statement of financial position should be read in conjunction with the notes to the interim consolidated financial statements.

Interim consolidated statement of changes in equity
for the half-year ended June 30, 2026

		Share capital	Share capital reserve	Other reserves	Accumulated losses	Total equity
	Note	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Balance as at January 1, 2026		479,962	(11,612)	101,564	(154,538)	415,376
Profit for the period		-	-	-	38,330	38,330
Other comprehensive loss		-	-	(28,872)	-	(28,872)
Total comprehensive income		-	-	(28,872)	38,330	9,458
Issue of shares on acquisitions	8.1	2,790	-	-	-	2,790
Issue of shares on exercise of options	8.1	8,168	(6,796)	-	-	1,372
Repurchase of convertible bonds	6.1	-	(43,254)	-	-	(43,254)
Issue of convertible bonds	6.1	-	91,709	-	-	91,709
Transaction costs arising on convertible bonds issue		-	(1,905)	-	-	(1,905)
Share-based payments to employees	8.2	-	-	12,129	-	12,129
Transfer on exercise of options	8.2	-	-	(5,312)	5,312	-
		10,958	39,754	6,817	5,312	62,841
Balance as at June 30, 2026		490,920	28,142	79,509	(110,896)	487,675
Balance as at January 1, 2025		414,012	15,945	75,894	(152,914)	352,937
Loss for the period		-	-	-	(2,292)	(2,292)
Other comprehensive income		-	-	5,547	-	5,547
Total comprehensive income		-	-	5,547	(2,292)	3,255
Issue of shares on acquisitions		30,127	-	-	-	30,127
Issue of shares on exercise of options		24,513	(23,837)	-	-	676
Share-based payments to employees		-	-	11,786	-	11,786
Share-based payments associated with acquisitions		-	-	23,160	-	23,160
Transfer on satisfaction of acquisition performance rights		4,458	-	(4,458)	-	-
Transfer on exercise of options		-	-	(4,224)	4,224	-
		59,098	(23,837)	26,264	4,224	65,749
Balance as at June 30, 2025		473,110	(7,892)	107,705	(150,982)	421,941

The above interim consolidated statement of changes of equity should be read in conjunction with the notes to the interim consolidated financial statements.

Interim consolidated statement of cash flows
for the half-year ended June 30, 2026

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Cash flows from operating activities		
Receipts from customers	442,884	372,005
Receipts from collaboration agreements	40,000	-
Payments to suppliers and employees	(439,037)	(348,629)
Payments for contingent consideration	(1,250)	-
Income taxes paid	(14,806)	(3,357)
Interest received	2,222	3,617
Interest paid	(6,977)	(5,887)
Net cash from operating activities	23,036	17,749
Cash flows from investing activities		
Payments for investments in financial assets	(1,000)	(826)
Payments for acquisition of subsidiaries, net of cash acquired	-	(224,659)
Purchases of intangible assets	(332)	(17,109)
Purchases of other non-current assets	(4,509)	(4,577)
Purchases of property, plant and equipment	(14,456)	(6,668)
Payments for contingent consideration	(8,808)	(5,015)
Payments for deferred consideration	(4,612)	-
Net cash used in investing activities	(33,717)	(258,854)
Cash flows from financing activities		
Proceeds from borrowings	587,453	-
Repayment of borrowings	(466,453)	(451)
Principal element of lease payments	(3,939)	(3,148)
Proceeds from issue of shares and other equity	1,366	676
Net cash provided by/(used in) financing activities	118,427	(2,923)
Net increase/(decrease) in cash held	107,746	(244,028)
Net foreign exchange differences	2,298	11,185
Cash and cash equivalents at the beginning of the half-year	141,866	439,999
Cash and cash equivalents at the end of the half-year	251,910	207,156

The above interim consolidated statement of cash flows should be read in conjunction with the notes to the interim consolidated financial statements.

Notes to the interim consolidated financial statements

1. Corporate information

Telix Pharmaceuticals Limited ("Telix" or "the Company") is a for-profit company incorporated and domiciled in Australia. It is limited by shares that are publicly traded on the Australian Securities Exchange (ASX: TLX) and on the Nasdaq Global Select Market (NASDAQ: TLX). Telix develops and distributes commercial radiopharmaceutical products and continues to develop a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases.

Telix is the ultimate parent company of the Telix Pharmaceuticals Group (the Group).

This consolidated financial report of Telix Pharmaceuticals Limited for the half-year ended June 30, 2026 was authorized for issue in accordance with a resolution of the Directors on August 20, 2026.

2. Material accounting policy information

This Interim financial report for the half-year reporting period ended June 30, 2026 has been prepared in accordance with IAS 34 / AASB 134 Interim Financial Reporting and the Corporations Act 2001 (Cth). This Interim financial report does not include all the notes of the type normally included in an Annual financial report. Accordingly, this report is to be read in conjunction with the Annual Report for the year ended December 31, 2025.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

A number of new or amended standards became applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting these standards. The Group has identified that there is no impact of new standards issued but not yet applied.

2.1. Going concern

These financial statements have been prepared on the basis that the Company is a going concern.

For the half-year ended June 30, 2026, the Group generated a profit after income tax of \$38,330,000 (June 30, 2025 : loss after income tax of \$2,292,000) and cash generated from operating activities of \$23,036,000 (June 30, 2025 : \$17,749,000). As at June 30, 2026, the net assets of the Group stood at \$487,675,000 (December 31, 2025 : \$415,376,000) with cash on hand of \$251,910,000 (December 31, 2025 : \$141,866,000).

Cash on hand and anticipated future cash inflows in relation to commercial activities are considered sufficient to meet the Group's forecasted cash outflows in relation to research and development activities currently underway and other committed business activities for at least 12 months from the date of this report.

On this basis, the Directors are satisfied that the Group continues to be a going concern as at the date of issuance of these financial statements. Further, the Directors are of the opinion that no asset is likely to be realized for an amount less than the amount at which it is recorded in the consolidated statement of financial position as at June 30, 2026.

As such, no adjustment has been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or the classification of liabilities that might be necessary should the Group not continue as a going concern.

2.2. Other income

Other income includes income recognized in profit or loss that arises from operating activities that does not stem from relationships with customers. This income arises from certain types of arrangements, as outlined below.

Collaboration agreements

The Group may enter into collaboration agreements to research, develop, manufacture, and commercialize products and/or product candidates. Each agreement is unique in nature and such arrangements may involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. At contract inception, the Group assesses whether these agreements would be within the scope of IFRS 15 / AASB 15 Revenue from Contracts with Customers or IFRS 11 / AASB 11 Joint Arrangements.

A counterparty to the contract would not be a customer if, for example, the counterparty has contracted with the Group to participate in an activity or process in which the parties to the contract share in the risks and benefits that result from the activity or process (such as developing assets in a collaboration agreement) rather than to obtain the output of the entity's ordinary activities.

In such collaboration agreements where research costs are shared, any reimbursement of costs from the collaboration partner are recognized on a net basis in research expense.

3. Segment reporting

The Group has operations in the Americas, Asia-Pacific, and Europe, Middle East and Africa (EMEA) regions, with a significant presence in the U.S., Australia and Belgium.

Reportable segments

The Group's operating segments are based on the reports reviewed by the Group Chief Executive Officer who is considered to be the chief operating decision maker.

Segment performance is evaluated based on Adjusted earnings before interest, tax, depreciation and amortization ("Adjusted EBITDA"). Adjusted EBITDA excludes the effects of the remeasurement of contingent consideration and government grant liabilities and other gains/(losses) which may have an impact on the quality of earnings such as impairments where the impairment is the result of an isolated, non-recurring event. Interest income and finance costs are not allocated to segments as this activity is managed by a central treasury function, which manages the cash position of the Group.

Segment assets and liabilities are measured in the same way as in the financial statements. The assets and liabilities are allocated based on the operations of the segment.

Reportable segment	Principal activities
Precision Medicine	Commercial sales of Illuccix, Gozellix and other diagnostic products subsequent to obtaining regulatory approvals. This segment includes the development activities of the Group's diagnostic pipeline. The Group's International and Medical Technologies businesses are operating segments that are included within the Precision Medicine reportable segment due to the similar nature of the diagnostic products being sold or developed for commercialization.
Therapeutics	Developing the Group's core therapeutic pipeline for commercialization. This segment includes revenue received from license agreements prior to commercialization, income from collaboration agreements and research and development services. This segment includes the development activities of the Group's therapeutic pipeline.
Manufacturing Solutions	This segment comprises revenues and costs associated with the Group's radiopharmacy network, other manufacturing facilities and assets associated with the Group's vertically integrated manufacturing and supply chain. This business includes facilities at Brussels South, IsoTherapeutics, TMS Sacramento, North Melbourne, ARTMS and RLS Radiopharmacies.

Reconciling items include head office and centrally managed costs.

3.1. Segment performance

	Precision Medicine	Therapeutics	Manufacturing Solutions	Inter- segment eliminations	Total segment
For the half-year ended June 30, 2026	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Revenue from contracts with customers	388,633	-	88,717	-	477,350
Inter-segment revenue	-	-	57,543	(57,543)	-
Cost of sales	(134,600)	-	(138,435)	56,034	(217,001)
Gross profit	254,033	-	7,825	(1,509)	260,349
Other income	-	40,000	-	-	40,000
Research and development costs	(54,482)	(67,968)	(2,828)	1,450	(123,828)
Selling and marketing expenses	(49,236)	-	(9,122)	-	(58,358)
Manufacturing and distribution costs	(6,625)	(2,348)	(19,740)	-	(28,713)
General and administration costs	(12,508)	(2,215)	(8,902)	-	(23,625)
Other gains/(losses) (net)	1,195	1,240	(176)	-	2,259
Operating profit/ (loss)	132,377	(31,291)	(32,943)	(59)	68,084
Other (gains)/losses (net)	(1,195)	(1,240)	176	-	(2,259)
Depreciation and amortization	707	149	9,811	-	10,667
Adjusted earnings/ (loss) before interest, tax, depreciation and amortization	131,889	(32,382)	(22,956)	(59)	76,492

For the half-year ended June 30, 2025	Precision Medicine	Therapeutics	Manufacturing Solutions	Inter-segment eliminations	Total segment
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Revenue from contracts with customers	305,835	3,994	80,530	-	390,359
Inter-segment revenue	-	-	33,761	(33,761)	-
Cost of sales	(108,839)	(108)	(103,485)	30,696	(181,736)
Gross profit	196,996	3,886	10,806	(3,065)	208,623
Research and development costs	(38,116)	(43,868)	(2,664)	3,065	(81,583)
Selling and marketing expenses	(40,886)	(464)	(7,623)	-	(48,973)
Manufacturing and distribution costs	(4,105)	(1,710)	(13,034)	-	(18,849)
General and administration costs	(11,317)	(2,002)	(7,116)	-	(20,435)
Other (losses)/gains (net)	(1,593)	19	27	-	(1,547)
Operating profit/(loss)	100,979	(44,139)	(19,604)	-	37,236
Other losses/(gains) (net)	1,593	(19)	(27)	-	1,547
Depreciation and amortization	2,074	117	6,969	-	9,160
Adjusted earnings/(loss) before interest, tax, depreciation and amortization	104,646	(44,041)	(12,662)	-	47,943

Activities between segments are carried out at arm's length and are eliminated on consolidation. The amounts presented are measured consistently with the Group's external reporting. Segment assets are allocated based on the operations of the segment and the physical location of the asset.

3.2. Reconciliation of total segment adjusted EBITDA to profit/(loss) before income tax

		June 30 2026	June 30 2025
	Note	US\$'000	US\$'000
Total segment adjusted EBITDA		76,492	47,943
Unallocated income, expenses and eliminations:			
General and administration costs		(25,038)	(27,288)
Other gains/(losses) (net)		5,575	(1,105)
Finance income		2,274	3,616
Finance costs	4.5	(19,388)	(18,842)
Depreciation and amortization	4.3	(10,667)	(9,160)
Profit/(loss) before income tax		29,248	(4,836)

General and administration costs include employment costs of \$9,800,000 (2025 : \$17,189,000) and other centrally managed IT, legal and other corporate costs. The reduction in employment costs within General and administration costs was due to the allocation of employee share based payments to segments from January 1, 2026.

3.3. Operating segment assets and liabilities

	Precision Medicine	Therapeutics	Manufacturing Solutions	Total segment	Reconciling items	Group
June 30, 2026	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Total assets	323,308	232,997	523,819	1,080,124	281,727	1,361,851
Total liabilities	157,343	25,828	141,994	325,165	549,011	874,176
Additions to non-current assets	668	172	23,658	24,498	—	24,498

	Precision Medicine	Therapeutics	Manufacturing Solutions	Total segment	Reconciling items	Group
December 31, 2025	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Total assets	233,252	228,110	515,429	976,791	187,195	1,163,986
Total liabilities	159,523	17,099	156,599	333,221	415,389	748,610
Additions to non-current assets	19,503	67,715	324,472	411,690	7,840	419,530

Reconciling items primarily comprise cash and cash equivalents held centrally \$143,494,000 (2025 : \$82,833,000), investments in financial assets \$39,412,000 (2025 : \$37,094,000), property, plant and equipment \$8,638,000 (2025 : \$6,915,000) and borrowings (convertible bonds) \$496,237,000 (2025 : \$383,023,000) which are managed centrally.

3.4. Geographical information

	June 30, 2026	June 30, 2025
	Revenue by location of customer	Revenue by location of customer
	US\$'000	US\$'000
United States	468,074	381,051
Other countries	9,276	9,308
Total	477,350	390,359

	June 30, 2026	December 31, 2025
	Non-current assets by location of asset	Non-current assets by location of asset
	US\$'000	US\$'000
Australia	110,383	101,753
Belgium	58,441	59,460
Canada	83,156	86,643
United Kingdom	39,146	37,071
United States	492,532	481,181
Other countries	4,877	8,245
Total	788,535	774,353

The total non-current assets figure above excludes deferred tax assets.

4. Profit and loss information**4.1. Revenue from contracts with customers**

Disaggregation of revenue from contracts with customers.

The Group derives revenue from the sale and transfer of goods and services over time and at a point in time under the following major business activities:

			June 30 2026	June 30 2025
	Recognition	Operating segment	US\$'000	US\$'000
Sale of goods	At a point in time	Precision Medicine	388,210	305,765
Sale of goods	At a point in time	Manufacturing Solutions	83,606	76,807
Royalty income	At a point in time	Precision Medicine	423	55
Provision of services	At a point in time	Manufacturing Solutions	-	15
Provision of services	Over time	Manufacturing Solutions	5,111	3,708
Research and development services	Over time	Precision Medicine	-	15
Research and development services	Over time	Therapeutics	-	3,994
Total revenue from continuing operations			477,350	390,359

4.2. Employment costs

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Salaries and wages	117,683	94,813
Sales commissions	4,914	3,235
Share-based payment charge	12,129	11,585
Non-Executive Directors' fees	416	386
	135,142	110,019

Salaries and wages of \$1,098,000 (2025 : \$916,000) are included within cost of sales in the interim consolidated statement of comprehensive income.

4.3. Depreciation and amortization

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Amortization of intangible assets	4,204	4,620
Depreciation	6,951	4,965
	11,155	9,585

4.4. Other income

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Other income from collaboration agreements	(40,000)	-
	(40,000)	-

*Regeneron Pharmaceuticals, Inc.*Overview

In April 2026, Telix entered into a research and development collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") to jointly develop and commercialize next generation radiopharmaceutical therapeutic candidates and radio-diagnostics to support patient selection and treatment response assessment. The collaboration leverages Regeneron's capabilities in antibody discovery and development and Telix's radiopharmaceutical platform, development expertise and manufacturing capabilities.

The parties will conduct research and development activities pursuant to jointly agreed research and development plans and budgets, overseen through joint governance committees. The collaboration is structured for four initial therapeutic programs, with Regeneron having the option to expand to include four additional programs. Each party is responsible for activities aligned to its respective technical expertise.

The parties will share agreed research and development costs equally, with each party responsible for funding the activities it performs and reimbursing the other party for its share of agreed costs. Telix and Regeneron will also share equally in the global commercialization costs and potential profits, with Telix retaining the option to co-promote certain potential products. If Telix elects to opt out of the co-funding model for a particular program, it would be entitled to receive development and commercial milestones, plus low double-digit royalties on future net sales, for that program.

Treatment of initial consideration

The Group has determined that the arrangement is that of a collaboration whereby Regeneron and Telix are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. As such, Regeneron is not determined to be a customer to which Telix transferred control of goods or services. The \$40,000,000 initial consideration received from Regeneron has been recognized as other income to reflect the contribution of Telix's background intellectual property into the collaboration at inception of the arrangement.

Treatment of subsequent expenditure through the collaboration

All future spending under the collaboration will be shared equally between Regeneron and Telix. Any reimbursements of research costs from Regeneron to Telix will be recognized on a net basis in research expense. Further Telix's obligation to fund its portion of the collaboration's expenditure will be recognized within research expense.

4.5. *Finance costs*

	June 30 2026	June 30 2025
	US\$'000	US\$'000
Unwind of discount	14,533	12,410
Interest expense on lease liabilities	1,783	1,054
Convertible bond interest expense	5,334	4,911
(Gain) on repurchase of convertible bond	(2,935)	-
Interest expense	303	231
Bank fees	370	236
Finance costs	19,388	18,842

The Group recognized a gain of \$2,935,000 on repurchase of the Existing Bonds being the difference between the carrying amount of the financial liability that has been extinguished and the consideration paid. Refer to note 6.1 for further details.

5. Intangible assets

	Goodwill	Intellectual property	Customer relationships and brands	Software	Patents	Licenses	Total
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Balance at January 1, 2026	198,988	231,399	85,197	4,324	372	72,543	592,823
Additions	-	172	167	-	-	-	339
Reclassifications	-	-	-	-	-	-	-
Amortization charge	-	-	(3,000)	(196)	(3)	(1,005)	(4,204)
Changes in provisions	-	(539)	-	-	-	-	(539)
Exchange differences	(1,475)	(2,000)	-	(96)	1	(239)	(3,809)
Balance at June 30, 2026	197,513	229,032	82,364	4,032	370	71,299	584,610
Cost	197,513	249,036	91,389	4,756	710	74,816	618,220
Accumulated amortization	-	(20,004)	(9,025)	(724)	(340)	(3,517)	(33,610)
Net book amount	197,513	229,032	82,364	4,032	370	71,299	584,610
Balance as at January 1, 2025	66,586	176,426	741	2,284	318	11,503	257,858
Acquisition of businesses	143,660	-	90,200	806	-	15,400	250,066
Additions	-	32,410	127	1,291	46	46,030	79,904
Measurement period adjustments	4,731	-	-	-	-	-	4,731
Reclassifications	(18,759)	18,759	-	-	-	-	-
Amortization charge	-	(2,026)	(5,871)	(460)	(17)	(1,508)	(9,882)
Impairments	-	-	-	-	-	(566)	(566)
Changes in provisions	6	(565)	-	-	-	-	(559)
Exchange differences	2,764	6,395	-	403	25	1,684	11,271
Balance at December 31, 2025	198,988	231,399	85,197	4,324	372	72,543	592,823
Cost	198,988	250,952	91,230	4,805	715	75,095	621,785
Accumulated amortization	-	(19,553)	(6,033)	(481)	(343)	(2,552)	(28,962)
Net book amount	198,988	231,399	85,197	4,324	372	72,543	592,823

The Group has considered reasonably possible changes in the key assumptions and has not identified any instances that could cause the carrying amounts of the intangible assets at June 30, 2026 to exceed their recoverable amounts.

6. Borrowings

	June 30, 2026		December 31, 2025	
	Current	Non-current	Current	Non-current
	US\$'000	US\$'000	US\$'000	US\$'000
<i>Secured</i>				
Bank loans	690	8,716	1,418	8,989
Working capital facility	-	(76)	-	(98)
Total secured borrowings	690	8,640	1,418	8,891
<i>Unsecured</i>				
Convertible bonds	10,818	496,237	11,692	383,023
Total unsecured borrowings	10,818	496,237	11,692	383,023
Total borrowings	11,508	504,877	13,110	391,914

6.1. Convertible bonds

On April 15, 2026, the Group announced the successful settlement of the issue of \$600,000,000 1.50 per cent Convertible Notes due 2031 (New Bonds). The Group concurrently completed the on-market repurchase of approximately A\$637,000,000 in principal of the A\$650,000,000 2.375% Convertible Bonds due 2029 issued by Telix in July 2024 (Existing Bonds). The Existing Bonds repurchased represent approximately 98% of the outstanding Existing Bonds. In May 2026, the Group repurchased a further A\$5,000,000 of the Existing Bonds. The New Bonds are listed on the Singapore Exchange Securities Trading Limited (SGX-ST).

The New Bonds will bear interest at a rate of 1.50 per cent per annum. Interest is payable quarterly in arrears on January 22, April 22, July 22 and October 22 in each year, beginning on July 22, 2026. The New Bonds will mature on or about April 22, 2031, unless redeemed, repurchased, or converted in accordance with their terms.

The convertible bonds are presented in the Group's consolidated statement of financial position as follows:

	June 30 2026	December 31 2025
	US\$'000	US\$'000
Opening balance	394,715	344,218
Unwind of discount	13,741	22,502
Interest expense	5,334	9,945
Interest paid	(5,101)	(9,871)
Repurchase of Existing Bonds	(422,499)	-
Face value of New Bonds issued	600,000	-
Transaction costs	(10,747)	-
Other equity securities - value of conversion rights	(91,709)	-
Exchange differences	23,321	27,921
Closing balance	507,055	394,715
Current	10,818	11,692
Non-current	496,237	383,023
Total convertible bond liability	507,055	394,715

Repurchase of existing convertible bonds

The total repurchase consideration is allocated between the liability and equity components using a methodology consistent with the initial recognition at issuance. The liability component is measured as the fair value of the remaining contractual cash flows at the repurchase date, discounted using prevailing market rates for comparable debt.

The equity component associated with the repurchase was \$43,254,000, calculated as the residual after allocating the fair value to the liability component. A resultant gain of \$2,935,000 was recognized in profit or loss only in respect of the liability component, being the difference between the carrying amount of the liability component immediately prior to repurchase and the portion of the repurchase consideration allocated to that liability component.

Issue of New Bonds

The initial fair value of the liability portion of the New Bonds was determined using a market interest rate for an equivalent non-convertible bond at the issue date. This fair value has been reduced by directly attributable transaction costs associated with the issue of the convertible bonds. The liability is subsequently recognized on an amortized cost basis until extinguished on conversion or maturity of the bonds, which has been assessed as April 22, 2029. The remainder of the proceeds is allocated to the conversion option and recognized as part of the share capital reserve, net of income tax and a proportion of transaction costs, and is not subsequently remeasured.

6.2 Fair value

For bank loans, the fair values are not materially different to their carrying amounts, since the interest payable on those borrowings is either close to current market rates or the borrowings are of a short-term nature.

For the convertible bonds, the fair value of the liability component is outlined below. The fair value is based on discounted cash flows using a current borrowing rate. They are classified as level 3 fair values in the fair value hierarchy due to the use of unobservable inputs, including own credit risk.

	June 30, 2026		December 31, 2025	
	Carrying amount	Fair value	Carrying amount	Fair value
	US\$'000	US\$'000	US\$'000	US\$'000
Bank loans	9,330	9,330	10,309	10,309
Convertible bonds	507,055	506,039	394,715	399,348

7. Contractual maturities of financial liabilities

	1-6 months	6-12 months	1-5 years	Over 5 years	Total contractual cash flows	Carrying amount of liabilities
As at June 30, 2026	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Non-derivatives						
Trade and other payables	169,954	691	256	-	170,901	168,972
Other non-current liabilities	-	-	4,534	-	4,534	3,224
Borrowings	5,114	5,228	644,763	2,117	657,222	516,385
Lease liabilities	7,373	7,279	36,108	40,948	91,708	63,476
Government grant liability	552	319	633	-	1,504	1,448
Contingent consideration	401	7,759	6,219	1,793	16,172	14,601
Total financial liabilities	183,394	21,276	692,513	44,858	942,041	768,106

	1-6 months	6-12 months	1-5 years	Over 5 years	Total contractual cash flows	Carrying amount of liabilities
As at December 31, 2025	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Non-derivatives						
Trade and other payables	114,261	36,088	-	-	150,349	150,349
Other non-current liabilities	-	-	3,673	-	3,673	3,517
Borrowings	5,860	5,958	469,257	3,024	484,099	405,024
Lease liabilities	3,051	3,969	44,409	34,994	86,423	62,082
Government grant liability	837	564	1,236	169	2,806	2,046
Contingent consideration	8,755	3,545	11,737	665	24,702	22,234
Total financial liabilities	132,764	50,124	530,312	38,852	752,052	645,252

8. Equity

8.1. Share capital

	June 30 2026	December 31 2025	June 30 2026	December 31 2025
	Number '000	Number '000	US\$'000	US\$'000
Opening balance	338,778	334,725	479,962	414,012
Shares issued through the exercise of share options and warrants	742	1,693	8,168	29,722
Shares issued for Dedicaid ²	-	38	-	467
Shares issued for Lightpoint ³	-	269	-	4,467
Shares issued for Imaginab ⁴	265	2,053	2,790	31,294
Closing balance	339,785	338,778	490,920	479,962

1. Options exercised during the year through the employee Equity Incentive Plan resulted in 742,000 (2025 : 1,693,000) shares being issued for a total value of \$8,168,000 (2025 : \$29,722,000).

2. On April 27, 2023 , the Group completed the acquisition of Dedicaid GmbH. The consideration for the acquisition comprised 207,000 in Telix shares at a 10-day volume weighted average price of shares on the execution date of A\$8.73 per share. During the prior year, the Group issued 37,575 fully paid ordinary shares upon satisfaction of certain milestones.

3. On November 1, 2023 , the Group completed the acquisition of Lightpoint through the issue of 3,298,000 fully paid ordinary Telix shares at A\$9.37 per share. During the prior year, the Group issued 269,075 fully paid ordinary shares in satisfaction of Lightpoint milestone rights.

4. On January 30, 2025 , the Group completed the acquisition of ImaginAb. The consideration included the issue of 2,053,311 fully paid ordinary Telix shares at A\$24.37 per share. On May 8, 2026 the Group issued 264,943 fully paid ordinary shares at A\$14.75 to settle the deferred consideration on conclusion of a 15-month indemnity period.

The weighted average ordinary shares for the period January 1, 2026 to June 30, 2026 is 339,220,212 (2025 : 331,226,491). The Company does not have a limited amount of authorized capital under Australian law.

8.2. Other reserves

	Foreign currency translation reserve	Share-based payments reserve	Financial assets at FVOCI reserve	Total
	US\$'000	US\$'000	US\$'000	US\$'000
Balance as at January 1, 2026	(7,368)	114,073	(5,141)	101,564
Other comprehensive (loss)/income	(30,079)	-	1,207	(28,872)
Total comprehensive (loss)/income	(30,079)	-	1,207	(28,872)
Share-based payments to employees	-	12,129	-	12,129
Transfer on exercise of options	-	(5,312)	-	(5,312)
	-	6,817	-	6,817
Balance as at June 30, 2026	(37,447)	120,890	(3,934)	79,509

	Foreign currency translation reserve	Share-based payments reserve	Financial assets at FVOCI reserve	Total
	US\$'000	US\$'000	US\$'000	US\$'000
Balance as at January 1, 2025	(1,611)	81,404	(3,899)	75,894
Other comprehensive	(5,757)	-	(1,242)	(6,999)
Total comprehensive (loss)/income	(5,757)	-	(1,242)	(6,999)
Share-based payments to employees	-	19,350	-	19,350
Share-based payments associated with acquisitions	-	23,287	-	23,287
Transfer on satisfaction of acquisition performance rights	-	(4,467)	-	(4,467)
Transfer on exercise of options	-	(5,501)	-	(5,501)
	-	32,669	-	32,669
Balance as at December 31, 2025	(7,368)	114,073	(5,141)	101,564

9. Fair value

This section explains the judgments and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value in the financial statements.

9.1. Financial assets

Financial assets are categorized as either level 1 or level 3 financial assets and remeasured at each reporting date with movements recognized in other comprehensive income. The inputs used in the level 1 fair value calculations are with reference to published price quotations for the associated equity instruments in an active market. The sensitivity analysis below reflects exposure to financial assets measured by reference to published price quotations, which excludes the Group's restricted cash balance.

Level 3 financial assets are subject to key assumptions and unobservable inputs which include risk adjusted post-tax discount rates and forecasted discounted cashflows. These inputs significantly impact the underlying value of these assets.

Sensitivity of level 1 financial assets

An increase/(decrease) of 10% in the share price of each financial asset while holding all other variables constant will increase/(decrease) other comprehensive income by \$224,000 (December 31, 2025 : \$102,000).

Sensitivity of level 3 financial assets

An increase/(decrease) of 10% in the discounted cashflows of each financial asset while holding all other variables constant will increase/(decrease) other comprehensive income by \$274,000 (December 31, 2025 : \$266,000).

9.2. Financial liabilities

Contingent consideration liabilities are categorized as level 3 financial liabilities and remeasured at each reporting date with movements recognized in profit or loss, except in instances where changes are permitted to be added to/reduce an associated asset. The inputs used in fair value calculations are determined by Management.

The carrying amount of financial liabilities measured at fair value is principally calculated based on inputs other than quoted prices that are observable for these financial liabilities, either directly (i.e. as unquoted prices) or indirectly (i.e. derived from prices). Where no price information is available from a quoted market source, alternative market mechanisms or recent comparable transactions, fair value is estimated based on Management's views on relevant future prices, net of valuation allowances to accommodate liquidity, modelling and other risks implicit in such estimates.

Sensitivity of level 3 financial liabilities

The potential effect of using reasonably possible alternative assumptions in valuation models, based on a change in the most significant input, such as sales volumes, by an increase/(decrease) of 10% while holding all other variables constant will increase/(decrease) profit before tax by \$239,000 (December 31, 2025 : \$275,000).

Valuation processes

The finance team of the Group performs the valuation of contingent consideration liabilities required for financial reporting purposes, including level 3 fair values. This team reports directly to the Chief Financial Officer (CFO). Discussions of valuation processes and results are held between the CFO and Board at least once every six months, in line with the Group's half-yearly reporting periods.

The main level 3 inputs used by the Group in measuring the fair value of contingent consideration liabilities are derived and evaluated as follows:

- discount rates are determined by an independent third-party using a weighted average cost of capital model to calculate a post-tax rate that reflects current market assessments of the time value of money and the risk specific to the asset.
- regulatory/marketing authorization approval dates and approval for marketing authorization probability risk factors are derived in consultation with the Group's regulatory team.
- expected sales volumes and net sales price per unit are estimated based on market information on annual incidence rates and information for similar products and expected market penetration.
- contingent consideration cash flows are estimated based on the terms of the sale contract. Changes in fair values are analyzed at the end of each reporting period during the half-yearly valuation discussion between the CFO and Board. As part of this discussion the CFO presents a report that explains the reason for the fair value movement.

10. Contingent liabilities

The Group has received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Group's disclosures regarding the development of the Group's prostate cancer therapeutic candidates. This matter remains a fact-finding request. Telix is cooperating with the subpoena including responding to the SEC's requests. The SEC has not asserted any charges against the Group or any of its personnel, and no conclusions have been reached. At this stage, the Group cannot predict the duration, scope or outcome of this matter. The Group will continue to monitor the inquiry and update its disclosures as appropriate.

On November 10, 2025, a putative securities class action complaint was filed in the United States District Court for the Southern District of Indiana seeking, among other relief, class certification, designation of a lead plaintiff, damages and a jury trial. On January 20, 2026, the Group was formally served the complaint on behalf of a purported U.S. shareholder. The Group has filed a motion to dismiss this matter. This case is still in its earliest stages, and the Group plans to rigorously defend itself in this matter. No class has been certified and the court has not ruled on any dispositive motions. At this stage, the Group cannot predict the duration, scope or outcome of this matter.

Legal fees and other costs associated with contingent matters, including litigation, regulatory inquiries and investigations, are expensed as incurred.

10.1. Commitments

The Group has commitments against existing development activities and capital commitments relating to property plant and equipment and the purchase of isotope raw materials. R&D commitments are estimated based on the contractual obligations included within agreements entered into by the Group, to the extent that a work order has been executed with the vendor.

The Group's supply agreements contain minimum purchase commitments in certain situations, the amount and timing of which are not known. Additionally, the Group enters into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for preclinical studies and clinical trials, research supplies and other services and drugs for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancellable contracts.

The Group has entered into in-licensing arrangements with various companies. Such agreements may require the Group to make payments on achievement of stages of development, launch or revenue milestones and may include variable payments that are based on unit sales or profit (e.g., royalty and profit share payments). The amount of variable payments under these agreements are inherently uncertain and difficult to predict, given the direct link to future sales, profit levels and the range of outcomes. These payments are not included in this table of contractual obligations.

To the extent a commitment is determined to be onerous, these are provided for within provisions in the Consolidated statement of financial position.

At June 30, 2026 and at the date of these financial statements, the Group had capital commitments relating to the construction of the Seneffe (Brussels South) manufacturing facility and the purchase of isotope raw materials from a vendor over a three-year period.

	Due < 1 year	Due > 1 year
	US\$'000	US\$'000
As at June 30, 2026		
Capital commitments	42,665	6,410
R&D commitments	53,234	13,309
	95,899	19,719
As at December 31, 2025		
Capital commitments	35,822	11,367
R&D commitments	30,402	7,601
	66,224	18,968

11. Events occurring after the reporting period

There were no subsequent events that required adjustment to or disclosure in the financial statements of the Group for the half-year ended June 30, 2026.

p for

Directors' declaration

In the opinion of the Directors:

- a. the financial statements and notes of the Group are in accordance with the *Australian Corporations Act 2001 (Cth)*, including:
 - i. giving a true and fair view of the Group's financial position as at June 30, 2026 and of its performance for the half-year ended on that date.
 - ii. complying with applicable Accounting Standards, the Corporations Regulation 2001 and other mandatory professional reporting requirements.
- b. there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Directors and has been made after receiving the declarations by the Chief Executive Officer and Chief Financial Officer for the half-year ended June 30, 2026 .



Mark Nelson
Interim Chair
August 20, 2026



Christian Behrenbruch
Managing Director and Group CEO
August 20, 2026

